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Abstract	  
Cardiac	  failure	  following	  myocardial	  infarction	  is	  an	  important	  global	  health	  issue	  and	  a	  leading	  cause	  of	  morbidity	  and	  mortality	  worldwide.	  	  Current	  treatments	  do	  not	  address	  the	  underlying	  problem	  of	  massive	  cardiomyocyte	  loss.	  	  New	  tissue	  engineering	  strategies	  may	  be	  capable	  of	  regenerating	  or	  repairing	  cardiac	  tissue.	  
The	  aim	  of	  this	  thesis	  was	  to	  design	  a	  cardiac	  tissue	  engineering	  strategy	  including	  aspects	  of	  biomaterials,	  cells	  and	  soluble	  factors.	  	  	  
For	  the	  biomaterial	  arm	  a	  polyethylene	  glycol	  (PEG)	  based	  hydrogel	  was	  designed	  to	  match	  the	  mechanical	  properties	  of	  myocardial	  tissue	  whilst	  remaining	  degradable	  and	  with	  the	  capability	  of	  supporting	  live	  cells.	  	  Injection	  of	  the	  hydrogel	  into	  the	  myocardium	  demonstrated	  no	  significant	  adverse	  effects	  using	  a	  Langendorff	  and	  in	  vivo	  model.	  	  Induced	  pluripotent	  stem	  cell-­‐derived	  cardiomyocytes	  (iPS-­‐CM)	  were	  used	  as	  the	  cellular	  component	  of	  the	  strategy,	  with	  Erythropoietin	  (Epo)	  demonstrating	  protective	  effects	  in	  an	  in	  vitro	  model	  of	  cellular	  injury.	  	  	  	  	  	  	  
A	  model	  of	  rat	  myocardial	  infarction	  was	  used.	  	  The	  left	  anterior	  descending	  artery	  was	  ligated	  in	  vivo	  to	  create	  an	  infarction.	  	  Combinations	  of	  hydrogel,	  iPS-­‐CM,	  and	  Epo	  were	  injected	  into	  the	  infarct	  border	  zones	  with	  follow	  up	  for	  8-­‐10	  weeks.	  	  A	  combination	  of	  hydrogel,	  iPS-­‐CM	  and	  Epo	  demonstrated	  significantly	  more	  muscularisation	  and	  thickness	  of	  the	  infarct	  zone,	  with	  improvements	  noted	  in	  ejection	  fraction	  over	  infarct	  controls.	  	  	  
These	  results	  support	  a	  multidisciplinary	  approach	  to	  cardiac	  tissue	  engineering.	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Introduction	  
	  
1.1	  The	  Clinical	  Problem	  of	  Cardiac	  Failure	  
Cardiac	  Failure	  is	  a	  major	  and	  increasing	  health	  problem	  in	  countries	  worldwide.	  	  In	  the	  United	  Kingdom,	  approximately	  707,000	  patients	  over	  the	  age	  of	  45	  have	  a	  diagnosis	  of	  cardiac	  failure,	  with	  68,000	  new	  cases	  being	  diagnosed	  every	  year(Allender,	  Peto	  et	  al.	  2008).	  	  In	  the	  United	  States,	  over	  5.7	  million	  patients	  (2.4%	  of	  the	  population)	  have	  been	  diagnosed	  with	  cardiac	  failure,	  with	  another	  670,000	  patients	  over	  the	  age	  of	  45	  being	  diagnosed	  yearly(Roger,	  Go	  et	  al.).	  	  The	  prognosis	  following	  diagnosis	  with	  cardiac	  failure	  is	  poor	  despite	  best	  medical	  therapy	  (Figure	  1-­‐1	  and	  1-­‐2),	  with	  approximately	  50%	  of	  patients	  dying	  within	  2	  years(Roger,	  Go	  et	  al.	  ,	  Levy,	  Kenchaiah	  et	  al.	  2002,	  Roger,	  Weston	  et	  al.	  2004).	  	  One	  in	  nine	  deaths	  in	  the	  US	  has	  cardiac	  failure	  mentioned	  as	  a	  contributing	  cause	  on	  the	  death	  certificate	  (281,437	  deaths),	  with	  56,830	  deaths	  directly	  attributable	  to	  cardiac	  failure	  in	  2008(Roger,	  Go	  et	  al.).	  	  
	  
Figure	   1-­‐1:	   	   One	   year	   survival	   of	   patients	   following	   diagnosis	   of	   heart	   failure.	   	   Adapted	   from	  Cowie	  et	  al. (2000)	  (Cowie,	  Wood	  et	  al.	  2000)	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Figure	  1-­‐2:	  	  The	  one	  year	  survival	  rate	  of	  patients	  following	  a	  diagnosis	  of	  heart	  failure	  (red	  bar)	  in	   comparison	   to	   common	   cancers	   in	   the	   UK.	   	   Source:	   British	   Heart	   Foundation,	  www.heartstats.org	  
	  
	  
Cardiac	  failure	  also	  represents	  a	  significant	  financial	  burden	  on	  healthcare	  services,	  accounting	  for	  approximately	  2%	  of	  total	  health	  care	  expenditure(McMurray	  and	  Pfeffer	  2005).	  	  In	  the	  US,	  cardiac	  failure	  is	  responsible	  for	  over	  3	  million	  visits	  to	  a	  primary	  care	  doctor	  per	  year	  and	  over	  600,000	  emergency	  room	  visits.	  	  83%	  of	  patients	  diagnosed	  with	  cardiac	  failure	  are	  likely	  to	  require	  hospital	  admission	  at	  least	  once,	  with	  43%	  of	  patients	  requiring	  at	  least	  4	  admissions(Roger,	  Go	  et	  al.).	  	  As	  cardiac	  failure	  is	  recognized	  as	  a	  ‘disease	  of	  the	  elderly’(Kannel	  and	  Belanger	  1991),	  the	  worldwide	  ageing	  population	  is	  likely	  to	  result	  in	  increasing	  morbidity,	  mortality	  and	  financial	  demands	  in	  the	  near	  future.	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1.2	  The	  Pathophysiology	  of	  Cardiac	  Failure	  
Cardiac	  failure	  is	  a	  complex	  clinical	  syndrome	  that	  results	  from	  any	  structural	  or	  functional	  disorder	  of	  the	  heart	  that	  can	  impair	  the	  ability	  of	  the	  ventricle	  to	  fill	  with	  or	  eject	  blood(Hunt	  2005).	  	  This	  leads	  to	  in	  the	  classical	  clinical	  symptoms	  of	  cardiac	  failure:	  shortness	  of	  breath	  (dyspnoea)	  on	  exertion,	  and	  fluid	  retention.	  	  These	  symptoms	  can	  affect	  the	  functional	  capacity	  and	  quality	  of	  life	  of	  patients	  to	  a	  large	  degree,	  with	  quality	  of	  life	  being	  more	  significantly	  impaired	  by	  cardiac	  failure	  than	  any	  other	  chronic	  diseases(Cowie,	  Wood	  et	  al.	  2000,	  McMurray	  and	  Pfeffer	  2005).	  	  The	  typical	  clinical	  picture	  of	  cardiac	  failure	  is	  a	  progressive	  one	  with	  a	  tendency	  of	  deterioration	  in	  symptoms	  over	  time.	  	  	  
Cardiac	  failure	  itself	  can	  be	  caused	  by	  any	  disease	  process	  that	  affects	  the	  great	  vessels,	  pericardium,	  myocardium	  or	  endocardium.	  	  However,	  the	  vast	  majority	  of	  cases	  are	  caused	  by	  myocardial	  disease	  resulting	  in	  functional	  impairment	  of	  the	  left	  ventricle	  (LV).	  	  This	  typically	  will	  result	  in	  changes	  to	  measures	  of	  cardiac	  performance	  such	  as	  the	  ejection	  fraction	  (EF),	  although	  increased	  understanding	  of	  the	  cardiac	  failure	  syndrome	  has	  questioned	  the	  relationship	  between	  measures	  of	  ventricular	  function	  and	  clinical	  symptoms(Hunt	  2005).	  	  Coronary	  artery	  disease	  is	  responsible	  for	  approximately	  two	  thirds	  of	  cardiac	  failure	  cases	  with	  low	  EF.	  	  Generation	  and	  rupture	  of	  atheromatous	  plaques	  within	  the	  coronary	  artery	  wall	  leads	  to	  restriction	  or	  complete	  interruption	  of	  blood	  supply	  to	  the	  highly	  metabolically	  active	  myocardial	  tissue.	  	  This	  results	  in	  tissue	  ischaemia	  and	  infarction,	  and	  consequently	  myocardial	  cell	  death.	  	  The	  myocardial	  injury	  causes	  change	  in	  LV	  geometry,	  with	  LV	  dilatation	  and	  hypertrophy,	  resulting	  in	  a	  typically	  spherical	  appearance	  –	  a	  process	  referred	  to	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as	  “cardiac	  remodeling”.	  	  This	  process	  increases	  the	  haemodynamic	  stress	  on	  the	  ventricular	  wall	  through	  LaPlace’s	  law,	  which	  can	  not	  only	  impair	  mechanical	  performance,	  but	  can	  also	  increase	  regurgitant	  blood	  flow	  through	  the	  mitral	  valve,	  further	  impairing	  LV	  function.	  	  Together,	  these	  processes	  serve	  to	  continue	  the	  cycle	  of	  cardiac	  failure	  and	  ventricular	  remodeling	  resulting	  in	  progressively	  worsening	  function	  and	  symptoms.	  	  Patients	  in	  this	  cycle	  will	  normally	  require	  lifelong	  medical	  treatment	  to	  control	  their	  symptoms,	  which	  may	  continue	  to	  worsen	  despite	  best	  therapy.	  	  	  
	  
1.3	  Current	  Treatments	  for	  Cardiac	  Failure	  
The	  current	  treatment	  strategies	  for	  cardiac	  failure	  encompass	  all	  aspects	  of	  the	  disease	  process,	  starting	  with	  primary	  prevention	  using	  risk	  factor	  control	  of	  conditions	  including	  (but	  not	  exclusive	  to)	  hypertension,	  diabetes,	  obesity	  and	  coronary	  artery	  disease.	  	  Identifying	  patients	  at	  high	  risk	  of	  developing	  cardiac	  failure	  provides	  the	  earliest	  and	  best	  opportunity	  of	  reducing	  the	  impact	  of	  cardiac	  failure	  upon	  public	  health(Hunt	  2005).	  	  For	  patients	  suffering	  myocardial	  infarction,	  revasularization	  strategies	  to	  reduce	  infarct	  size	  have	  improved	  significantly	  over	  the	  past	  decade	  with	  the	  use	  of	  thrombolytic	  therapy	  or	  percutaneous	  coronary	  intervention	  (PCI)	  with	  angioplasty	  and	  stenting	  resulting	  in	  a	  reduction	  in	  mortality	  as	  well	  as	  a	  reduction	  in	  the	  risk	  of	  subsequent	  cardiac	  failure(Guerci,	  Gerstenblith	  et	  al.	  1987).	  	  The	  majority	  of	  patients	  with	  established	  cardiac	  failure	  are	  managed	  on	  a	  combination	  of	  medical	  therapies	  including	  diuretics,	  angiotensin-­‐converting-­‐enzyme	  inhibitors	  (ACEi),	  aldosterone	  receptor	  blockers	  (ARBs)	  and	  beta	  blockers(1999).	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Subgroups	  of	  patients	  may	  also	  benefit	  from	  exercise	  training	  as	  well	  as	  cardiac	  resynchronization	  therapy(Hunt	  2005).	  	  For	  end-­‐stage	  refractory	  cardiac	  failure,	  cardiac	  transplantation	  is	  the	  only	  established	  surgical	  approach	  for	  treatment.	  	  However,	  due	  to	  donor	  shortages,	  this	  is	  only	  available	  to	  less	  than	  2,500	  patients	  every	  year	  in	  the	  US(1999),	  and	  the	  adverse	  effects	  from	  long	  term	  immnosuppression	  should	  not	  be	  underestimated.	  	  Left	  ventricular	  assist	  devices	  (LVAD)	  can	  provide	  long	  term	  haemodynamic	  support	  for	  end	  stage	  cardiac	  failure	  patients,	  but	  are	  typically	  used	  as	  a	  bridge	  to	  transplantation,	  and	  suffer	  significant	  adverse	  events	  including	  bleeding,	  infection,	  thromboembolic	  events	  and	  device	  failure(Rose,	  Moskowitz	  et	  al.	  1999).	  	  	  
Despite	  significant	  advances	  in	  all	  these	  treatment	  areas,	  no	  current	  treatment	  strategy	  is	  able	  to	  address	  the	  fundamental	  underlying	  problem	  in	  the	  majority	  of	  cardiac	  failure	  cases	  –	  the	  loss	  of	  functioning	  cardiomyocytes.	  	  Therapies	  aimed	  at	  reversing	  the	  effects	  of	  myocardial	  injury	  and	  death,	  have	  the	  potential	  of	  improving	  the	  lives	  of	  millions	  of	  patients	  worldwide.	  	  	  
	  
1.4	  Stem	  Cell	  Therapy	  for	  Cardiac	  Failure	  
As	  a	  result	  of	  the	  current	  limitations	  in	  therapy	  for	  cardiac	  failure,	  recent	  years	  have	  seen	  a	  growing	  interest	  in	  the	  potential	  use	  of	  stem	  cell-­‐based	  therapy	  for	  cardiac	  repair	  and	  regeneration,	  with	  the	  ultimate	  aim	  being	  a	  complete	  reversal	  of	  cardiac	  injury.	  	  	  
Stem	  cells	  have	  the	  innate	  ability	  of	  indefinite	  self-­‐renewal	  making	  them	  an	  ideal	  source	  of	  cells	  for	  cardiac	  regenerative	  strategies.	  	  These	  cells	  are	  normally	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under	  tight	  regulation	  within	  the	  body	  although	  their	  growth	  can	  be	  amplified	  in	  tissue	  culture,	  an	  attribute	  which	  is	  very	  useful	  for	  cell	  therapy(Buttery	  and	  Shakesheff	  2008).	  	  Stem	  cell	  potency	  refers	  to	  the	  range	  of	  cell	  types	  that	  a	  stem	  cell	  can	  differentiate	  into.	  	  This	  can	  be	  classified	  as:	  
	  
• Totipotent	  –	  the	  stem	  cell	  is	  able	  to	  differentiate	  into	  all	  cell	  types	  needed	  in	  an	  organism.	  	  Totipotency	  is	  restricted	  to	  a	  zygote	  or	  fertilized	  egg.	  
• Pluripotent	  –	  the	  stem	  cell	  is	  able	  to	  form	  cells	  from	  all	  3	  germ	  layers	  (endoderm,	  mesoderm,	  ectoderm),	  but	  is	  not	  able	  to	  form	  placental	  tissues.	  	  A	  good	  example	  of	  these	  cells	  are	  Embryonic	  Stem	  Cells	  (ESC)	  derived	  from	  the	  inner	  cell	  mass	  of	  the	  blastocyst,	  or	  the	  newly	  discovered	  induced	  pluripotent	  stem	  cells	  (iPS).	  
• Multipotent	  –	  the	  stem	  cell	  is	  able	  to	  form	  cells	  from	  a	  particular	  tissue.	  	  These	  usually	  refer	  to	  the	  ‘adult’	  stem	  cells	  such	  as	  haemopoetic	  stem	  cells	  (HSC).	  	  
Totipotent	  or	  pluripotent	  stem	  cells	  seem	  to	  be	  the	  most	  logical	  choice	  source	  of	  cells	  for	  regenerative	  medicine.	  	  Their	  ability	  to	  differentiate	  into	  all	  tissues	  of	  the	  body	  means	  that	  theoretically	  they	  could	  be	  used	  to	  regenerate	  any	  tissue	  type	  required.	  	  Studies	  using	  human	  ESC	  derived	  cardiomyoctes	  have	  recently	  demonstrated	  formation	  of	  human	  myocardial	  tissue	  within	  infarcted	  rat	  hearts(Laflamme,	  Gold	  et	  al.	  2005,	  Laflamme,	  Chen	  et	  al.	  2007).	  	  However,	  the	  ethical	  and	  immunological	  aspects	  associated	  with	  ESC	  use,	  as	  well	  as	  the	  potential	  safety	  concerns	  of	  teratoma	  formation	  have	  so	  far	  precluded	  their	  use	  in	  human	  clinical	  trials	  for	  heart	  disease.	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However,	  these	  concerns	  are	  limited	  with	  the	  use	  of	  adult	  stem	  cells.	  	  Use	  of	  adult	  stem	  cells	  is	  an	  attractive	  option	  as	  autologous	  cells	  may	  potentially	  be	  used,	  thus	  avoiding	  problems	  of	  immunosuppresion.	  	  Similarly	  ethical	  and	  supply	  issues	  are	  also	  easily	  overcome,	  further	  supporting	  their	  use.	  	  Adult	  stem	  cells	  that	  have	  been	  investigated	  include	  skeletal	  myoblasts(Menasche	  2008),	  cardiac	  progenitor	  cells	  (CPCs)(Oh,	  Bradfute	  et	  al.	  2003,	  Wang,	  Hu	  et	  al.	  2006),	  cardiospheres(Carr,	  Stuckey	  et	  al.	  ,	  Lee,	  White	  et	  al.	  ,	  Smith,	  Barile	  et	  al.	  2007),	  mesenchymal	  stem	  cells	  (MSCs)(Dai,	  Hale	  et	  al.	  2005,	  Silva,	  Litovsky	  et	  al.	  2005,	  Rose,	  Jiang	  et	  al.	  2008),	  adipose-­‐derived	  stem	  cells	  (ADSCs)(Cai,	  Johnstone	  et	  al.	  2009,	  Schenke-­‐Layland,	  Strem	  et	  al.	  2009),	  and	  induced	  pluripotent	  stem	  (iPS)	  cells(Yoshida	  and	  Yamanaka	  ,	  Nelson,	  Martinez-­‐Fernandez	  et	  al.	  2009).	  	  	  
Gathering	  evidence	  of	  adult	  stem	  cell	  success	  in	  animal	  models	  led	  to	  several	  human	  trials	  of	  the	  use	  of	  adult	  stem	  cells	  to	  treat	  heart	  failure	  following	  myocardial	  infarction(Wollert	  and	  Drexler).	  	  A	  substantial	  number	  of	  human	  trials	  have	  been	  completed	  to	  investigate	  the	  effects	  of	  adult	  bone	  marrow-­‐derived	  cells	  (BMC)	  in	  stem	  cell	  therapy	  for	  acute	  myocardial	  infarction(Traverse,	  McKenna	  et	  al.	  ,	  Wohrle,	  Merkle	  et	  al.	  ,	  Wollert,	  Meyer	  et	  al.	  2004,	  Janssens,	  Dubois	  et	  al.	  2006,	  Lunde,	  Solheim	  et	  al.	  2006,	  Schachinger,	  Erbs	  et	  al.	  2006,	  Huikuri,	  Kervinen	  et	  al.	  2008,	  van	  der	  Laan,	  Hirsch	  et	  al.	  2008,	  Hare,	  Traverse	  et	  al.	  2009,	  Tendera,	  Wojakowski	  et	  al.	  2009)	  and	  ischaemic	  heart	  failure(Assmus,	  Honold	  et	  al.	  2006,	  Menasche,	  Alfieri	  et	  al.	  2008,	  Dib,	  Dinsmore	  et	  al.	  2009).	  	  	  The	  results	  of	  these	  studies	  have	  been	  inconsistent,	  and	  even	  though	  a	  recent	  meta-­‐analysis	  has	  found	  an	  overall	  significant	  increase	  in	  left	  ventricular	  ejection	  fraction	  (LVEF)	  of	  2.93%,	  and	  a	  decrease	  in	  left	  ventricular	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end	  diastolic	  volume	  (LVEDV)	  of	  8.61ml(Jiang,	  He	  et	  al.),	  it	  is	  clear	  that	  further	  studies	  need	  to	  be	  performed	  with	  standardization	  of	  aspects	  such	  as	  stem	  cell	  processing,	  dosage,	  timing	  of	  therapy,	  and	  route	  of	  cell	  administration(Menasche	  2011).	  	  	  Studies	  also	  need	  to	  be	  adequately	  powered	  in	  order	  to	  examine	  hard	  clinical	  end	  points	  such	  as	  mortality	  and	  repeat	  cardiac	  events	  as	  opposed	  to	  radiographical	  indices	  of	  cardiac	  function.	  	  Skeletal	  myoblasts	  have	  also	  been	  used	  in	  a	  number	  of	  clinical	  trials,	  but	  lack	  of	  efficacy	  as	  well	  as	  lingering	  doubts	  regarding	  the	  risk	  of	  arrhythmias	  have	  brought	  these	  to	  a	  halt(Menasche,	  Alfieri	  et	  al.	  2008).	  	  	  
Despite	  these	  caveats,	  it	  is	  encouraging	  that	  these	  trials	  have	  hinted	  at	  the	  possible	  therapeutic	  effects	  of	  some	  stem	  cell	  therapies,	  and	  also	  have	  gone	  some	  way	  to	  demonstrate	  the	  safety	  of	  these	  approaches	  with	  up	  to	  10	  years	  of	  follow	  up	  on	  BMC	  therapy	  (Menasche	  2011).	  	  	  
	  
1.5	  Limitations	  of	  current	  stem	  cell	  therapy	  strategies	  
It	  is	  now	  widely	  thought	  that	  the	  reparative	  potential	  of	  adult	  cells	  such	  as	  BMSCs	  most	  likely	  come	  from	  paracrine	  effects	  as	  opposed	  to	  direct	  regeneration	  from	  the	  transplanted	  cells	  themselves(Wollert	  and	  Drexler	  2005).	  	  True	  replacement	  of	  functional	  cardiomyocytes	  may	  only	  be	  possible	  with	  the	  use	  of	  pluripotent	  cells.	  	  The	  recent	  discovery	  of	  iPS	  cells	  whereby	  scientists	  have	  been	  able	  to	  ‘reprogram’	  an	  adult	  cell	  back	  to	  a	  pluripotent	  state(Takahashi	  and	  Yamanaka	  2006),	  has	  rejuvenated	  the	  field	  and	  may	  eventually	  be	  able	  to	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provide	  a	  patient	  specific	  cell	  source	  that	  is	  free	  of	  the	  ethical	  and	  immunological	  constraints	  of	  other	  pluripotent	  cell	  sources.	  	  
However,	  even	  when	  the	  iPS	  field	  is	  deemed	  ready	  to	  provide	  a	  safe	  and	  consistent	  pool	  of	  cells,	  other	  obstacles	  will	  still	  need	  to	  be	  overcome	  that	  are	  common	  to	  all	  cell	  therapy	  techniques.	  	  	  
Current	  cell	  therapy	  is	  severely	  limited	  by	  the	  problems	  of	  cell	  engraftment,	  retention	  and	  survival.	  	  MRI	  studies	  of	  radiolabelled	  bone	  marrow	  cells	  demonstrate	  only	  up	  to	  2.6%	  uptake	  into	  the	  myocardium	  following	  intracoronary	  transfer,	  with	  no	  retention	  activity	  detected	  in	  the	  myocardium	  following	  peripheral	  venous	  transfer(Hofmann,	  Wollert	  et	  al.	  2005).	  	  Even	  following	  direct	  myocardial	  injection	  of	  fluorescent	  microspheres	  in	  animal	  models,	  immediate	  retention	  rates	  were	  found	  to	  only	  be	  up	  to	  11.1%	  due	  to	  the	  mechanical	  effect	  of	  myocardial	  contraction(Teng,	  Luo	  et	  al.	  2006).	  	  Experiments	  using	  neonatal	  cardiomyoctes	  demonstrated	  of	  the	  cells	  that	  are	  retained	  within	  the	  myocardium,	  survival	  rates	  are	  low	  with	  estimates	  of	  1	  to	  33%	  of	  cells	  surviving	  7	  days(Zhang,	  Methot	  et	  al.	  2001).	  	  	  The	  importance	  of	  achieving	  delivery	  of	  a	  large	  number	  of	  cells	  to	  the	  targeted	  area	  of	  myocardium	  is	  supported	  by	  limited	  clinical	  data	  where	  patients	  injected	  with	  a	  higher	  dose	  of	  cells	  had	  improved	  outcomes	  compared	  with	  low	  dose	  groups(Menasche,	  Alfieri	  et	  al.	  2008).	  	  The	  issues	  of	  cell	  retention	  and	  survival	  is	  critical	  to	  the	  success	  of	  cell	  therapy,	  regardless	  of	  the	  type	  of	  cell	  chosen.	  	  Therefore	  a	  multimodal	  approach	  may	  be	  required	  to	  address	  these	  problems.	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1.6	  Tissue	  Engineering	  for	  Cardiac	  Failure	  
Tissue	  Engineering,	  as	  described	  by	  Langer	  and	  Vacanti	  in	  1993,	  is:	  	  
“an	  interdisciplinary	  field	  that	  applies	  the	  principles	  of	  engineering	  and	  life	  
sciences	  toward	  the	  development	  of	  biological	  substitutes	  that	  restore,	  maintain,	  or	  
improve	  tissue	  function	  or	  a	  whole	  organ”(Langer	  and	  Vacanti	  1993).	  	  
	  Many	  groundbreaking	  advances	  have	  been	  made	  since	  that	  first	  definition,	  and	  today	  a	  well-­‐rounded	  tissue	  engineering	  strategy	  includes	  a	  triad	  of	  cells,	  biomaterials	  and	  soluble	  factors.	  	  Using	  a	  tissue	  engineering	  strategy,	  with	  the	  appropriate	  biomaterials	  and	  soluble	  factors	  in	  combination	  with	  cell	  therapy,	  would	  appear	  to	  have	  the	  best	  chance	  of	  achieving	  the	  goal	  of	  cardiac	  regeneration.	  	  With	  this	  in	  mind,	  designing	  the	  ideal	  biomaterial	  scaffold	  is	  a	  critically	  important	  step.	  	  	  
Materials	  have	  been	  used	  to	  help	  treat	  human	  injury	  and	  disease	  for	  thousands	  of	  years,	  but	  only	  in	  recent	  history	  has	  the	  term	  ‘biomaterial’	  been	  defined.	  	  A	  biomaterial	  can	  be	  thought	  of	  as:	  
“…a	  substance	  that	  has	  been	  engineered	  to	  take	  a	  form	  which,	  alone	  or	  as	  part	  of	  a	  
complex	  system,	  is	  used	  to	  direct,	  by	  control	  of	  interactions	  with	  components	  of	  
living	  systems,	  the	  course	  of	  any	  therapeutic	  or	  diagnostic	  procedure,	  in	  human	  or	  
veterinary	  medicine”(Williams	  2009).	  
As	  well	  as	  utilising	  the	  bulk	  properties	  of	  materials	  to	  aid	  the	  healing	  and	  function	  of	  body	  tissues,	  new	  advances	  have	  allowed	  the	  complex	  design	  of	  biomaterials	  on	  a	  molecular	  level	  allowing	  the	  direction	  of	  specific	  cellular	  responses	  to	  presented	  signals	  and	  stimuli(Place,	  Evans	  et	  al.	  2009).	  	  By	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engineering	  the	  biomaterial’s	  surface	  chemistry,	  topography,	  and	  physical	  characteristics	  it	  is	  possible	  to	  guide	  cellular	  behaviour	  from	  proliferation	  to	  differentiation.	  	  Similarly	  various	  growth	  factors	  and	  other	  signalling	  molecules	  can	  be	  integrated	  or	  loaded	  into	  the	  biomaterial	  to	  provide	  further	  cues	  for	  cell	  survival.	  	  The	  advantages	  of	  these	  strategies	  may	  contribute	  significantly	  to	  the	  success	  of	  any	  tissue	  engineering	  strategy.	  
Biomaterials	  have	  been	  used	  in	  several	  ways	  for	  the	  treatment	  of	  cardiac	  failure	  following	  myocardial	  infarction(Christman	  and	  Lee	  2006)	  (Figure	  1-­‐3).	  	  For	  example	  they	  have	  been	  used	  as	  a	  support	  for	  in	  vitro	  tissue	  engineering,	  where	  a	  cell-­‐scaffold	  construct	  is	  developed	  and	  grown	  outside	  of	  the	  body	  prior	  to	  surgical	  implantation.	  	  Alternatively	  they	  have	  been	  applied	  as	  a	  patch	  to	  the	  myocardium,	  thus	  allowing	  cell	  transfer	  as	  well	  as	  mechanical	  support	  via	  infarct	  restraint.	  	  Finally	  it	  is	  possible	  to	  directly	  inject	  a	  biomaterial	  in	  the	  form	  of	  a	  liquid	  gel	  directly	  into	  the	  myocardium.	  	  This	  gel	  can	  be	  loaded	  with	  cells	  and	  growth	  factors	  allowing	  tissue	  regeneration	  in	  situ.	  	  	  	  	  
	  
	   39	  
	  
Figure	  1-­‐3:	  	  Therapeutic	  strategies	  for	  biomaterials	  in	  heart	  failure.	  	  (a)	  Use	  of	  a	  polymer	  mesh	  as	  a	   ventricular	   restraint	   to	   prevent	   ventricular	   dilatation.	   (b)	   In	   vitro	   culturing	   of	   cells	   on	   a	  biomaterial	   scaffold	   prior	   to	   surgical	   attachment	   to	   the	   epicardium.	   (c)	  Direct	   intramyocardial	  injection	   of	   cells	   with	   biomaterial	   scaffold.	   (d)	   Direct	   intramyocardial	   injection	   of	   biomaterial	  alone.	   	   (e)	   Direct	   intramyocardial	   injection	   of	   other	   agents	   such	   as	   proteins	   or	   gene	   therapy.	  	  Source:	  Christman	  et	  al.	  (2006)	  J.	  Am.	  Coll.	  Cardiol.(Christman	  and	  Lee	  2006)	  
	  
A	  good	  early	  example	  of	  an	  injectable	  biomaterial	  system	  was	  described	  by	  Dai	  et	  
al.	  who	  demonstrated	  that	  simple	  injections	  of	  collagen	  into	  1	  week	  old	  rat	  myocardial	  infarcts	  resulted	  in	  significantly	  increased	  myocardial	  scar	  thickness	  compared	  with	  saline	  injected	  controls	  (Dai,	  Wold	  et	  al.	  2005).	  	  This	  corresponded	  with	  a	  significant	  increase	  in	  stroke	  volume	  and	  ejection	  fraction,	  with	  reduction	  in	  paradoxical	  systolic	  bulging	  in	  the	  collagen	  injected	  groups.	  	  Christman	  et	  al.	  went	  one	  step	  further	  and	  used	  fibrin	  glue	  combined	  with	  skeletal	  myoblasts	  in	  a	  rat	  model	  of	  myocardial	  ischaemia-­‐reperfusion	  	  (Christman,	  Fok	  et	  al.	  2004).	  	  Although	  injections	  did	  result	  in	  maintenance	  of	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fractional	  shortening	  and	  infarct	  thickness,	  no	  significant	  advantages	  of	  adding	  a	  cellular	  component	  were	  found.	  	  Kraehenbuehl	  et	  al.	  used	  an	  elegant	  combination	  of	  a	  matrix-­‐metalloproteinase	  responsive	  synthetic	  hydrogel,	  loaded	  with	  thymosin-­‐β4	  and	  human	  embryonic	  stem	  cell-­‐derived	  vascular	  cells	  to	  demonstrate	  that	  a	  combination	  of	  the	  three	  treatment	  arms	  produced	  the	  greatest	  beneficial	  effect	  in	  terms	  of	  infarct	  size,	  end	  diastolic	  volume,	  end	  systolic	  volume	  and	  ejection	  fraction	  (Kraehenbuehl,	  Ferreira	  et	  al.	  2010).	  
Cardiac	  patches	  have	  also	  been	  investigated	  extensively,	  with	  Chen	  et	  al.	  designing	  a	  polyglycerol	  sebacate	  (PGS)	  patch	  to	  match	  the	  mechanical	  properties	  of	  myocardium	  (Chen,	  Bismarck	  et	  al.	  2008).	  	  Although	  a	  stiff	  titanium-­‐enhanced	  version	  of	  this	  gel	  was	  shown	  to	  have	  deleterious	  effects	  on	  cardiac	  function	  (Stuckey,	  Ishii	  et	  al.	  2010),	  a	  softer	  PGS-­‐only	  version	  was	  able	  to	  support	  stem	  cell-­‐derived	  cardiomyocytes	  for	  up	  to	  3	  months,	  with	  absence	  of	  harmful	  effects	  upon	  cardiac	  function	  (Chen,	  Ishii	  et	  al.	  2010).	  
Picking	  the	  ideal	  biomaterial	  also	  requires	  an	  appreciation	  of	  its	  clinical	  implications.	  	  For	  example,	  creation	  of	  a	  cardiac	  patch	  to	  be	  applied	  to	  the	  surface	  of	  the	  heart	  would	  almost	  certainly	  require	  an	  invasive	  open	  chest	  procedure,	  with	  its	  associated	  morbidity.	  	  On	  the	  other	  hand,	  use	  of	  an	  injectable	  gel	  system	  could	  potentially	  be	  administered	  via	  minimally	  invasive	  catheter	  techniques,	  which	  in	  theory	  bring	  reduced	  risk	  to	  the	  patient.	  	  For	  this	  reason,	  injectable	  biomaterials	  have	  been	  the	  most	  extensively	  investigated.	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1.7	  Scope	  of	  the	  Thesis	  
This	  thesis	  is	  concerned	  with	  describing	  the	  creation	  of	  a	  tissue	  engineering	  strategy	  for	  the	  treatment	  of	  cardiac	  failure	  following	  a	  myocardial	  infarction.	  	  In	  recent	  years	  the	  initial	  excitement	  surrounding	  cell	  therapy	  for	  cardiac	  failure	  has	  been	  replaced	  by	  a	  degree	  of	  skepticism	  due	  to	  disappointing	  results	  from	  clinical	  trials,	  which	  demonstrate	  the	  effect	  of	  translational	  barriers.	  	  A	  broad	  tissue	  engineering	  strategy	  comprising	  of	  cells,	  biomaterial	  scaffolds	  and	  soluble	  factors	  is	  a	  promising	  way	  of	  addressing	  the	  issues	  of	  early	  cell	  death	  seen	  in	  many	  cell	  therapy	  experiments.	  	  The	  production	  of	  iPS	  cells	  along	  with	  advances	  in	  biomaterial	  science	  in	  particular	  may	  well	  pave	  the	  way	  for	  successful	  cardiac	  tissue	  engineering	  approaches	  in	  the	  future.	  	  	  
The	  aims	  of	  this	  series	  of	  experiments	  is	  threefold:	  
1) To	  develop	  and	  characterize	  an	  injectable	  biomaterial	  scaffold	  that	  is	  suitable	  for	  cardiac	  tissue	  regenerative	  strategies	  2) To	  identify	  suitable	  protective	  factors	  that	  can	  serve	  to	  improve	  survival	  of	  donor	  iPS-­‐CM.	  3) To	  investigate	  the	  effects	  of	  a	  combined	  tissue	  regeneration	  strategy	  on	  cardiac	  function	  following	  MI.	  
This	  thesis	  consists	  of	  a	  general	  methods	  chapter	  (Chapter	  2)	  followed	  by	  5	  experimental	  chapters	  (Chapters	  3-­‐7)	  describing	  the	  compilation	  of	  an	  integrated	  tissue	  engineering	  strategy.	  
The	  first	  experimental	  chapter	  (Chapter	  3):	  Hydrogel	  Development	  and	  
Characterization	  describes	  the	  creation	  and	  characterization	  of	  an	  injectable	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polyethylene	  glycol	  (PEG)-­‐based	  hydrogel	  scaffold.	  	  Close	  attention	  was	  paid	  to	  gelation	  and	  degradation	  kinetics,	  mechanical	  properties,	  ease	  of	  modification,	  and	  biocompatibility	  of	  the	  hydrogel,	  as	  these	  properties	  are	  crucial	  to	  plan	  translation	  to	  clinical	  use.	  	  	  
The	  second	  experimental	  chapter	  (Chapter	  4):	  The	  effects	  of	  intramyocardial	  
hydrogel	  injections	  on	  the	  healthy	  heart	  describes	  the	  investigation	  of	  how	  PEG	  hydrogel	  injections	  may	  affect	  the	  heart.	  	  	  Particular	  areas	  of	  interest	  were	  how	  hydrogel	  injections	  would	  affect	  cardiac	  electrical	  activity,	  as	  well	  as	  ventricular	  pump	  activity.	  	  Detrimental	  effects	  in	  these	  key	  cardiac	  functions	  would	  preclude	  use	  of	  this	  strategy	  in	  further	  experiments.	  	  	  
The	  third	  experimental	  chapter	  (Chapter	  5):	  The	  Protective	  Effects	  of	  
Erythropoietin	  describes	  the	  investigation	  of	  erythropoietin	  (Epo)	  as	  a	  potential	  protective	  factor	  within	  a	  cardiac	  tissue	  engineering	  strategy.	  	  Epo	  was	  chosen	  due	  to	  several	  recent	  studies	  demonstrating	  its	  protective	  effects	  on	  many	  tissue	  types	  including	  myocardium.	  	  	  
The	  fourth	  experimental	  chapter	  (Chapter	  6):	  Establishing	  the	  in	  vivo	  rat	  
model	  of	  Myocardial	  Infarction	  describes	  the	  set	  up	  of	  this	  animal	  model.	  	  Left	  anterior	  descending	  artery	  ligation	  was	  investigated,	  with	  measurement	  of	  myocardial	  infarct	  size	  and	  ventricular	  function	  to	  ensure	  adequate,	  consistent	  and	  reproducible	  effects.	  	  	  	  	  
The	  final	  experimental	  chapter	  (Chapter	  7):	  Tissue	  Engineering	  Strategies	  for	  
cardiac	  failure	  in	  a	  rat	  model	  of	  Myocardial	  Infarction	  describes	  the	  combination	  of	  iPS-­‐CM,	  PEG	  hydrogel	  and	  Epo	  in	  a	  treatment	  strategy	  using	  a	  rat	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Materials	  and	  Methods	  
	  
2.1	  Rheology	  
2.1.1	  Rheology	  -­‐	  Background	  
Rheology	  is	  the	  study	  of	  flow	  of	  matter,	  and	  within	  materials	  science	  is	  often	  used	  to	  study	  the	  viscoelastic	  properties	  of	  a	  material.	  	  Viscoelasticity	  is	  the	  property	  of	  materials	  that	  exhibit	  both	  viscous	  and	  elastic	  characteristics	  when	  undergoing	  deformation.	  	  Viscous	  materials,	  like	  honey,	  resist	  shear	  flow	  and	  will	  exhibit	  strain	  in	  a	  linear	  fashion	  with	  time	  when	  a	  stress	  is	  applied	  to	  them.	  	  Elastic	  materials,	  like	  a	  rubber	  band,	  strain	  instantaneously	  when	  stressed,	  and	  return	  to	  their	  normal	  state	  when	  the	  stress	  is	  removed.	  	  A	  viscoelastic	  material	  has	  elements	  of	  both	  properties.	  
Rheology	  is	  the	  primary	  experimental	  method	  by	  which	  researchers	  investigate	  the	  viscoelastic	  properties	  of	  hydrogels.	  	  This	  is	  performed	  using	  a	  rheometer,	  which	  carries	  out	  small	  deformation	  experiments	  on	  a	  material,	  typically	  in	  the	  form	  of	  small	  amplitude	  oscillatory	  shear	  (SAOS)	  measurements.	  	  Small	  deformations	  are	  used	  to	  ensure	  that	  measurements	  are	  carried	  out	  within	  the	  linear	  viscoelastic	  region	  of	  a	  material.	  	  This	  means	  that	  the	  measured	  hydrogel	  properties	  will	  be	  independent	  of	  the	  magnitude	  of	  imposed	  strain	  or	  stress	  –	  ie:	  the	  results	  are	  not	  affected	  by	  the	  experimental	  variables,	  but	  purely	  by	  the	  material	  tested.	  	  	  
With	  SAOS	  measurements,	  a	  shear	  strain	  is	  applied	  to	  the	  hydrogel	  sample	  in	  a	  sinusoidal	  oscillation,	  and	  the	  resultant	  shear	  stress	  is	  measured	  from	  the	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hydrogel.	  	  The	  measured	  shear	  stress	  can	  be	  seen	  as	  a	  phase-­‐shifted	  sine	  wave	  with	  the	  phase	  difference	  denoted	  as	  δ.	  	  For	  a	  purely	  elastic	  material,	  the	  strain	  and	  stress	  waves	  are	  in	  phase	  (δ=0°)	  whilst	  a	  purely	  viscous	  material	  shows	  the	  two	  waves	  completely	  out	  of	  phase	  (δ=90°).	  	  A	  viscoelastic	  material	  will	  demonstrate	  δ	  between	  the	  two(Yan	  and	  Pochan)	  (Figure	  2-­‐1).	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Figure	  2-­‐2:	  	  Rheological	  relationships	  of	  the	  storage	  modulus	  (G’),	  loss	  modulus	  (G’’)	  and	  loss	  factor	  (tanδ).	  	  G’	  gives	  a	  measure	  of	  the	  elastic	  (solid)	  properties	  of	  a	  material.	  G’’	  gives	  a	  measure	  of	  the	  visous	  (liquid)	  properties	  of	  a	  material.	  	  If	  G’>G’’	  the	  material	  behaves	  more	  like	  a	  solid.	  	  If	  G’’>G’	  the	  material	  behaves	  more	  like	  a	  liquid.	  
	  
In	  the	  case	  of	  hydrogel	  materials,	  G’,	  G’’	  and	  tanδ	  are	  usually	  measured	  against	  time,	  strain	  and	  frequency.	  	  Measuring	  the	  evolution	  of	  G’	  and	  G’’	  against	  time	  allows	  the	  observation	  of	  the	  gelation	  process.	  	  Monitoring	  G’	  and	  G’’	  against	  strain	  demonstrates	  the	  linear	  viscoelastic	  region	  of	  the	  hydrogel	  whereby	  G’	  and	  G’’	  are	  independent	  of	  shear	  strain.	  	  Measurement	  of	  G’	  and	  G’’	  at	  short	  and	  long	  frequencies	  is	  also	  important	  as	  materials	  can	  act	  as	  a	  solid	  at	  high	  frequencies	  and	  as	  a	  liquid	  at	  low	  frequencies.	  	  These	  factors	  as	  well	  as	  the	  final	  gel	  stiffness	  are	  very	  important	  properties	  of	  the	  hydrogel	  which	  will	  influence	  the	  uses	  of	  the	  material.	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2.1.2	  Rheology	  –	  Methods	  
Rheology	  experiments	  were	  carried	  out	  using	  an	  AR	  2000ex	  rheometer	  (TA	  Instruments,	  Crawley,	  West	  Sussex,	  England).	  	  Experiments	  were	  performed	  using	  parallel	  plate	  geometry	  (8mm	  to	  25mm)	  at	  37°C.	  	  	  
	  
2.2	  Cell	  lines	  
The	  cell	  lines	  used	  in	  these	  experiments	  were	  isolated	  rat	  bone	  marrow	  cells	  (RBMC),	  induced	  pluripotent	  stem	  cell	  derived	  cardiomyocytes	  (iPS-­‐CM).	  
	  
2.2.1	  Rat	  Bone	  Marrow	  Stromal	  Cells	  (RBMC)	  
2.2.1.1	  	  RBMC	  Isolation	  Procedure	  
RBMCs	  were	  isolated	  from	  the	  femurs	  of	  adult	  Sprague	  Dawley	  Rats.	  	  These	  were	  sacrificed	  via	  a	  schedule	  1	  method	  and	  transferred	  immediately	  to	  the	  cell	  laboratory.	  	  All	  subsequent	  work	  was	  performed	  in	  aseptic	  conditions	  under	  an	  extractor	  hood.	  
Rat	  carcasses	  were	  sprayed	  down	  thoroughly	  with	  70%	  ethanol.	  	  Using	  a	  sterile	  scalpel	  blade	  the	  femur	  was	  dissected	  free.	  	  The	  femur	  was	  cleaned	  of	  excess	  soft	  tissue	  by	  scraping	  with	  the	  scalpel	  blade.	  	  The	  cleaned	  femur	  was	  then	  transferred	  to	  a	  petri	  dish.	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The	  femur	  was	  washed	  thoroughly	  with	  sterile	  phosphate	  buffered	  saline	  (PBS),	  using	  forceps	  to	  remove	  any	  last	  remaining	  pieces	  of	  soft	  tissue,	  before	  transferring	  again	  to	  a	  fresh	  petri	  dish.	  	  This	  washing	  step	  was	  repeated	  twice.	  
The	  femur	  was	  next	  transferred	  to	  a	  petri	  dish	  containing	  a	  solution	  of	  20%	  penicillin	  in	  PBS.	  	  This	  was	  left	  in	  the	  cell	  culture	  hood	  under	  ultraviolet	  (UV)	  light	  for	  5	  minutes	  with	  the	  lid	  of	  the	  petri	  dish	  removed.	  
Following	  a	  further	  wash	  step	  with	  PBS	  in	  a	  fresh	  petri	  dish,	  the	  femur	  was	  held	  with	  forceps	  and	  using	  sterile	  scissors	  the	  epiphyses	  were	  cut	  away.	  	  	  
Using	  a	  20ml	  syringe	  and	  22G	  needle,	  the	  marrow	  cavity	  was	  flushed	  with	  20ml	  of	  alpha-­‐minimum	  essential	  media	  solution	  (α-­‐MEM,	  Sigma	  Aldrich)	  into	  a	  50ml	  centrifuge	  tube.	  	  Care	  was	  taken	  to	  flush	  the	  marrow	  cavity	  from	  both	  ends	  and	  to	  use	  the	  needle	  tip	  to	  scrape	  the	  inside	  of	  the	  marrow	  cavity	  to	  free	  up	  adherent	  cells.	  	  The	  femur	  was	  noted	  to	  turn	  opaque	  when	  flushing	  was	  complete.	  
The	  marrow	  contents	  were	  titurated	  with	  a	  syringe	  and	  needle	  to	  break	  up	  the	  bone	  marrow	  particles	  before	  being	  transferred	  to	  cell	  culture	  flasks.	  	  Cell	  cultures	  were	  left	  for	  4	  days	  before	  exchanging	  media	  with	  filtered	  complete	  growth	  medium	  (CGM,	  88%	  α-­‐MEM,	  10%	  Foetal	  Bovine	  Serum,	  1%	  Penicillin/Streptomycin,	  1%	  L-­‐Glutamine).	  	  Bone	  marrow	  stromal	  cells	  were	  separated	  in	  culture	  from	  haemopoietic	  cells	  by	  their	  adhesion	  to	  tissue	  culture	  plastic	  (Krebsbach,	  Kuznetsov	  et	  al.	  1999).	  	  Typically	  by	  day	  7-­‐10	  RBMC	  cultures	  were	  near	  confluent	  and	  ready	  for	  passaging.	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2.2.1.2	  	  RBMC	  Passaging	  Procedure	  
RBMC	  cultures	  were	  passaged	  under	  aseptic	  conditions	  	  when	  approximately	  70-­‐80%	  confluent	  by	  visual	  inspection.	  	  	  
Media	  was	  aspirated	  from	  the	  cell	  cultures	  and	  cells	  were	  washed	  twice	  with	  sterile	  PBS	  for	  2	  minutes.	  	  Following	  aspiration	  of	  the	  PBS,	  	  trypsin	  –EDTA	  was	  added	  to	  the	  cultures	  taking	  care	  to	  cover	  the	  culture	  surface	  evenly.	  	  The	  cultures	  were	  left	  in	  the	  incubator	  at	  37°C	  for	  3-­‐5	  minutes.	  	  	  
Trypsinisation	  was	  checked	  periodically	  under	  a	  light	  microscope	  to	  view	  detachment	  with	  tapping	  of	  the	  cell	  culture	  flask	  as	  required.	  	  Trypsin	  was	  neutralized	  using	  a	  2-­‐3x	  excess	  of	  serum	  containing	  media	  (CGM).	  	  The	  cell	  mixture	  was	  titurated	  several	  times	  to	  ensure	  the	  majority	  of	  cells	  were	  detatched	  and	  in	  solution.	  
The	  cell	  mixture	  was	  transferred	  to	  an	  appropriate	  centrifuge	  tube	  and	  centrifuged	  for	  5	  minutes	  at	  500rpm.	  	  The	  supernatant	  was	  removed	  carefully	  and	  the	  cell	  pellet	  resuspended	  gently	  in	  10ml	  of	  CGM	  prior	  to	  cell	  counting	  using	  a	  haemacytometer.	  
Cells	  were	  either	  frozen	  down	  or	  reseeded	  at	  a	  density	  of	  1,000	  –	  1,500	  cells/cm2.	  	  Cells	  were	  only	  used	  for	  experiments	  between	  passages	  1	  and	  5.	  
	  
2.2.2	  	  Induced	  Pluripotent	  Stem	  Cell	  Derived	  Cardiomyocytes	  (iPS-­‐CM)	  
iPS-­‐CM	  were	  purchased	  frozen	  from	  Cellular	  Dynamics	  International	  (CDI,	  Madison,	  USA).	  	  This	  cell	  line	  consists	  of	  highly	  purified	  human	  cardiomyoctes	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derived	  from	  induced	  pluripotent	  stem	  (iPS)	  cells	  via	  CDI’s	  proprietary	  differentiation	  and	  purification	  protocols.	  	  iPS	  cells	  are	  derived	  from	  human	  fibroblasts	  based	  upon	  methods	  described	  by	  Yu	  et	  al.	  who	  utilized	  an	  oriP/EBNA1	  episomal	  vector	  to	  express	  reprogramming	  factors:	  OCT4,	  SOX2,	  
NANOG,	  LIN28,	  c-­‐Myc	  ,	  KLF4,	  and	  SV40LT.	  	  The	  advantages	  of	  this	  method	  are	  the	  gains	  in	  transfection	  efficiency	  as	  well	  as	  the	  lack	  of	  permanent	  integration	  into	  the	  genome,	  removing	  the	  risk	  of	  insertional	  mutogenesis	  and	  allowing	  the	  simple	  removal	  of	  plasmids	  by	  culturing	  in	  the	  absence	  of	  drug	  selection(Yu,	  Hu	  et	  al.	  2009).	  
Cardiomyocyte	  differentiation	  is	  perfomed	  using	  monomeric	  red	  fluorescent	  protein	  (mRFP)	  expression	  and	  blasticidin	  resistance,	  under	  the	  control	  of	  the	  alpha-­‐myosin	  heavy	  chain	  (Myh6)	  promoter,	  allowing	  simultaneous	  cardiomyocyte	  purification	  and	  identification.	  
Studies	  utilizing	  iPS-­‐CM	  have	  investigated	  their	  similarities	  to	  embryonic-­‐derived	  and	  adult	  cardiomyocyte	  characteristics.	  	  Firstly	  the	  appropriate	  expression	  of	  myofilament	  proteins	  and	  sarcomeric	  organization	  have	  been	  demonstrated	  using	  immunolabelling	  techniques	  (figure	  2-­‐3)	  (Zhang,	  Wilson	  et	  al.	  2009,	  Ma,	  Guo	  et	  al.	  2011).	  	  Spontaneously	  contracting	  iPS-­‐CM	  also	  produce	  ventricular,	  atrial	  and	  nodal	  action	  potentials,	  with	  ventricular	  action	  potentials	  being	  the	  most	  common	  (Zhang,	  Wilson	  et	  al.	  2009,	  Ma,	  Guo	  et	  al.	  2011).	  	  	  	  Electrical	  stimulation	  of	  iPS-­‐CM	  also	  results	  in	  the	  normal	  compensatory	  decrease	  in	  action	  potential	  duration	  with	  β-­‐adrenergic	  stimulation	  using	  isoproterenol	  giving	  a	  positive	  chronotropic	  effect	  and	  shortening	  of	  action	  potential	  durations,	  as	  would	  be	  expected	  from	  adult	  cardiomyocytes	  (Zhang,	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Wilson	  et	  al.	  2009).	  	  The	  voltage	  dependence	  of	  ion	  channel	  gating	  properties	  were	  also	  found	  to	  be	  very	  similar	  to	  human	  cardiac	  myoctes	  (Ma,	  Guo	  et	  al.	  2011).	  	  
Therefore	  these	  cells	  are	  thought	  to	  provide	  a	  novel	  and	  reliable	  source	  of	  human	  cardiomyocytes	  for	  scientific	  research.	  	  	  
	  
Figure	  2-­‐3:	  	  Immunolabelling	  of	  iPS-­‐CM.	  	  A	  –	  iPS-­‐CM	  monolayer	  stained	  for	  sarcomeric	  actinin	  (red)	  with	  anti-­‐nucleic	  acid	  stain	  (blue).	  	  Scale	  bar	  =	  50µm.	  	  Higher	  magnification	  demonstrates	  the	  sarcomeric	  structure	  (inset,	  scale	  bar	  20µm)	  [images	  from	  Ma,	  Guo	  et	  al.	  2011].	  	  B	  –	  iPS-­‐CM	  stained	  for	  cardiac	  Troponin	  T	  (cTnT	  –	  green),	  with	  nuclear	  Hoechst	  stain	  (blue).	  Scale	  bar	  =	  50µm.	  [images	  from	  Zhang,	  Wlison	  et	  al.	  2009]	  
	  
2.2.2.1	  	  Thawing	  and	  plating	  of	  iPS-­‐CM	  
iPS-­‐CM	  were	  thawed	  according	  to	  manufacturer’s	  instructions.	  	  In	  brief,	  vials	  of	  iPS-­‐CM	  were	  stored	  in	  the	  vapour	  phase	  of	  liquid	  nitrogen	  until	  immediately	  before	  thawing.	  	  These	  were	  thawed	  for	  4	  minutes	  in	  a	  37°C	  waterbath	  before	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spraying	  with	  70%	  ethanol	  and	  transfer	  to	  the	  cell	  culture	  hood.	  	  Cells	  were	  gently	  transferred	  to	  a	  50ml	  centrifuge	  tube	  using	  a	  1ml	  pipette.	  	  The	  cell	  vial	  was	  rinsed	  with	  1ml	  of	  CDI	  plating	  medium,	  which	  was	  added	  to	  the	  cells	  dropwise.	  	  A	  further	  8mls	  of	  plating	  media	  was	  then	  added	  slowly	  to	  the	  cell	  mixture	  prior	  to	  mixing	  by	  inversion.	  	  Viable	  cells	  were	  counted	  using	  a	  haemocytometer	  and	  trypan	  blue	  exclusion.	  	  Using	  the	  plating	  efficiency	  data	  provided	  by	  CDI	  (batch	  specific)	  iPS-­‐CM	  were	  plated	  onto	  0.1%	  gelatin	  coated	  surfaces	  at	  a	  density	  of	  47,000	  –	  63,000	  cells	  per	  cm2.	  	  	  
Cell	  cultures	  were	  kept	  in	  an	  incubator	  at	  37°C	  for	  48	  hours	  before	  the	  first	  media	  exchange.	  	  At	  this	  time	  cultures	  were	  washed	  with	  CDI	  maintenance	  media	  3	  times	  to	  remove	  cell	  debris	  before	  being	  covered	  with	  CDI	  maintenance	  media.	  	  Media	  was	  changed	  every	  48	  hours.	  	  Following	  this	  protocol	  cells	  formed	  a	  beating	  syncitium	  within	  5-­‐7	  days.	  	  For	  these	  experiments	  iPS-­‐CM	  were	  used	  7-­‐10	  days	  after	  initial	  thawing	  and	  plating.	  	  	  
	  
2.3	  	  Animal	  Models	  
In-­‐Vivo	  experiments	  were	  carried	  out	  using	  either	  Sprague	  Dawley	  rats	  or	  Nude	  Rats.	  
	  
2.3.1	  Sprague	  Dawley	  Rats	  
Sprague	  Dawley	  rats	  (Figure	  2-­‐4)	  are	  an	  outbred	  strain	  of	  albino	  rats	  first	  bred	  in	  Madison,	  Wisconsin,	  in	  1925.	  	  They	  are	  extensively	  used	  in	  medical	  research	  due	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to	  their	  ease	  of	  handling	  and	  calm	  nature,	  and	  are	  well	  established	  as	  a	  reliable	  strain	  for	  physiological	  experiments	  involving	  the	  cardiovascular	  system.	  	  Although	  outbreeding	  does	  introduce	  a	  degree	  of	  genetic	  variation,	  the	  Sprague	  Dawley	  strain	  was	  initially	  derived	  by	  inbreeding	  over	  many	  generations,	  thus	  limiting	  the	  current	  genetic	  variability	  between	  animals.	  	  This	  allows	  a	  relatively	  stable	  strain,	  giving	  an	  excellent	  model	  for	  studies	  of	  physiology	  and	  disease,	  whilst	  minimizing	  costs	  compared	  with	  genetically	  inbred	  rat	  strains.	  	  	  
The	  typical	  lifespan	  of	  a	  Sprague	  Dawley	  rat	  is	  2.5	  to	  3.5	  years,	  with	  an	  adult	  body	  weight	  of	  250-­‐300g	  for	  females	  and	  450-­‐520g	  for	  males.	  	  Normal	  heart	  rate	  is	  250-­‐450	  beats	  per	  minute	  with	  a	  respiratory	  rate	  of	  75-­‐115	  breaths	  per	  minute.	  
For	  the	  course	  of	  these	  experiments	  Sprague	  Dawley	  rats	  were	  purchased	  from	  Harlan	  Laboratories,	  United	  Kingdom.	  	  They	  were	  housed	  in	  a	  stable	  environment	  with	  a	  12/12	  light/dark	  cycle	  with	  access	  to	  rodent	  chow	  and	  fresh	  drinking	  water.	  	  All	  animals	  were	  allowed	  to	  acclimatize	  for	  7	  days	  prior	  to	  commencement	  of	  experimental	  procedures.	  
	  
	  
Figure	  2-­‐4:	  	  The	  Sprague	  Dawley	  Rat.	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2.3.2	  Nude	  Rats	  
The	  Nude	  rat	  is	  also	  commonly	  known	  as	  the	  Rowett	  nude	  rat,	  Athymic	  rat,	  and	  
rnu	  rat	  (Figure	  2-­‐5).	  	  This	  strain	  was	  originally	  developed	  at	  the	  National	  Institutes	  of	  Health	  in	  1979-­‐1980	  through	  a	  series	  of	  matings	  in	  which	  the	  Rowett	  nude	  gene	  was	  crossed	  with	  8	  inbred	  rat	  strains.	  	  The	  nude	  trait	  is	  transmitted	  in	  an	  autosomal	  recessive	  manner	  with	  the	  homozygous	  rat	  being	  athymic,	  T-­‐Cell	  deficient,	  and	  having	  depleted	  cell	  populations	  in	  the	  thymus-­‐dependent	  areas	  of	  the	  peripheral	  lymphoid	  organs.	  	  The	  rat	  has	  a	  normal	  component	  of	  bone-­‐marrow	  dependent	  B-­‐cells.	  	  The	  Nude	  rat	  is	  commonly	  used	  for	  experiments	  involving	  tumour	  biology,	  immunology	  and	  xenograft	  research.	  
For	  the	  course	  of	  these	  experiments	  Nude	  rats	  were	  purchased	  from	  Charles	  River	  Limited,	  Germany.	  	  They	  were	  kept	  in	  autoclaved	  cages	  in	  a	  stable	  environment	  with	  a	  12/12	  light/dark	  cycle.	  	  Animals	  had	  access	  to	  irradiated	  rat	  chow	  and	  autoclaved	  drinking	  water.	  	  All	  animals	  were	  allowed	  to	  acclimatize	  for	  7	  days	  prior	  to	  the	  commencement	  of	  experimental	  procedures.	  	  	  
	  
	  
Figure	  2-­‐5:	  	  The	  Nude	  Rat.	  	  Also	  commonly	  known	  as	  the	  Rowett	  nude	  rat,	  athymic	  rat,	  and	  rnu	  rat.	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2.3.3	  The	  Langendorff	  	  (Isolated	  Perfused	  Rat	  Heart)	  Model	  	  
The	  model	  of	  the	  isolated	  perfused	  mammalian	  heart	  was	  developed	  in	  1897(Skrzypiec-­‐Spring,	  Grotthus	  et	  al.	  2007)	  and	  has	  been	  refined	  in	  several	  ways	  since.	  	  It	  remains	  a	  popular	  method	  by	  which	  to	  study	  cardiac	  physiology.	  	  Multiple	  species	  have	  been	  used	  as	  the	  source	  animal	  for	  this	  model	  including	  mouse,	  guinea	  pig	  and	  rabbit,	  although	  rat	  hearts	  are	  the	  most	  commonly	  used	  and	  therefore	  the	  best	  characterized.	  	  The	  essential	  principle	  is	  the	  delivery	  of	  blood	  or	  perfusion	  solution	  via	  a	  cannula	  inserted	  into	  the	  ascending	  aorta.	  	  Retrograde	  flow	  down	  the	  aorta	  causes	  closure	  of	  the	  aortic	  valve	  allowing	  perfusion	  of	  the	  myocardium	  through	  the	  coronary	  arteries.	  	  The	  solution	  or	  blood	  then	  flows	  into	  the	  cardiac	  chambers	  (right	  atrium)	  via	  the	  coronary	  sinus.	  	  Continual	  perfusion	  can	  be	  maintained	  either	  by	  constant	  hydrostatic	  pressure,	  or	  via	  constant	  flow	  using	  a	  pump	  (Figure	  2-­‐6).	  	  	  
The	  advantages	  of	  this	  model	  are	  the	  following:	  it	  can	  produce	  highly	  consistent	  results,	  with	  low	  cost,	  and	  fast	  turnover.	  	  It	  allows	  a	  wide	  variety	  of	  physiological,	  biochemical	  and	  pharmacological	  experiments	  to	  be	  conducted.	  	  The	  Langendorff	  heart	  is	  free	  from	  most	  confounding	  variables	  that	  affect	  cardiac	  function	  in	  vivo,	  with	  responses	  from	  neuro-­‐hormonal	  stimulation	  and	  vascular	  coupling	  being	  much	  reduced.	  	  This	  allows	  the	  investigation	  of	  myocardial	  physiology	  independently	  using	  a	  whole	  intact	  organ.	  	  	  
However,	  the	  clinical	  extrapolation	  of	  results	  from	  the	  Langendorff	  model	  can	  be	  called	  into	  question	  given	  the	  isolated	  nature	  of	  the	  preparation,	  which	  is	  thus	  an	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advantage	  and	  disadvantage.	  	  Similarly,	  the	  Langendorff	  heart	  is	  not	  in	  a	  stable	  state	  despite	  the	  use	  of	  constant	  tissue	  perfusion.	  	  The	  myocardial	  tissue	  will	  deteriorate	  continuously,	  becoming	  more	  oedematous	  with	  time.	  	  The	  window	  for	  obtaining	  usable	  data	  therefore	  is	  limited,	  and	  experiments	  must	  be	  carefully	  designed	  and	  executed	  because	  of	  this.	  	  The	  Langendorff	  heart	  is	  also	  unloaded,	  with	  the	  influences	  of	  left	  ventricular	  filling	  pressures	  on	  myocardial	  contraction	  being	  lost,	  as	  well	  as	  the	  effects	  of	  interaction	  with	  the	  right	  ventricle.	  





	   59	  
	  
Figure	   2-­‐6:	   	   A	   schematic	   diagram	   demonstrating	   the	   layout	   of	   the	   Langendorff	   circuit.	   	   A	  mammalian	   heart	   is	   perfused	   through	   the	   ascending	   aorta	   with	   perfusion	   solution,	   allowing	  perfusion	  of	  the	  myocardium	  through	  the	  coronary	  arteries.	  	  Continual	  perfusion	  is	  provided	  by	  either	   hydrostatic	   pressure	   or	   pump.	   	   Electrical	   activity	   of	   the	   heart	   can	   be	  measured	   directly	  with	  electrodes	  attached	  to	  the	  myocardium.	  	  Left	  ventricular	  pressure	  can	  be	  estimated	  through	  the	  insertion	  of	  a	  left	  ventricular	  balloon	  attached	  to	  a	  transducer.	  	  Source:	  Skrzypiec-­‐Spring	  et	  al.	  (2007)	  J.	  Pharmacol.	  Toxicol.	  Methods.	  
	  
2.3.4	  	  The	  Langendorff	  Model	  –	  Set	  up	  
The	  Langendorff	  circuit	  was	  prepared	  as	  described	  previously(Skrzypiec-­‐Spring,	  Grotthus	  et	  al.	  2007).	  	  In	  brief:	  a	  male	  Sprague	  Dawley	  Rat	  (weight	  250-­‐350g)	  was	  terminally	  anaesthetized	  with	  isoflurane	  and	  culled	  using	  Schedule	  1	  techniques.	  	  The	  heart	  was	  rapidly	  excised	  and	  placed	  in	  heparinised	  ice	  cold	  Krebs	  buffer	  (200-­‐300	  units	  in	  40ml	  ice	  cold	  Kreb’s	  buffer,	  NaCl	  118.5mM,	  NaHCO3	  25mM,	  KCl	  4.7mM,	  MgSO4	  1.2mM,	  KH2PO4	  1.2mM,	  glucose	  11mM,	  CaCl2	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2.5mM).	  	  The	  heart	  was	  transferred	  to	  a	  Petri	  dish	  with	  ice	  cold	  Kreb’s,	  and	  dissected	  free	  of	  excess	  soft	  tissue.	  	  The	  aorta	  was	  transected	  to	  expose	  the	  aortic	  root,	  which	  was	  slipped	  over	  a	  cannula	  attached	  to	  the	  Langendorff	  circuit	  and	  secured	  with	  a	  silk	  tie.	  	  The	  cannula	  was	  connected	  to	  the	  outflow	  of	  a	  reservoir	  containing	  oxygenated	  Kreb’s	  solution(Sutherland	  and	  Hearse	  2000)	  at	  37°C.	  	  The	  perfusion	  solution	  was	  delivered	  down	  the	  aortic	  root	  by	  constant	  hydrostatic	  pressure	  (100-­‐110	  cm	  H20),	  thus	  closing	  the	  aortic	  leaflet	  and	  allowing	  flow	  of	  the	  perfusion	  solution	  down	  the	  coronary	  arteries.	  	  	  
Once	  the	  circuit	  was	  set	  up,	  the	  heart	  was	  allowed	  to	  stabilize	  for	  5-­‐10	  minutes	  until	  beating	  regularly.	  	  Experiments	  were	  conducted	  within	  the	  following	  20-­‐30	  minutes	  before	  signs	  of	  myocardial	  deterioration	  (arrhythmias,	  and	  mottling	  of	  the	  myocardial	  surface)	  were	  evident.	  	  
	  
2.3.5	  	  Anaesthesia,	  Peri-­‐operative	  and	  Post-­‐operative	  management	  
Studies	  were	  performed	  on	  Sprague	  Dawley	  male	  rats	  (200-­‐250g)	  or	  Nude	  male	  rats	  (6-­‐7	  weeks	  age,	  approx	  150-­‐200g).	  
Induction	  of	  anaesthesia	  was	  performed	  by	  inhalation	  of	  a	  5%	  isoflurane	  +	  95%	  oxygen	  mix,	  performed	  in	  a	  closed	  induction	  chamber.	  	  On	  completion	  of	  induction	  the	  rat	  was	  transferred	  to	  a	  Bain	  coaxial	  circuit	  and	  maintained	  on	  5%	  isoflurane.	  	  The	  left	  anterior	  chest	  wall	  was	  shaved	  using	  an	  electric	  shaver.	  
Intubation	  was	  performed	  directly	  using	  the	  hanging	  teeth	  method.	  	  The	  rat	  was	  placed	  supine	  on	  a	  polystyrene	  board,	  and	  the	  neck	  extended	  using	  an	  elastic	  band	  looped	  over	  the	  front	  teeth.	  	  Under	  direct	  illumination	  the	  vocal	  cords	  were	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visualized	  and	  a	  16G	  intravenous	  cannula	  with	  blunted	  stilette	  (used	  as	  an	  endotracheal	  tube)	  was	  passed	  across	  the	  vocal	  cords.	  	  The	  endotracheal	  cannula	  was	  attached	  to	  a	  Harvard	  Small	  Animal	  Ventilator	  (Model	  683,	  Harvard	  Apparatus,	  Massachusetts,	  USA),	  and	  the	  animal	  was	  ventilated	  using	  volume	  controlled	  ventilation	  at	  a	  ventilatory	  rate	  of	  80-­‐90	  breaths	  per	  minute,	  with	  a	  tidal	  volume	  of	  1.5-­‐2.0ml.	  	  This	  gave	  a	  minute	  volume	  of	  120ml	  –	  180ml/minute.	  	  Accurate	  intubation	  was	  confirmed	  by	  observing	  chest	  wall	  movements,	  as	  well	  as	  observing	  the	  abdomen	  for	  signs	  of	  gastric	  insufflation.	  	  In	  the	  case	  of	  oesophageal	  intubation,	  the	  endotracheal	  cannula	  was	  removed,	  and	  the	  rat	  was	  replaced	  in	  the	  induction	  chamber	  for	  a	  further	  attempt	  at	  intubation.	  	  	  
Upon	  successful	  endotracheal	  intubation,	  the	  rat	  was	  transferred	  to	  the	  operating	  field,	  and	  placed	  supine	  on	  a	  heating	  pad.	  	  The	  endotracheal	  tube	  was	  secured	  in	  place	  using	  adhesive	  tape.	  	  	  The	  forelegs	  were	  taped	  spread	  to	  the	  sides	  in	  a	  cruciform	  position,	  and	  the	  hind-­‐quarters	  rotated	  to	  lie	  on	  their	  right	  side	  with	  the	  hind-­‐legs	  taped	  together	  (Figure	  2-­‐7).	  	  This	  allowed	  excellent	  access	  to	  the	  left	  side	  of	  the	  chest.	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Figure	  2-­‐7:	  	  Operative	  positioning	  of	  the	  rat.	  	  The	  forelegs	  are	  taped	  outstretched	  in	  a	  cruciform	  position.	  	  The	  hind-­‐legs	  are	  taped	  together	  with	  the	  hindquarters	  rotated	  to	  the	  right.	  	  This	  gives	  exposure	  to	  the	  anterior	  left	  chest	  wall.	  
	  
Prior	  to	  commencing	  surgery	  prophylactic	  antibiotics	  were	  administered	  in	  the	  form	  of	  enrofloxacin	  (5mg/kg	  by	  intramuscular	  injection)	  and	  analgesia	  given	  in	  the	  form	  of	  buprenorphine	  (0.1mg/kg	  by	  intramuscular	  injection).	  
Anaesthesia	  was	  maintained	  using	  2%	  isoflurane	  /	  98%	  oxygen	  unless	  stated	  otherwise.	  	  Aseptic	  conditions	  were	  maintained	  throughout	  all	  procedures.	  	  The	  shaved	  area	  was	  cleaned	  using	  1%	  Chlorhexidine,	  and	  the	  operative	  field	  prepared	  with	  sterile	  drapes.	  	  All	  surgical	  instruments	  were	  autoclaved	  prior	  to	  surgery.	  	  Surgery	  for	  Nude	  rats	  was	  performed	  under	  an	  extractor	  hood.	  
On	  completion	  of	  cardiac	  surgery	  a	  brief	  period	  of	  continuous	  positive	  airway	  pressure	  (CPAP)	  was	  applied	  by	  temporary	  constriction	  of	  the	  ventilator	  exit	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pipe	  for	  2-­‐3	  ventilatory	  cycles	  to	  optimize	  lung	  expansion.	  	  The	  surgical	  wound	  was	  cleaned	  with	  1%	  Chlorhexidine.	  	  In	  the	  case	  of	  excessive	  intra-­‐operative	  bleeding	  a	  2ml	  bolus	  of	  warm	  saline	  was	  administered	  by	  subcutaneous	  injection.	  	  Animals	  were	  weaned	  from	  the	  ventilator	  on	  100%	  oxygen,	  and	  transferred	  spontaneously	  breathing	  to	  the	  Bain	  coaxial	  circuit.	  	  The	  endotracheal	  tube	  was	  removed	  after	  the	  animal	  had	  regained	  consciousness.	  
Following	  extubation	  the	  animal	  was	  placed	  in	  a	  clean	  warming	  chamber	  and	  kept	  under	  observation	  until	  they	  were	  judged	  to	  be	  fully	  awake	  and	  moving	  normally.	  
Surviving	  rats	  were	  housed	  in	  single	  cages	  in	  a	  stable	  environment	  with	  a	  12/12	  light	  cycle,	  with	  access	  to	  rat	  chow	  and	  fresh	  drinking	  water.	  	  Rats	  were	  checked	  daily	  for	  signs	  of	  distress	  or	  wound	  complications.	  	  	  	  
	  
2.3.6	  Rat	  in	  vivo	  intra-­‐myocardial	  injection	  protocol	  
Rats	  were	  anaesthetized	  and	  prepared	  as	  described	  in	  section	  2.3.5.	  	  The	  thoracic	  cavity	  and	  heart	  were	  exposed	  via	  a	  left	  thoracotomy	  incision	  in	  the	  3rd	  or	  4th	  left	  intercostal	  space	  (Figure	  2-­‐8).	  	  The	  pericardial	  sac	  was	  divided	  prior	  to	  intramyocardial	  injections.	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Figure	  2-­‐8:	  	  The	  thoracic	  cavity	  is	  opened	  via	  a	  left	  sided	  thoracotomy	  in	  the	  3rd-­‐4th	  intercostal	  spaces.	  	  This	  allowed	  excellent	  access	  to	  the	  lungs	  and	  heart.	  
	  
Hydrogel	  components	  were	  mixed	  together	  in	  1.5ml	  Eppendorf	  tubes	  immediately	  prior	  to	  injection.	  	  The	  hydrogel	  mixture	  was	  drawn	  up	  into	  a	  1	  ml	  syringe	  using	  an	  18G	  needle.	  	  The	  needle	  was	  then	  changed	  to	  a	  27G	  needle,	  and	  all	  air	  bubbles	  removed.	  	  The	  tip	  of	  the	  needle	  was	  bent	  to	  a	  45	  degree	  angle	  using	  a	  pair	  of	  needle	  holders	  to	  aid	  accurate	  injection.	  
Three	  50µl	  aliquots	  of	  hydrogel	  was	  injected	  into	  the	  anterior	  wall	  of	  the	  left	  ventricle	  under	  direct	  vision.	  	  The	  injection	  was	  performed	  within	  3	  minutes	  of	  mixing	  the	  hydrogel	  components	  to	  ensure	  that	  gelation	  occurred	  in-­‐situ	  within	  the	  myocardium.	  	  If	  gelation	  occurred	  within	  the	  syringe,	  injection	  of	  the	  hydrogel	  was	  not	  possible,	  and	  a	  new	  batch	  of	  hydrogel	  needed	  to	  be	  prepared.	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Upon	  completion	  of	  the	  intramyocardial	  injection	  the	  chest	  wall	  was	  closed	  using	  a	  4/0	  Ethibond	  suture	  (Ethicon	  Inc.)	  	  Overlying	  muscle	  layers	  were	  repositioned,	  and	  the	  skin	  was	  closed	  using	  a	  4/0	  Ethibond	  suture	  (Figure	  2-­‐9).	  
	  
Figure	  2-­‐9:	  	  The	  appearance	  of	  the	  surgical	  wound	  after	  closure.	  
	  
2.3.7	  Rat	  in-­‐vivo	  Pressure-­‐Volume	  loop	  measurement	  	  
The	  assessment	  of	  left	  ventricular	  systolic	  and	  diastolic	  function,	  along	  with	  myocardial	  contractility	  is	  central	  to	  understanding	  cardiac	  physiology	  and	  disease.	  	  The	  combined	  pressure-­‐volume	  measurement	  catheter	  was	  first	  developed	  in	  1975,	  and	  since	  then	  multiple	  studies	  have	  utilized	  this	  technology	  to	  assess	  cardiac	  function	  in	  rodent	  studies(Lyon,	  MacLeod	  et	  al.	  2009).	  	  	  
Pressure	  volume	  loop	  analysis	  is	  carried	  out	  by	  the	  placement	  of	  a	  specialized	  catheter	  within	  the	  left	  ventricular	  chamber	  (Figure	  2-­‐10).	  	  This	  can	  be	  performed	  in-­‐vivo	  under	  general	  anaesthesia.	  	  The	  catheter	  allows	  simultaneous,	  continuous	  real-­‐time	  measurement	  of	  pressure	  and	  relative	  volume.	  	  Pressure	  is	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measured	  directly	  through	  the	  catheter,	  whereas	  volume	  is	  measured	  using	  the	  principle	  of	  conductance,	  where	  it	  is	  assumed	  that	  the	  volume	  of	  a	  uniform	  electrical	  conductor	  (in	  this	  case	  blood)	  is	  directly	  proportional	  to	  its	  electrical	  conductance.	  	  The	  catheter	  includes	  electrodes	  that	  emit	  a	  low	  amplitude	  constant	  current,	  creating	  an	  electric	  field	  within	  the	  ventricle.	  	  The	  conductance	  of	  the	  ventricular	  blood	  changes	  as	  the	  ventricle	  contracts	  and	  expands	  during	  the	  cardiac	  cycle.	  	  These	  changes	  are	  recorded	  by	  sensing	  electrodes	  allowing	  calculation	  of	  the	  relative	  volumes	  of	  the	  chamber	  (relative	  volume	  units	  –	  RVUs).	  	  By	  calibrating	  these	  signals	  against	  known	  volumes	  of	  blood,	  this	  can	  be	  converted	  into	  absolute	  measures	  of	  volume.	  	  	  
Studying	  the	  relationship	  between	  pressure	  and	  volume	  in	  the	  intact	  heart	  allows	  direct	  assessment	  of	  ventricular	  properties.	  	  The	  characteristic	  pressure	  volume	  loop	  of	  the	  cardiac	  cycle	  can	  be	  seen	  in	  Figure	  2-­‐11	  with	  the	  end-­‐systolic	  point	  (closure	  of	  the	  aortic	  valve)	  seen	  at	  the	  top	  left	  corner,	  and	  the	  end-­‐diastolic	  point	  (closure	  of	  the	  mitral	  valve	  and	  beginning	  of	  isovolumetric	  contraction)	  at	  the	  bottom	  right	  corner.	  	  This	  loop	  repeats	  itself	  with	  every	  cardiac	  cycle.	  	  From	  these	  measurements,	  basic	  haemodynamic	  data	  such	  as	  left	  ventricular	  end	  systolic	  and	  end-­‐diastolic	  pressures	  can	  be	  measured	  as	  well	  as	  volumetric	  data	  (ESV:end-­‐systolic	  volume	  and	  EDV:	  end-­‐diastolic	  volumes).	  	  From	  this	  it	  is	  also	  possible	  to	  calculate	  stroke	  volume	  (SV	  =	  EDV	  –	  ESV)	  and	  ejection	  fraction	  (EF	  =	  SV/EDV),	  which	  is	  a	  widely	  used	  measure	  of	  cardiac	  function.	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Figure	  2-­‐11:	  Schematic	  of	  a	  pressure	  volume	  loop.	  	  This	  loop	  repeats	  itself	  continuously	  with	  the	  cardiac	  cycle	  and	  is	  recorded	  by	  a	  pressure	  volume	  catheter	  placed	  in	  the	  left	  ventricular	  cavity.	  	  The	   end-­‐systolic	   point	   is	   found	   at	   the	   top	   left	   of	   the	   loop,	   with	   the	   end-­‐diastolic	   point	   at	   the	  bottom	  right	  of	  the	  loop.	  	  	  
	  
One	  of	  the	  advantages	  of	  pressure	  volume	  loop	  measurement	  in	  comparison	  to	  other	  non-­‐invasive	  imaging	  techniques	  such	  as	  echocardiography	  or	  MRI	  is	  the	  ability	  to	  measure	  the	  end-­‐systolic	  pressure	  volume	  relationship	  (ESPVR)	  and	  end	  diastolic	  pressure	  volume	  relationship	  (EDPVR).	  	  This	  is	  made	  possible	  by	  applying	  an	  intervention	  that	  can	  acutely	  alter	  the	  loading	  conditions	  of	  the	  heart,	  without	  inherently	  affecting	  the	  myocardial	  properties.	  	  This	  can	  be	  performed	  by	  maneuvers	  such	  as	  transient	  inferior	  vena	  cava	  (IVC)	  occlusion	  to	  reduce	  cardiac	  filling	  or	  preload.	  	  This	  action	  results	  in	  a	  series	  of	  loops	  from	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which	  the	  end-­‐systolic	  points	  and	  end-­‐diastolic	  points	  can	  be	  plotted.	  	  The	  linear	  relationship	  of	  the	  end	  systolic	  points	  characterizes	  the	  maximal	  contractile	  properties	  of	  the	  myocardium	  and	  the	  slope	  is	  measured	  as	  the	  ESPVR.	  	  The	  linear	  relationship	  of	  the	  end-­‐diastolic	  points	  characterizes	  the	  diastolic	  properties	  of	  the	  myocardium	  and	  the	  slope	  measured	  as	  the	  EDPVR.	  	  The	  ESPVR	  will	  increase	  in	  response	  to	  positively	  inotropic	  stimulants	  such	  as	  catecholamines,	  and	  decrease	  in	  response	  to	  negatively	  inotropic	  agents	  such	  as	  calcium	  antagonists	  or	  in	  cases	  of	  systolic	  dysfunction.	  	  Thus	  the	  ESPVR	  can	  be	  thought	  of	  as	  a	  measure	  of	  the	  inotropic	  state	  of	  the	  myocardium.	  	  The	  EDPVR	  provides	  an	  estimate	  of	  the	  passive	  diastolic	  properties	  of	  the	  myocardium,	  or	  myocardial	  stiffness,	  and	  will	  rise	  in	  scenarios	  of	  increased	  chamber	  stiffness	  such	  as	  cardiac	  fibrosis.	  	  The	  ESPVR	  and	  EDPVR	  are	  the	  main	  outcome	  measures	  of	  pressure	  volume	  loop	  assessment.	  	  	  
	  
2.3.8	  Rat	  in-­‐vivo	  Pressure-­‐Volume	  loop	  measurement	  protocol	  
Rats	  were	  anaesthetized	  and	  prepared	  as	  described	  in	  section	  2.3.5.	  	  The	  thoracic	  cavity	  and	  heart	  were	  exposed	  via	  a	  median	  sternotomy	  incision.	  	  Peri-­‐cardiac	  adhesions	  were	  carefully	  divided	  prior	  to	  any	  cardiac	  surgery.	  
For	  placement	  of	  the	  pressure	  volume	  catheter	  (Millar	  Instruments,	  Houston,	  Texas,	  USA)	  a	  25G	  needle	  was	  used	  to	  puncture	  the	  cardiac	  apex,	  into	  the	  left	  ventricular	  cavity.	  	  This	  was	  withdrawn	  and	  quickly	  replaced	  with	  the	  pressure	  volume	  catheter	  –	  allowing	  measurement	  of	  the	  pressure-­‐volume	  loop	  cycle	  (Figure	  2-­‐12).	  	  Transient	  occlusion	  of	  the	  inferior	  vena	  cava	  (IVC)	  which	  could	  be	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located	  at	  the	  postero-­‐inferior	  aspect	  of	  the	  heart,	  using	  a	  pair	  of	  artery	  forceps	  allowed	  calculation	  of	  the	  end-­‐systolic	  and	  end-­‐diastolic	  pressure	  volume	  relationships	  (ESPVR	  and	  EDPVR).	  




Figure	  2-­‐12:	  Placement	  of	  the	  Pressure-­‐Volume	  Catheter	  through	  the	  apex	  of	  the	  left	  ventricle.	  
	  
2.3.9	  Rat	  Myocardial	  Infarction	  Model	  
Rats	  were	  anaesthetized	  and	  prepared	  as	  described	  in	  section	  2.3.5.	  	  The	  thoracic	  cavity	  and	  heart	  were	  exposed	  via	  a	  left	  thoracotomy	  incision	  in	  the	  3rd	  or	  4th	  left	  intercostal	  space.	  	  The	  pericardial	  sac	  was	  divided	  prior	  to	  induction	  of	  myocardial	  infarction.	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A	  7/0	  prolene	  suture	  (Ethicon	  Inc.)	  on	  a	  round	  bodied	  curved	  needle	  was	  used	  to	  ligate	  the	  proximal	  part	  of	  the	  left	  anterior	  descending	  artery	  (LAD).	  	  As	  the	  LAD	  becomes	  intramyocardial	  shortly	  after	  its	  origin	  and	  is	  rarely	  visible	  on	  the	  epicardial	  surface,	  the	  landmark	  for	  ligation	  was	  approximated	  as	  being	  1-­‐2mm	  distal	  to	  the	  inferior	  border	  of	  the	  left	  atrium,	  along	  an	  axis	  parallel	  to	  the	  atrioventricular	  groove.	  	  	  
For	  the	  optimum	  technique,	  the	  suture	  needle	  was	  passed	  only	  through	  the	  myocardium	  for	  a	  distance	  of	  2-­‐3mm	  and	  did	  not	  enter	  the	  ventricular	  cavity.	  	  Successful	  ligation	  of	  the	  LAD	  was	  demonstrated	  by	  blanching	  and	  cyanosis	  of	  the	  myocardium,	  distal	  to	  the	  tied	  suture,	  indicating	  myocardial	  ischaemia	  (Figure	  2-­‐13).	  	  If	  the	  first	  suture	  did	  not	  result	  in	  an	  acceptable	  area	  of	  ischaemia	  further	  ligations	  were	  attempted	  lateral	  or	  medial	  to	  the	  first	  ligation	  point.	  	  This	  was	  continued	  until	  a	  significant	  ischaemic	  area	  had	  been	  induced.	  	  	  
Episodes	  of	  ventricular	  fibrillation	  following	  myocardial	  infarction	  were	  treated	  with	  direct	  cardiac	  massage,	  using	  a	  pair	  of	  non-­‐toothed	  forceps	  to	  compress	  the	  ventricles	  at	  a	  rate	  of	  100-­‐200	  beats	  per	  minute.	  
Following	  successful	  infarction,	  maintenance	  anaesthesia	  was	  reduced	  to	  1.0%	  isoflurane,	  and	  the	  chest	  wall	  was	  closed	  using	  a	  4/0	  Ethibond	  suture.	  (Ethicon	  Inc.)	  	  Overlying	  muscle	  layers	  were	  repositioned,	  and	  the	  skin	  was	  closed	  using	  a	  4/0	  Ethibond	  suture.	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Figure	  2-­‐13	  	  Myocardial	  Infarction.	  	  Following	  ligation	  of	  the	  suture	  around	  the	  left	  anterior	  descending	  artery	  blanching	  of	  the	  myocardium	  can	  be	  seen	  distal	  to	  the	  suture	  (area	  a),	  in	  comparison	  to	  the	  normal	  well	  perfused	  tissue	  (area	  b).	  
	  
2.4	  Cardiac	  Imaging	  	  
Small	  rodents	  (mice	  and	  rats)	  are	  the	  most	  commonly	  used	  species	  for	  the	  experimental	  investigation	  of	  cardiac	  disease.	  	  A	  non-­‐invasive	  and	  accurate	  measure	  of	  cardiovascular	  parameters	  such	  as	  ventricular	  geometries,	  ejection	  fraction,	  and	  ventricular	  mass	  are	  desirable	  outcome	  measures,	  and	  essential	  for	  the	  evaluation	  of	  novel	  therapies.	  	  This	  allows	  longitudinal	  study	  of	  individual	  animals	  over	  multiple	  time	  points,	  in	  an	  in-­‐vivo	  environment,	  without	  the	  danger	  of	  causing	  damage	  to	  the	  myocardium,	  which	  may	  influence	  results.	  
At	  present	  echocardiography	  is	  the	  most	  commonly	  used	  non-­‐invasive	  method	  for	  measuring	  rodent	  cardiac	  function.	  	  Basic	  M-­‐mode	  and	  two-­‐dimensional	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echocardiography	  (2D-­‐echo)	  are	  the	  most	  usual	  techniques	  used	  despite	  the	  availability	  of	  more	  complex	  bi-­‐planar	  and	  three	  dimensional	  techniques.	  	  This	  allows	  repeated	  measurement	  of	  cardiac	  indices	  such	  as	  fractional	  shortening	  and	  ejection	  fraction	  in	  the	  same	  animal.	  	  With	  echocardiography,	  high	  throughput	  is	  also	  a	  possibility	  as	  rodents	  only	  require	  a	  light	  anaesthetic	  for	  the	  procedure.	  	  However,	  2D-­‐echo	  is	  severely	  limited	  due	  to	  its	  dependence	  upon	  a	  skilled	  operator,	  making	  inter-­‐operator	  variability	  high	  with	  up	  to	  a	  25%	  variability	  seen	  for	  measures	  of	  cardiac	  output(Wasmeier,	  Melnychenko	  et	  al.	  2007).	  	  With	  echocardiography	  there	  is	  also	  a	  very	  small	  acoustic	  window	  between	  the	  ribs	  to	  acquire	  images,	  which	  can	  be	  made	  even	  more	  difficult	  in	  the	  post-­‐surgical	  scenario.	  	  	  The	  assumptions	  that	  are	  often	  made	  about	  left	  ventricular	  geometry	  with	  echocardiography	  also	  do	  not	  always	  apply	  to	  the	  asymmetric	  left	  ventricle	  as	  is	  seen	  following	  myocardial	  infarction(Buck,	  Hunold	  et	  al.	  1997,	  Bellenger,	  Marcus	  et	  al.	  2002,	  van	  den	  Bosch,	  Robbers-­‐Visser	  et	  al.	  2006).	  	  	  	  	  	  	  	  
Magnetic	  Resonance	  Imaging	  (MRI)	  is	  widely	  used	  as	  a	  non-­‐invasive	  method	  for	  the	  measurement	  of	  cardiac	  morphology	  and	  function	  in	  humans,	  but	  	  is	  not	  widely	  available	  for	  the	  measurement	  of	  cardiac	  function	  in	  rodents.	  	  As	  the	  rodent	  heart	  is	  several	  hundred	  times	  smaller	  than	  the	  human	  heart,	  much	  higher	  field	  strengths	  are	  required	  to	  obtain	  sufficient	  signal-­‐noise	  ratios.	  	  Also,	  the	  much	  higher	  heart	  and	  respiratory	  rates	  in	  the	  rodent	  require	  additional	  gating	  strategies	  to	  gather	  information.	  	  Despite	  these	  technical	  hurdles,	  MRI	  can	  produce	  a	  much	  wider	  range	  of	  measurements	  than	  standard	  echocardiography,	  with	  fewer	  geometric	  assumptions,	  as	  a	  stack	  of	  short-­‐axis	  images	  can	  be	  used	  to	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cover	  the	  entire	  length	  of	  the	  left	  ventricle.	  	  In	  this	  way	  MRI	  is	  much	  less	  dependent	  upon	  operator	  skill	  than	  echocardiography.	  	  As	  a	  true	  tomographic	  technique,	  MRI	  is	  also	  not	  limited	  in	  terms	  of	  acquiring	  views	  of	  the	  ventricle,	  and	  with	  excellent	  soft	  tissue	  resolution	  is	  a	  suitable	  method	  for	  imaging	  of	  small	  animals	  post	  surgery.	  	  Recent	  work	  has	  demonstrated	  that	  an	  MRI	  technique	  is	  more	  accurate	  and	  more	  reproducible	  than	  echocardiography,	  with	  echocardiography	  potentially	  requiring	  5	  times	  more	  animals	  to	  find	  a	  statistically	  significant	  difference(Stuckey,	  Carr	  et	  al.	  2008).	  	  In	  addition	  to	  these	  benefits,	  MRI	  can	  also	  benefit	  from	  contrast	  agents	  such	  as	  the	  use	  of	  late	  gadolinium	  enhancement	  for	  identification	  of	  infarcted	  tissue(Kim,	  Wu	  et	  al.	  2000).	  	  For	  these	  reasons,	  cardiac	  MRI	  was	  chosen	  as	  the	  main	  outcome	  measure	  of	  cardiac	  function	  for	  these	  studies.	  
	  
2.4.1.	  Cardiac	  MRI	  -­‐	  Protocol	  
The	  cardiac	  MRI	  protocol	  was	  performed	  by	  Dr	  Daniel	  J	  Stuckey.	  	  	  
Rats	  were	  anaesthetized	  in	  an	  induction	  chamber	  using	  a	  95%	  oxygen	  and	  5%	  isoflurane	  mix.	  	  Once	  induction	  of	  anaesthesia	  was	  complete,	  rats	  were	  transferred	  to	  a	  cradle,	  where	  they	  were	  maintained	  with	  1.5%	  isoflurane	  delivered	  by	  nose	  cone	  (Figure	  2-­‐14).	  	  Rats	  were	  positioned	  supine.	  	  The	  forelegs	  were	  taped	  in	  place	  extended	  cranially	  and	  the	  hind	  legs	  placed	  extended	  caudally.	  	  	  
ECG	  monitoring	  was	  attached	  to	  the	  rat	  in	  the	  way	  of	  subcutaneous	  needles	  placed	  on	  the	  anterior	  chest	  wall.	  	  Respiration	  monitoring	  was	  accomplished	  by	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placing	  a	  sensor	  on	  the	  anterior	  abdominal	  wall.	  	  These	  provided	  real-­‐time	  monitoring	  allowing	  the	  status	  of	  the	  rat	  to	  be	  monitored	  at	  all	  times	  during	  the	  scanning	  protocol.	  
Once	  the	  rat	  was	  secured	  in	  position	  and	  monitoring	  attached	  and	  functioning	  properly,	  the	  cradles	  were	  placed	  within	  a	  4.7	  Tesla	  DirectDrive	  Varian	  MRI	  System	  (Palo	  Alto,	  CA,	  USA)	  (Figure	  2-­‐15).	  	  40	  G/cm	  gradients	  were	  used	  with	  a	  72mm	  volume,	  quadrature	  driven	  RF	  coil.	  	  	  
Cardiac	  and	  respiratory	  gated	  cine-­‐MRI	  was	  performed	  in	  the	  true	  short-­‐axis	  orientation	  and	  covered	  the	  whole	  LV	  (1.5	  mm	  slice	  thickness,	  TE/TR	  1.6/5	  ms;	  17.5°	  pulse;	  field	  of	  view	  51.2	  ×	  51.2	  mm;	  matrix	  size	  128	  ×	  128;	  voxel	  size	  400	  ×	  400	  ×	  1500	  μm;	  25	  to	  35	  frames	  per	  cardiac	  cycle,	  3	  signal	  averages)	  (Figure	  2-­‐16).	  Infarct	  size	  was	  assessed	  by	  late	  gadolinuium	  enhanced	  MRI	  preformed	  25	  mins	  after	  i.p.	  injection	  of	  0.5mg/kg	  Gd-­‐DTPA	  using	  a	  multi	  slice	  inversion	  recovery	  sequence	  (1	  mm	  slice	  thickness,	  TE/TR	  1.6/3.2	  ms;	  90°	  excitation	  pulse;	  field	  of	  view	  51.2	  ×	  51.2	  mm;	  matrix	  size	  192	  ×	  192;	  voxel	  size	  266	  ×	  266	  ×	  1000	  μm,	  1	  signal	  average).	  Data	  were	  analysed	  using	  Image	  J	  software	  (National	  Institutes	  of	  Health).	  End	  diastolic	  and	  end	  systolic	  volumes	  were	  measured	  by	  semi	  automated	  segmentation	  of	  each	  slice	  and	  ejection	  fractions	  were	  calculated	  as	  (end	  diastolic	  volume	  -­‐	  end	  systolic	  volume)	  /	  end	  diastolic	  volume.	  LV	  mass	  was	  measured	  by	  semi	  automated	  segmentation	  of	  the	  myocardial	  area	  in	  all	  slices	  of	  the	  inversion	  recovery	  acquisition	  multiplied	  by	  the	  slice	  thickness	  (1	  mm)	  and	  the	  specific	  gravity	  of	  the	  myocardium	  (1.05).	  Infarct	  mass	  was	  measured	  in	  every	  slice	  as	  the	  area	  of	  myocardial	  tissue	  with	  signal	  intensity	  >2	  s.d.	  above	  SI	  of	  remote	  tissue,	  multiplied	  by	  the	  slice	  thickness	  (1	  mm)	  and	  the	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specific	  gravity	  of	  the	  myocardium	  (1.05).	  Infarct	  surface	  area	  was	  measured	  as	  the	  epicardial	  length	  of	  the	  enhanced	  tissue	  multiplied	  by	  the	  slice	  thickness,	  and	  was	  also	  expressed	  relative	  to	  the	  epicardial	  circumference	  of	  the	  whole	  LV	  (LGE	  surface	  area	  %)	  (Figure	  2-­‐17).	  
	  
Figure	  2-­‐14:	  	  Positioning	  of	  the	  rat	  in	  the	  MRI	  cradle.	  
	  
Figure	   2-­‐15:	   The	   MRI	   scanner.	   	   Rats	   and	   cradles	   were	   inserted	   into	   the	   central	   opening	   for	  scanning.	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Figure	  2-­‐16:	  	  Examples	  of	  typical	  in	  vivo	  cine-­‐MRI	  images	  acquired	  in	  the	  short-­‐axis	  (base,	  mid-­‐LV,	  and	  apex)	  and	  long-­‐axis	  (two-­‐chamber)	  views.	  	  Images	  taken	  at	  end	  diastole	  and	  end-­‐systole.	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Figure	  2-­‐17:	  	  Late	  gadolinium	  enhancement.	  	  A	  –	  example	  image	  demonstrating	  late	  gadolinium	  enhancement	  of	  the	  anterior	  left	  ventricular	  wall	  indicating	  myocardial	  infarction.	  	  B	  –	  Processed	  image	  using	  ImageJ	  software.	  	  Infarct	  surface	  area	  was	  measured	  as	  the	  epicardial	  length	  of	  the	  enhanced	  tissue	  multiplied	  by	  the	  slice	  thickness,	  and	  was	  also	  expressed	  relative	  to	  the	  epicardial	  circumference	  of	  the	  whole	  left	  ventricle.	  
	  
2.5	  	  Myocardial	  Histology	  
Hearts	  prepared	  for	  histology	  underwent	  fixation	  using	  10%	  formalin.	  	  For	  animals	  that	  died	  during	  MI	  surgery	  hearts	  were	  quickly	  explanted	  after	  asystole,	  immersed	  in	  10%	  formalin	  and	  stored	  for	  24	  hours	  at	  room	  temperature.	  	  Following	  this	  hearts	  were	  rinsed	  and	  re-­‐immersed	  in	  10%	  sucrose	  solution	  for	  at	  least	  24	  hours.	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Animals	  sacrificed	  at	  later	  timepoints	  underwent	  in-­‐vivo	  cardiac	  fixation.	  	  Animals	  were	  anaesthetized	  with	  a	  95%	  oxygen	  and	  5%	  isoflurane	  mix	  in	  an	  induction	  chamber.	  	  Once	  anaesthetized,	  animals	  were	  transferred	  to	  a	  bain	  coaxial	  circuit	  and	  maintained	  with	  3%	  isoflurane.	  
The	  thoracic	  cavity	  was	  accessed	  with	  a	  median	  sternotomy	  incision,	  and	  the	  heart	  carefully	  dissected	  away	  from	  the	  chest	  wall	  in	  the	  case	  of	  postoperative	  adhesions.	  
20ml	  of	  physiological	  saline	  was	  injected	  via	  the	  apex	  into	  the	  left	  ventricle	  using	  a	  25G	  needle.	  	  This	  was	  followed	  by	  an	  injection	  of	  20ml	  10%	  formalin.	  	  The	  heart	  could	  be	  seen	  to	  slow	  and	  stop	  following	  injection.	  	  The	  heart	  was	  quickly	  explanted,	  immersed	  in	  10%	  formalin	  and	  stored	  for	  24	  hours	  at	  room	  temperature.	  	  Following	  this	  hearts	  were	  rinsed	  and	  re-­‐immersed	  in	  10%	  sucrose	  solution	  for	  at	  least	  24	  hours.	  
Hearts	  were	  placed	  in	  a	  heart	  cutting	  matrix	  and	  sectioned	  in	  the	  short	  axis.	  	  A	  4-­‐5mm	  section	  just	  inferior	  to	  the	  point	  of	  LAD	  ligation	  was	  obtained	  in	  this	  fashion.	  	  This	  provided	  a	  cross	  section	  of	  the	  ventricles,	  including	  the	  area	  of	  myocardial	  infarct.	  
For	  frozen	  sections	  myocardial	  sections	  were	  embedded	  in	  Optimal	  Cutting	  Temperature	  (OCT)	  compound	  and	  block	  frozen	  in	  liquid	  nitrogen-­‐cooled	  isopentane	  baths.	  	  Tissue	  blocks	  were	  stored	  at	  -­‐80°C.	  	  10µM	  sections	  were	  taken	  using	  a	  cryotome	  at	  -­‐20°C.	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For	  paraffin	  embedded	  sections,	  myocardial	  sections	  were	  placed	  in	  embedding	  cassettes	  and	  dehydrated	  in	  a	  series	  of	  ethanol	  baths	  prior	  to	  fixation	  in	  hot	  liquid	  paraffin.	  	  The	  paraffin	  embedded	  tissue	  was	  sectioned	  with	  a	  microtome.	  
	  
2.5.1	  Masson’s	  Trichrome	  Stain	  
Masson’s	  Trichrome	  staining	  was	  performed	  by	  Miss	  Lorraine	  Lawrence.	  	  Sections	  were	  stained	  with	  Slidder’s	  Haematoxylin	  for	  5	  minutes.	  	  They	  were	  next	  dedifferentiated	  in	  1%	  acid	  alcohol,	  washed	  in	  running	  tap	  water	  for	  1	  minute,	  and	  stained	  with	  Masson	  Ponceau	  Fuschin	  stain	  for	  5	  minutes.	  	  Sections	  were	  rinsed	  with	  1%	  acetic	  acid,	  treated	  with	  4%	  phospho-­‐molybdic	  acid	  until	  the	  collagen	  turned	  pale	  pink	  in	  colour	  and	  rinsed	  with	  1%	  acetic	  acid.	  	  Sections	  were	  then	  counterstained	  with	  light	  green	  for	  2-­‐5	  minutes,	  dehydrated	  in	  graded	  alcohols,	  rinsed	  in	  xylene	  and	  mounted	  in	  DPX	  mounting	  media.	  	  
2.5.2	  Immunohistochemistry	  	  Immunohistochemistry	  was	  performed	  by	  Dr	  Mark	  Rocco.	  Unstained	  histological	  sections	   were	   prepared	   in	   the	   same	   manner	   as	   described	   in	   Chapter	   2.5.	  	  Following	   sectioning	   with	   a	   microtome,	   paraffin-­‐embedded	   sections	   were	  dewaxed	  and	  dehydrated	  after	  incubation	  in	  Histo-­‐Clear	  II	  (National	  Diagnostics)	  twice	   for	   15	  minutes	   each,	   followed	   by	   a	   brief	   30	   second	   incubation	   in	   100%	  ethanol	  (Sigma-­‐Aldrich)	  and	  then	  again	  in	  90%	  ethanol.	  	  Endogenous	  peroxidase	  activity	   was	   blocked	   in	   a	   1:100	   solution	   of	   30%	   (w/w)	   hydrogen	   peroxide	  (Sigma-­‐Aldrich)	  in	  pure	  methanol	  (Sigma-­‐Aldrich)	  for	  approximately	  10	  minutes	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and	   washed	   under	   running	   tap	   water	   for	   approximately	   an	   additional	   10	  minutes.	  	  Histological	  sections	  were	  subjected	  to	  antigen	  retrieval	  using	  a	  10	  mM	  citrate	  buffer	   at	   pH	  6.0	   and	  boiled	   in	   the	  microwave	   for	   a	   total	   of	   10	  minutes.	  	  Boiled	   slides	   were	   cooled	   and	   washed	   under	   running	   tap	   water	   for	  approximately	  another	  10	  minutes.	  	  All	  endogenous	  biotin,	  biotin	  receptors,	  and	  avidin	   binding	   sites	   that	   are	   present	   in	   tissues	   were	   blocked	   using	   an	  Avidin/Biotin	   Kit	   (Vector	   Laboratories)	   according	   to	   the	   manufacturer’s	  instructions.	   	  Lastly,	  non-­‐specific	  interactions	  were	  blocked	  in	  a	  blocking	  buffer	  containing	   1%	   horse	   serum	   (Sigma-­‐Aldrich)	   in	   PBS	   for	   60	   minutes	   at	   room	  temperature.	  	  Immunostaining	   was	   achieved	   using	   the	   following	   primary	   antibodies:	   mouse	  monoclonal	  1ºα-­‐human	  cardiac	  troponin	  T	  (Abcam)	  diluted	  1:2000	  in	  incubation	  buffer	   (1%	   bovine	   serum	   albumin	   (Sigma-­‐Aldrich),	   1%	   normal	   donkey	   serum	  (Sigma-­‐Aldrich),	  0.1%	  Tween-­‐20	  in	  phosphate	  buffered	  saline	  (PBS))	  and	  mouse	  primary	   IgG	   at	   the	   same	   concentration	   in	   incubation	   buffer,	   used	   as	   the	  histological	  control	  (Vector	  Laboratories).	  The	  following	  secondary	  antibody	  was	  used	   as	   appropriate:	   	   IRDye	   800CW	   goat	   anti-­‐mouse	   IgG	   (H+L)	   (LiCor	  Biosciences)	  diluted	  1:500	  in	  incubation	  buffer.	  	  Following	  immunostaining,	  histological	  slides	  were	  washed	  thrice	  in	  PBST	  (0.1%	  Tween-­‐20	  in	  PBS)	  for	  5	  minutes	  each	  and	  dehydrated	  in	  a	  graded	  ethanol	  series	  from	   70%	   up	   to	   100%	   ethanol	   for	   30	   seconds	   each.	   	   Finally,	   sections	   were	  incubated	   thrice	   in	   Histo-­‐Clear	   II	   for	   5	   minutes	   each,	   coverslipped	   using	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Histomount	  mounting	  solution	  (National	  Diagnostics)	  and	  imaged	  on	  the	  Li-­‐Cor	  Odyssey	  system	  at	  identical	  exposures.	  	  Frozen	   sections	   were	   prepared	   in	   an	   identical	   manner	   with	   the	   following	  exceptions:	   	   exogenous	   peroxidase	   activity	  was	   blocked	   in	   a	   1:100	   solution	   of	  30%	  (w/w)	  hydrogen	  peroxide	  in	  water	  for	  30	  minutes	  and	  no	  antigen	  retrieval	  step	  was	  necessary.	  	  
2.6	  Quantitative	  Polymerase	  Chain	  Reaction	  (qPCR)	  	  	  As	  shown	  in	  Figure	  2-­‐18,	  the	  infarct	  zone	  and	  remaining	  left	  ventricular	  wall	  was	  excised	   from	  ~3	  mm	   thick	   frozen	   heart	   sections	   and	   approximately	   30	  mg	   of	  each	  were	  placed	  separately	   into	   ice-­‐cold	  TRI	  Reagent	   (Sigma-­‐Aldrich).	   	  Tissue	  samples	  were	  disrupted	   and	  homogenized	   in	   the	  TRI	  Reagent	   solution	  using	   a	  rotor-­‐stator	  homogenizer.	  	  Following	  homogenization,	  total	  RNA	  was	  extracted	  from	  cardiac	  tissue	  samples	  using	  a	  RNeasy	  Mini	  Kit	  (Qiagen)	  according	  to	  the	  manufacturer’s	  specifications	  and	   cDNA	   was	   reverse	   transcribed	   from	   normalized	   amounts	   of	   RNA,	   as	  determined	   by	   absorbance	   at	   260	   nm	   (A260)	   in	   a	   NanoDrop	   8000	  spectrophotometer.	   	   All	   RNA	   procedures	   were	   conducted	   in	   an	   RNase-­‐free	  environment.	   All	   freshly	   synthesized	   cDNA	   was	   stored	   overnight	   at	   4oC.	   	   The	  following	   day,	   real-­‐time	   PCR	   was	   performed	   in	   technical	   triplicate	   using	   pre-­‐validated	   TaqMan®	   assays	   from	   Life	   TechnologiesTM	   in	   a	   Rotor	   Gene	   6000	  (Corbett	  Life	  Science)	  according	  to	  the	  manufacturers’	  instructions.	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  Figure	  2-­‐18.	  Cross-­‐section	  of	  a	  rat	  heart	  with	  the	  infarcted	  region	  highlighted	  in	  blue	  and	  the	  remaining	  left	  ventricular	  wall	  highlighted	  in	  red.	  	  
2.7	   Statistical	  Analysis	  Results	  were	  tabulated	  using	  Microsoft	  Excel	  and	  Graphpad	  Prism.	  	  Comparison	  between	  two	  groups	  was	  performed	  using	  a	  paired	  t-­‐test.	  	  For	  comparisons	  between	  multiple	  groups	  a	  one-­‐way	  between	  subjects	  ANOVA	  (α	  =	  0.05)	  was	  performed.	  	  If	  the	  results	  of	  the	  ANOVA	  were	  found	  to	  be	  significant,	  post-­‐hoc	  analysis	  was	  performed	  using	  the	  Tukey’s	  multiple	  comparisons	  test	  to	  compare	  results	  between	  groups.	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  Development	  and	  Characterization	  
	  
3.1	  Introduction	  
3.1.1	  	  Hydrogels	  
Hydrogels	  are	  hydrophilic	  networks	  of	  polymers	  that	  can	  absorb,	  swell	  with,	  and	  retain	  water.	  	  The	  polymers	  in	  question	  may	  be	  either	  naturally	  derived	  or	  synthetic	  (or	  even	  a	  mixture	  of	  both).	  	  Hydrogels	  continue	  to	  stimulate	  interest	  and	  research	  within	  the	  field	  of	  tissue	  engineering	  as	  a	  matrix	  to	  deliver	  cells,	  promote	  repair	  and	  tissue	  regeneration(Hoffman	  2002).	  
Hydrogel	  networks	  are	  held	  together	  by	  crosslinks	  between	  monomer	  molecules,	  which	  provide	  the	  network	  with	  visco-­‐elastic	  physical	  properties.	  	  Hydrogels	  may	  be	  chemically	  stable,	  or	  they	  may	  degrade	  with	  time	  and	  disintegrate,	  depending	  upon	  the	  stability	  of	  the	  crosslinking	  reactions.	  	  These	  crosslinks	  can	  be	  either	  chemical	  or	  physical	  in	  nature(Hennink	  and	  van	  Nostrum	  2002).	  	  	  
Physically	  crosslinked	  hydrogels	  are	  held	  together	  by	  molecular	  entanglements	  and	  secondary	  forces	  such	  as	  hydrogen	  bonds,	  hydrophobic	  forces	  or	  ionic	  forces.	  	  A	  commonly	  known	  example	  of	  a	  physical	  gel	  is	  calcium	  alginate(Augst,	  Kong	  et	  al.	  2006),	  whereby	  alginate	  molecules	  with	  negative	  side	  chains	  are	  crosslinked	  by	  ionic	  interactions	  with	  positively	  charged	  calcium	  ions.	  
Chemical	  hydrogels	  have	  covalent	  bonds	  acting	  as	  their	  crosslinks,	  with	  many	  being	  based	  upon	  the	  polyethylene	  glycol	  (PEG)	  molecule.	  	  	  PEG	  hydrogels	  have	  
	   86	  
extensively	  been	  used	  as	  a	  scaffold	  for	  drug	  and	  cell	  delivery(Lin	  and	  Anseth	  2009).	  	  Its	  excellent	  biocompatibility	  has	  led	  to	  a	  proven	  safety	  record	  and	  established	  approval	  for	  use	  in	  the	  medical	  field(Van	  Tomme,	  Storm	  et	  al.	  2008)	  (Figure	  3-­‐1).	  	  
A	  particularly	  attractive	  and	  elegant	  chemically	  crosslinked	  PEG	  hydrogel	  has	  been	  developed	  by	  Hubbell	  and	  colleagues	  who	  used	  the	  Michael-­‐type	  addition	  reaction	  to	  cross-­‐link	  PEG	  monomers	  that	  were	  functionalized	  with	  acrylate	  and	  thiol	  side	  groups(Elbert,	  Pratt	  et	  al.	  2001).	  	  	  	  




Figure	  3-­‐1:	  	  The	  chemical	  structure	  of	  polyethylene	  glycol	  (PEG)	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Figure	   3-­‐3	   	   A	   cysteine	   amino	   acid	   demonstrating	   the	   free	   thiol	   group	   (SH)	   available	   for	   the	  crosslinking	  reaction.	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3.1.2.	  Hydrogels	  in	  Cardiac	  tissue	  Engineering	  
Hydrogels	  have	  an	  attractive	  application	  within	  the	  field	  of	  cardiac	  tissue	  engineering	  for	  several	  reasons.	  	  	  
Firstly	  the	  possibility	  of	  creating	  an	  injectable	  solution	  that	  gels	  in-­‐situ,	  leads	  to	  their	  potential	  application	  via	  minimally	  invasive	  routes	  such	  as	  via	  cardiac	  catheter.	  	  Novel	  catheter	  systems	  such	  as	  the	  ,	  Myocath	  (Bioheart	  Inc.,	  Sunrise,	  FL,	  USA)	  (Figure	  3-­‐4),	  Myostar	  (Biologics	  Delivery	  Systems,	  Diamond	  Bar,	  CA,	  USA)	  (fgure	  3-­‐5),	  Helix	  (Biocardia	  Inc.,	  San	  Francisco,	  CA,	  USA)	  (Figure	  3-­‐6)and	  Stiletto	  (Boston	  Sceintific,	  Natick,	  MA,	  USA)	  (Figure	  3-­‐7)	  have	  already	  been	  developed	  which	  allow	  direct	  intramyocardial	  injections	  via	  the	  left	  ventricular	  chamber	  and	  a	  trans-­‐femoral	  approach(Sherman,	  Martens	  et	  al.	  2006).	  	  This	  would	  negate	  the	  requirement	  for	  open	  thoracic	  surgery	  in	  order	  to	  gain	  access	  to	  the	  affected	  area	  of	  myocardium	  and	  thus	  minimize	  the	  trauma	  of	  surgery.	  	  This	  is	  an	  extremely	  attractive	  clinical	  scenario	  and	  may	  allow	  applications	  within	  already	  common	  clinical	  situations	  such	  as	  primary	  percutaneous	  coronary	  intervention	  (PCI)	  following	  myocardial	  infarction	  or	  elective	  angioplasty	  and	  stenting	  in	  patients	  with	  known	  myocardial	  disease.	  
Secondly,	  the	  range	  of	  hydrogels	  available	  is	  incredibly	  diverse,	  ranging	  from	  naturally	  occurring	  compounds	  to	  completely	  synthetic	  molecules(Hoffman	  2002).	  	  The	  ability	  to	  modify	  biomaterial	  structures	  to	  incorporate	  adhesion	  molecules	  and	  other	  survival	  factors	  may	  significantly	  improve	  the	  potential	  for	  cellular	  therapy	  in	  cardiac	  disease(Biondi,	  Ungaro	  et	  al.	  2008,	  Place,	  Evans	  et	  al.	  2009).	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Figure	  3-­‐4.	  	  The	  Myocath	  catheter	  for	  intramyocardial	  injection	  of	  cells.	  	  (A)	  withdrawn	  position,	  (B)	  extended	  position,	  (C)	  straight	  catheter	  position	  (D)	  curved	  catheter	  position.	  	  Images	  from	  Bioheart	  Inc.,	  Sunrise,	  FL,	  USA	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Figure	  3-­‐5.	  	  The	  Myostar	  Catheter	  for	  intramyocardial	  injection	  of	  cells.	  	  (A)	  entire	  catheter	  system,	  (B)	  extended	  injection	  needle.	  	  Images	  from	  Biologics	  Delivery	  Systems,	  Diamond	  Bar,	  CA,	  USA.	  
	  
Figure	  3-­‐6.	  	  The	  Helix	  catheter	  for	  intramyocardial	  injection	  of	  cells.	  	  (A)	  independent	  deflectable	  guide	  catheter	  (B)	  helical-­‐shaped	  needle	  injection	  catheter	  tip.	  	  Images	  from	  BioCardia,	  San	  Francisco,	  CA,	  USA.	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Figure	  3-­‐7.	  	  The	  Stiletto	  catheter	  for	  intramyocardial	  injection	  of	  cells.	  	  The	  picture	  demonstrates	  extension	  of	  the	  injection	  needle	  from	  the	  catheter.	  	  Image	  from	  Boston	  Scientific,	  Natick,	  MA,	  USA.	  
	  
There	  have	  been	  numerous	  studies	  investigating	  the	  use	  of	  injectable	  hydrogels	  within	  the	  field	  of	  cardiac	  tissue	  engineering.	  	  These	  have	  included	  the	  use	  of	  naturally	  occurring	  materials	  such	  as	  fibrin(Christman,	  Fok	  et	  al.	  2004,	  Christman,	  Vardanian	  et	  al.	  2004,	  Christman,	  Fang	  et	  al.	  2005,	  Huang,	  Yu	  et	  al.	  2005,	  Ryu,	  Kim	  et	  al.	  2005,	  Mukherjee,	  Zavadzkas	  et	  al.	  2008,	  Martens,	  Godier	  et	  al.	  2009,	  Yu,	  Christman	  et	  al.	  2009),	  gelatin(Sakakibara,	  Nishimura	  et	  al.	  2002,	  Iwakura,	  Fujita	  et	  al.	  2003,	  Sakakibara,	  Tambara	  et	  al.	  2003,	  Liu,	  Sun	  et	  al.	  2006),	  alginate(Landa,	  Miller	  et	  al.	  2008,	  Mukherjee,	  Zavadzkas	  et	  al.	  2008,	  Tsur-­‐Gang,	  Ruvinov	  et	  al.	  2009,	  Yu,	  Christman	  et	  al.	  2009,	  Yu,	  Gu	  et	  al.	  2009),	  chitosan(Deng,	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Zhang	  et	  al.	  ,	  Lu,	  Wang	  et	  al.	  ,	  Wang,	  Zhang	  et	  al.	  ,	  Lu,	  Lu	  et	  al.	  2009),	  hyaluronic	  acid(Tous,	  Ifkovits	  et	  al.	  ,	  Yoon,	  Fang	  et	  al.	  2009,	  Ifkovits,	  Tous	  et	  al.	  2010),	  collagen(Deng,	  Zhang	  et	  al.	  ,	  Thompson,	  Nasseri	  et	  al.	  2003,	  Dai,	  Wold	  et	  al.	  2005,	  Huang,	  Yu	  et	  al.	  2005,	  Kutschka,	  Chen	  et	  al.	  2006,	  Zhang,	  Zhang	  et	  al.	  2006)	  and	  even	  decellularised	  ventricular	  extracellular	  matrix(Duan,	  Liu	  et	  al.	  ,	  Singelyn,	  Sundaramurthy	  et	  al.).	  	  Synthetic	  hydrogels	  include	  the	  use	  of	  PEG(Kraehenbuehl,	  Ferreira	  et	  al.	  ,	  Rane,	  Chuang	  et	  al.	  ,	  Dobner,	  Bezuidenhout	  et	  al.	  2009,	  Kadner,	  Dobner	  et	  al.	  2012),	  Polycaprolactone	  (PCL)(Jiang,	  Wang	  et	  al.	  2008,	  Wang,	  Jiang	  et	  al.	  2009,	  Wang,	  Jiang	  et	  al.	  2009,	  Wang,	  Wu	  et	  al.	  2009),	  Poly-­‐lactic-­‐co-­‐glycolic	  acid	  (PLGA)(Lee,	  Tan	  et	  al.	  2009),	  and	  N-­‐isopropylacrylamide	  (NIPAAm)(Garbern,	  Minami	  et	  al.	  ,	  Wall,	  Yeh	  et	  al.).	  	  Several	  studies	  have	  also	  utilized	  hydrogels	  as	  a	  carrier	  for	  varying	  therapeutic	  molecules	  including	  insulin-­‐like	  growth	  factor	  (IGF)(Cittadini,	  Monti	  et	  al.	  ,	  Ruvinov,	  Leor	  et	  al.	  ,	  Davis,	  Hsieh	  et	  al.	  2006),	  vascular	  endothelial	  growth	  factor	  (VEGF)(Cittadini,	  Monti	  et	  al.	  ,	  Wu,	  Zeng	  et	  al.	  ,	  Kwon,	  Park	  et	  al.	  2009),	  fibroblast	  growth	  factor	  (FGF)(Wang,	  Zhang	  et	  al.),	  hepatocyte	  growth	  factor	  (HGF)(Ruvinov,	  Leor	  et	  al.)	  and	  thymosin	  beta-­‐4	  (TB4)(Kraehenbuehl,	  Ferreira	  et	  al.).	  	  The	  vast	  majority	  of	  these	  studies	  report	  outcomes	  of	  improvement	  in	  terms	  of	  cardiac	  function	  or	  regeneration	  post	  infarction.	  
The	  minority	  of	  studies	  have	  deliberately	  investigated	  the	  mechanical	  properties	  	  of	  hydrogels	  in	  the	  cardiac	  regeneration	  setting(Ifkovits,	  Tous	  et	  al.	  2010).	  	  This	  is	  a	  key	  area	  that	  requires	  attention	  due	  to	  the	  extensive	  mechanical	  consequences	  of	  myocardial	  infarction.	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3.1.3	  The	  mechanical	  consequences	  of	  myocardial	  infarction	  
Much	  of	  the	  dysfunction	  seen	  in	  the	  failing	  heart	  following	  a	  myocardial	  infarction	  can	  be	  attributed	  to	  the	  array	  of	  mechanical	  changes	  that	  occur	  following	  injury	  and	  healing(Holmes,	  Borg	  et	  al.	  2005)	  (Figure	  3-­‐8).	  	  	  
The	   first	   change	   to	   occur	   following	   a	   myocardial	   infarct	   is	   that	   the	   area	   of	  affected	  myocardium	  loses	  its	  ability	  to	  produce	  systolic	  force,	  and	  thus	  begins	  to	  act	   as	   a	   passive	   visco-­‐elastic	   material.	   	   It	   does	   not	   contribute	   to	   systolic	  contraction	  and	  output,	  and	  in	  fact	  may	  even	  further	  impede	  cardiac	  output	  due	  to	   the	   effects	   of	   paradoxical	   systolic	   bulging,	   whereby	   the	   area	   of	   infarct	  stretches	  during	  systole,	   thus	  reducing	  systolic	  pump	   function(Holmes,	  Borg	  et	  al.	  2005).	  	  
Within	  the	  first	  few	  hours	  to	  days	  of	  a	  myocardial	   infarction,	  the	  major	  cellular	  processes	  are	   those	  of	  necrosis	  and	   inflammation.	   	  The	   inflammatory	  response	  relates	   to	   an	   activation	   of	   specific	   pro-­‐inflammatory	   genes	   such	   as	   NF-­‐κB	   and	  pro-­‐inflammatory	  cytokines	  such	  as	  tumour	  necrosis	  factor	  (TNF)-­‐α(Sun	  2009).	  	  This	   cascade,	   along	   with	   the	   expression	   of	   further	   adhesion	   molecules	   and	  chemo-­‐attractant	   molecules,	   draw	   inflammatory	   cells	   such	   as	   neutrophils	   and	  macrophages	   into	   the	   infarcted	   tissue.	   	   Upregulation	   of	   matrix	  metalloproteinase’s	   (MMPs)	   with	   continued	   phagocytosis	   causes	   further	  breakdown	   of	   extracellular	   matrix	   (ECM)	   proteins,	   allowing	   infarct	   expansion	  and	  ventricular	  chamber	  expansion.	  	  	  This	  in	  turn	  increases	  local	  and	  global	  wall	  stresses	  potentially	  further	  worsening	  problems	  and	  even	  leading	  to	  ventricular	  rupture.	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As	   the	   inflammatory	   response	   continues,	   deposition	   of	   new	   ECM	   proteins	  will	  begin,	   in	   an	   attempt	   to	   heal	   the	   area	   of	   infarct,	   eventually	   leading	   to	  massive	  collagen	   deposition	  within	   the	   infarcted	   area(Holmes,	   Borg	   et	   al.	   2005).	   	   This	  fibrotic	  phase	  is	  associated	  with	  a	  massive	  increase	  in	  ventricular	  wall	  stiffness.	  	  Although	  this	  aims	  to	  reduce	  systolic	  dysfunction,	  it	  has	  significant	  impact	  upon	  systole	  due	  to	  interference	  with	  the	  contraction	  of	  adjacent	  muscle	  fibres.	  	  It	  also	  significantly	   impairs	   diastolic	   function	   and	   filling	   due	   to	   elevated	   chamber	  stiffness.	   	   This	   in	   turn	  may	   impair	   systolic	   function	   as	   dictated	   by	   the	   Frank-­‐Starling	  mechanism.	  	  	  
In	   the	   long	   term,	   the	   ventricle	   attempts	   to	   remodel,	   by	   altering	   cross-­‐linking	  between	  collagen	  chains.	  At	  this	  stage,	  cardiac	  function	  may	  recover	  to	  an	  extent,	  although	  significant	  effects	  upon	  diastolic	   function	  remain	  due	  to	  the	   increased	  relative	  stiffness	  of	   infarcted	  myocardium	  compared	  with	  normal	  myocardium,	  and	  high	  diastolic	  calcium	  levels.	   	  With	  large	  infarcts,	  ventricular	  dilatation	  will	  continue	   to	   dominate,	   leading	   to	   increased	   wall	   stresses	   and	   progressively	  impaired	  ventricular	  function.	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Figure	  3-­‐8:	  	  An	  overview	  of	  the	  cellular	  and	  mechanical	  changes	  that	  occur	  following	  myocardial	  infarction	  leading	  to	  cardiac	  failure.	  	  ECM	  –	  extracellular	  matrix.	  	  LVEF	  –	  left	  ventricular	  ejection	  fraction.	  	  ESV	  –	  end	  systolic	  volume.	  EDV	  –	  end	  diastolic	  volume.	  	  	  
	  
Although	  many	  studies	  have	  demonstrated	  potentially	  beneficial	  effects	  from	  the	  injection	  of	  cells(Christman,	  Vardanian	  et	  al.	  2004,	  Wang,	  Jiang	  et	  al.	  2009),	  growth	  factors(Hsieh,	  Davis	  et	  al.	  2006,	  Wang,	  Jiang	  et	  al.	  2009),	  and	  biomaterials(Jiang,	  Wang	  et	  al.	  2008,	  Dobner,	  Bezuidenhout	  et	  al.	  2009)	  into	  the	  ventricular	  wall,	  it	  is	  unclear	  whether	  the	  benefits	  come	  from	  molecular	  interactions	  leading	  to	  various	  cellular	  regenerative	  and	  protective	  pathways,	  or	  due	  to	  basic	  alterations	  in	  ventricular	  geometry,	  thus	  altering	  the	  mechanical	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behavior	  of	  the	  heart.	  Finite	  element	  model	  simulations	  of	  intramyocardial	  injections	  have	  indicated	  that	  the	  addition	  of	  non-­‐contractile	  material	  to	  the	  left	  ventricular	  wall	  following	  infarction	  can	  have	  important	  effects	  on	  cardiac	  mechanics,	  potentially	  reducing	  fibre	  stresses	  and	  improving	  measures	  such	  as	  ejection	  fraction(Wall,	  Walker	  et	  al.	  2006).	  	  These	  mechanical	  effects	  were	  found	  to	  be	  short	  term	  and	  may	  depend	  upon	  injection	  location,	  volume	  and	  stiffness.	  
These	  simulations	  have	  been	  supported	  by	  several	   in	  vivo	   studies	   investigating	  the	  effects	  of	  various	  types	  of	  hydrogel	  injection	  upon	  cardiac	  function	  following	  myocardial	   infarction.	   	   	   	  Dai	  et	  al.	  used	  a	   rat	  model	  of	  myocardial	   infarction	   to	  investigate	   the	   effects	   of	   collagen	   injection	   upon	   left	   ventricular	   function(Dai,	  Wold	   et	   al.	   2005).	   	   They	   demonstrated	   that	   injection	   of	   collagen	   into	   the	  myocardial	   scar	   1	   week	   following	   infarction	   led	   to	   improvements	   in	   stroke	  volume,	   ejection	   fraction	   and	   scar	   thickness	   compared	   with	   saline	   injected	  controls.	   	   Also,	   analysis	   of	   regional	   wall	   motion	   demonstrated	   paradoxical	  systolic	   bulging	   in	   5	   out	   of	   10	   saline	   injected	   rats,	   but	   none	   of	   the	   collagen	  injected	   rats.	   	   Landa	   et	   al.	   also	   used	   a	   rat	   model	   of	   myocardial	   infarction	   to	  investigate	   injections	   of	   a	   calcium	  alginate	   hydrogel(Landa,	  Miller	   et	   al.	   2008).	  	  This	   demonstrated	   increased	   scar	   thickness	   and	   attenuated	   ventricular	  dilatation	   compared	   with	   controls.	   	   Jiang	   et	   al.	   demonstrated	   the	   beneficial	  effects	  of	  a	   synthetic	  MPEG-­‐PCL-­‐MPEG	  hydrogel	   injections	   in	  a	   rabbit	  model	  of	  myocardial	   infarction(Jiang,	   Wang	   et	   al.	   2008).	   	   Hydrogel	   injections	   in	   this	  experiment	   resulted	   in	   significantly	   improved	   ejection	   fraction	   and	   left	  ventricular	   end-­‐systolic	   and	   end-­‐diastolic	   volumes	   after	   4	  weeks.	   	  Wang	   et	   al.	  used	   a	   similar	   rabbit	   model	   to	   test	   a	   thermosensitive	   synthetic	   gel,	   and	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demonstrated	   reduction	   in	   scar	   expansion	   and	   wall	   thinning	   as	   well	   as	  improvements	  in	  ejection	  fraction	  and	  left	  ventricular	  dilatation	  compared	  with	  controls(Wang,	  Wu	  et	  al.	  2009).	   	   	  Dobner	  et	  al.	  used	  a	  rat	  model	  of	  myocardial	  infarction	  to	  investigate	  the	  effects	  of	  a	  non-­‐degradable	  PEG	  hydrogel	  on	  cardiac	  function(Dobner,	  Bezuidenhout	  et	  al.	  2009).	  	  Although	  no	  differences	  were	  seen	  in	   fractional	   shortening	   and	   infarct	   volume	   compared	   with	   saline	   injected	  controls,	   there	   was	   a	   significant	   reduction	   in	   left	   ventricular	   end-­‐diastolic	  diameter.	   	   However,	   this	   beneficial	   effect	   had	   disappeared	   by	   a	   13-­‐week	   time	  point.	  	  Ifkovits	  et	  al.	  used	  an	  ovine	  model	  to	  demonstrate	  the	  beneficial	  effects	  of	  a	  hyaluronic	  acid	  based	  hydrogel	  (Ifkovits,	  Tous	  et	  al.	  2010).	  	  They	  found	  that	  a	  stiffer	   hydrogel	   was	   associated	   with	   increased	   myocardial	   wall	   thickness,	  smaller	   infarct	   area,	   and	   reductions	   in	   left	   ventricular	   end-­‐systolic	   and	   end-­‐diastolic	   volumes.	   	   Cardiac	   function	   in	   terms	   of	   ejection	   fraction	   upon	  dobutamine	  stress	  testing	  was	  also	  improved	  compared	  with	  control	  groups.	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Reference	   Biomaterial	   Animal	  Model	   Time	  Course	   Outcomes	  (Dai,	  Wold	  et	  al.	  2005)	   Collagen	   Rat	   6	  weeks	   á	  Scar	  thickness	  áSV	  áEF	  
â	  PSB	  (Dobner,	  Bezuidenhout	  et	  al.	  2009)	   PEG	   Rat	   13	  weeks	   â	  EDV	  (4	  weeks)	  =	  EDV	  (13	  weeks)	  (Fujimoto,	  Ma	  et	  al.	  2009)	   NIPAAm,	  AAc,	  HEMEPTMC	   Rat	   8	  weeks	   á	  FAC	  â	  EDA	  (Ifkovits,	  Tous	  et	  al.	  2010)	   MeHA	   Sheep	   8	  weeks	   á	  EF	  (stress	  test)	  â	  ESV	  
â	  EDV	  (Jiang,	  Wang	  et	  al.	  2008)	   α-­‐CD,	  MPEG-­‐PCL-­‐MPEG	   Rabbit	   4	  weeks	   á	  EF	  â	  ESV	  
â	  EDV	  (Kadner,	  Dobner	  et	  al.	  2012)	   PEG	   Rat	   4	  weeks	   á	  FS	  á	  Scar	  thickness	  â	  ESD	  	  (Landa,	  Miller	  et	  al.	  2008)	   Alginate	   Rat	   8	  weeks	   á	  Scar	  thickness	  â	  LVSD	  
â	  LVDD	  (Mukherjee,	  Zavadzkas	  et	  al.	  2008)	   Fibrin	  -­‐	  Alginate	   Pig	   4	  weeks	   â	  Infarct	  Expansion	  (Wang,	  Wu	  et	  al.	  2009)	   Dex-­‐PCL-­‐HEMA/PNIPAAm	   Rabbit	   4	  weeks	   á	  EF	  â	  EDD	  (Yu,	  Christman	  et	  al.	  2009)	   Alginate	   Rat	   10	  weeks	   á	  FS	  â	  LVSD	  
â	  LVDD	  	  Table	  3.1	  Studies	  investigating	  the	  effects	  of	  intramyocardial	  hydrogel	  injections	  on	  cardiac	  function	  following	  myocardial	  infarction	  SV	  =	  Stroke	  Volume	  EF	  =	  Ejection	  Fraction	  FS	  =	  Fractional	  Shortening	  PSB	  =	  Paradoxical	  Systolic	  Bulging	  ESV	  =	  End	  Systolic	  Volume	  EDV	  =	  End	  Diastolic	  Volume	  ESD	  =	  End	  Systolic	  Diameter	  EDD	  =	  End	  Diastolic	  Diameter	  LVSD	  =	  Left	  Ventricular	  Systolic	  Diameter	  LVDD	  =	  Left	  Ventricular	  Diastolic	  Diameter	  NIPAAm	  =	  N-­‐isopropylacrylamide	  PNIPAAm	  =	  Poly(N-­‐isopropylacrylamide)	  PCL-­‐HEMA	  =	  Poly(caprolactone)-­‐2-­‐Hydroxylethyl	  methacrylate	  AAc	  =	  Acrylic	  Acid	  HEMAPTMC	  =	  Hydroxyethyl	  methacylate-­‐poly(trimethylene	  carbonate)	  EDA	  =	  End	  Diastolic	  Cavity	  Area	  FAC	  =	  Fractional	  Area	  Change	  HA	  =	  Hyaluronic	  Acid	  
α-­‐CD	  =	  alpha	  cyclodextrin	  MPEG-­‐PCL-­‐MPEG	  =	  poly(ethyleneglycol)-­‐b-­‐polycaprolactone-­‐(dodecanedioic	  acid)-­‐	  polycaprolactone-­‐	  poly(ethylene	  glycol	  PEG	  =	  Polyethylene	  Glycol	  Dex-­‐PCL-­‐HEMA/PNIPAAm	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3.2	  Materials	  and	  Methods	  
	  
3.2.1	  Hydrogel	  formation	  
Four-­‐arm	  PEG	  acrylate	  (PEG4A:	  Average	  MW	  =	  23,300)	  (Figure	  3-­‐9)	  and	  PEG	  dithiol	  (PEGDT:	  Average	  MW	  =	  1,019)	  (Figure	  	  3-­‐10)	  were	  purchased	  from	  Laysan	  Bio	  (Arab,	  AL,	  USA)	  and	  Sigma-­‐Aldrich	  (Dorset,	  England)	  respectively.	  	  Basic	  PEG	  hydrogels	  were	  formed	  using	  a	  Michael	  addition	  reaction	  by	  adding	  PEGDT	  to	  PEG4A	  (Figure	  3-­‐11).	  	  PEG4A	  was	  dissolved	  in	  phosphate	  buffer	  solution	  (PBS),	  pH	  7.4,	  at	  varying	  weight/volume	  concentrations.	  	  For	  example	  to	  make	  a	  10%	  solution,	  10mg	  of	  PEG4A	  was	  dissolved	  in	  90µl	  of	  PBS.	  	  A	  20%	  solution	  was	  made	  with	  20mg	  of	  PEG4A	  and	  80µl	  of	  PBS	  and	  so	  forth.	  	  PEGDT	  was	  dissolved	  in	  a	  mixture	  of	  PBS	  and	  1%	  triethanolamine,	  at	  pH	  9.4,	  also	  in	  varying	  w/v	  concentrations.	  	  The	  two	  solutions	  were	  combined	  at	  37°C	  in	  stoichiometrically	  balanced	  ratios.	  	  	  
PEG-­‐Peptide	  gels	  were	  formed	  using	  a	  Michael	  addition	  reaction	  by	  adding	  solutions	  of	  CCRGDSCC	  peptide	  to	  four-­‐arm	  PEG	  acrylate.	  	  The	  peptide	  was	  dissolved	  in	  a	  mixture	  of	  PBS	  and	  1%	  triethanolamine,	  pH	  9.4	  in	  varying	  w/v	  concentrations,	  and	  mixed	  with	  four-­‐arm	  PEG	  acrylate	  in	  stoichiometrically	  balanced	  ratios	  at	  37°C.	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Figure	  3-­‐10:	  	  The	  chemical	  structure	  of	  PEG	  dithiol.	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Figure	   3-­‐11:	   	   Schematic	   diagram	   to	   demonstrate	   combination	   of	   4	   arm	   PEG	   acrylate	   and	   PEG	  dithiol	  to	  produce	  a	  crosslinked	  hydrogel.	  	  	  
	  
3.2.2	  Peptide	  synthesis	  
Peptides	  were	  created	  by	  solid	  phase	  peptide	  synthesis	  using	  a	  Protein	  Technologies	  Inc	  (Tuscon,	  AZ,	  USA)	  Symphony	  4-­‐channel	  synthesizer,	  with	  Fmoc/HBTI/HOBT	  chemistry.	  	  Amino	  acids	  and	  activators	  were	  from	  AGTC	  Bioproducts	  Ltd	  (Hessle,	  UK).	  	  Peptides	  were	  cleaved	  from	  the	  resin	  for	  4-­‐6	  hours	  at	  room	  temperature	  using	  a	  cleavage	  solution	  comprised	  of	  95%	  trifluoroacetic	  acid	  (TFA)	  (Sigma-­‐Aldrich,	  Dorset,	  England),	  1.25%	  deionized	  water,	  1.25%	  dithiothreitol	  (DTT)	  (Sigma-­‐Aldrich,	  Dorset,	  England),	  and	  2.5%	  triisopropylsilane	  (Tis)	  (Sigma-­‐Aldrich,	  Dorset,	  England).	  	  The	  solution	  was	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precipitated	  and	  washed	  three	  times	  using	  cold	  diethyl	  ether	  (4oC),	  recovered	  by	  centrifugation	  (4000rpm,	  4oC,	  5	  minutes)	  and	  dried	  in	  air.	  	  The	  precipitate	  was	  dissolved	  in	  deionized	  water	  and	  the	  final	  peptide	  product	  recovered	  by	  lyophilization.	  	  	  
The	  peptide	  was	  analyzed	  using	  mass	  spectrometry	  and	  high	  pressure	  liquid	  chromatography	  (HPLC)	  (Trilution	  LC	  Software,	  Gilson,	  Middleton,	  WI,	  USA).	  	  Short	  oligopeptides	  with	  the	  sequence	  CCRGDSCC	  were	  synthesized	  and	  stored	  at	  -­‐20	  oC.	  	  .	  There	  was	  batch-­‐to-­‐batch	  variation	  in	  purity,	  possibly	  due	  to	  errors	  in	  the	  synthesis	  process.	  	  For	  this	  reason,	  only	  peptide	  batches	  with	  purity	  greater	  than	  80%	  were	  used	  for	  hydrogel	  preparation.	  	  	  
	  
3.2.3	  Rheometry	  	  
Hydrogels	  were	  studied	  using	  small	  strain	  oscillatory	  shear	  experiments	  on	  an	  AR	  2000ex	  rheometer	  (TA	  Instruments,	  Crawley,	  West	  Sussex,	  England).	  	  Experiments	  were	  carried	  out	  using	  parallel	  plate	  geometry	  at	  37°C.	  	  To	  determine	  the	  gelation	  point	  of	  the	  hydrogels,	  PEG4A	  and	  PEGDT	  or	  peptide	  solutions	  were	  mixed	  with	  a	  pipette	  tip	  in	  stoichiometrically	  balanced	  ratios,	  and	  150µl	  of	  the	  mixture	  placed	  on	  the	  bottom	  plate	  of	  the	  rheometer.	  	  The	  upper	  plate	  (diameter	  25mm)	  was	  immediately	  lowered	  to	  a	  gap	  of	  300µm	  and	  the	  dynamic	  oscillating	  measurement	  commenced.	  	  The	  progression	  of	  both	  storage	  modulus	  (G’)	  and	  loss	  modulus	  (G’’)	  at	  a	  constant	  frequency	  of	  1Hz	  and	  strain	  of	  0.042	  was	  recorded	  as	  a	  function	  of	  global	  time	  (seconds).	  	  The	  gelation	  point	  was	  taken	  as	  the	  point	  of	  crossover	  of	  G’	  and	  G’’.	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To	  analyze	  the	  final	  mechanical	  properties	  of	  the	  hydrogels,	  gels	  were	  prepared	  in	  circular	  rubber	  moulds	  (depth	  2.5mm,	  diameter	  8mm)	  and	  allowed	  to	  crosslink	  at	  37°C	  overnight.	  	  The	  gels	  were	  extracted	  carefully	  from	  the	  moulds	  and	  placed	  on	  the	  lower	  plate	  of	  the	  rheometer.	  	  The	  upper	  plate	  (8mm)	  was	  lowered	  to	  a	  gap	  of	  2.5mm	  and	  the	  dynamic	  oscillating	  measurement	  commenced.	  	  G’	  was	  measured	  at	  a	  constant	  strain	  of	  0.2	  and	  frequency	  of	  1Hz	  at	  37°C.	  	  Strain	  sweeps	  (strain	  of	  0.1	  to	  2.5	  at	  constant	  frequency	  of	  1Hz)	  were	  also	  performed.	  	  	  
	  
3.2.4	  Hydrogel	  swelling	  and	  degradation	  
Gels	  were	  synthesized	  (300µl	  in	  volume)	  in	  2ml	  eppendorf	  tubes	  as	  previously	  described	  in	  varying	  w/v	  concentrations.	  	  The	  initial	  weight	  of	  the	  hydrogel	  and	  tube	  were	  recorded	  and	  the	  hydrogel	  immersed	  in	  1ml	  of	  PBS	  (pH7.4)	  at	  room	  temperature.	  	  The	  wet	  weight	  of	  hydrogel	  was	  measured	  at	  varying	  time	  periods	  and	  the	  weight	  increase	  or	  decrease	  calculated	  as	  a	  percentage	  relative	  to	  the	  original	  weight.	  	  	  
	  
3.2.5	  Encapsulation	  of	  cells	  within	  hydrogels	  
Rat	  Bone	  Marrow	  Cells	  (RBMCs)	  were	  harvested	  as	  described	  in	  section	  2.2.1.1.	  	  Cells	  were	  allowed	  to	  grow	  to	  near	  confluence	  in	  tissue	  culture	  flasks	  prior	  to	  use	  in	  experiments.	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RBMC	  cultures	  were	  trypsinised	  using	  Trypsin-­‐EDTA	  	  for	  2-­‐3	  minutes	  at	  37°C.	  	  Trypsin	  was	  neutralized	  using	  5x	  serum	  containing	  media,	  and	  placed	  in	  a	  centrifuge	  for	  5	  minutes	  at	  500	  rpm.	  	  Cells	  were	  resuspended	  in	  media	  and	  counted	  prior	  to	  encapsulation	  within	  hydrogels.	  	  
To	  encapsulate	  cells	  within	  hydrogels,	  the	  cell	  suspension	  was	  mixed	  with	  an	  equal	  volume	  of	  PEG4A	  solution.	  	  The	  PEG4A	  solution	  was	  made	  up	  to	  be	  double	  of	  the	  final	  intended	  PEG	  hydrogel	  concentration.	  	  After	  mixing	  with	  the	  cell	  suspension,	  the	  final	  PEGDT	  concentration	  was	  the	  desired	  final	  concentration.	  	  For	  example,	  to	  encapsulate	  cells	  within	  a	  10%	  PEG	  hydrogel,	  cell	  suspension	  was	  mixed	  with	  an	  equal	  volume	  of	  20%	  PEG4A	  to	  give	  a	  10%	  PEG4A	  mixture	  containing	  cells.	  	  PEGDT	  solution	  was	  added	  to	  this	  mixture	  in	  stoichiometrically	  balanced	  ratios	  (as	  described	  above)	  and	  200µl	  gels	  formed	  by	  pipetting	  this	  mixture	  into	  64	  well	  tissue	  culture	  plates.	  	  In	  this	  manner	  approximately	  60,000	  RBMCs	  were	  encapsulated	  into	  each	  200µl	  hydrogel.	  	  Control	  cultures	  were	  prepared	  by	  plating	  60,000	  RBMSCs	  into	  64	  well	  plates	  without	  hydrogel.	  	  	  
	  
3.2.6	  Cell	  Viability	  Studies	  
At	  various	  timepoints	  cell	  media	  covering	  hydrogel	  samples	  or	  cell	  culture	  was	  exchanged	  for	  10%	  Alamar	  Blue	  	  reagent	  (Invitrogen)	  and	  left	  for	  4	  hours	  in	  an	  incubator	  at	  37°C.	  	  Following	  this	  100µl	  aliquots	  were	  transferred	  to	  a	  96	  well	  plate	  with	  black	  opaque	  walls	  and	  clear	  bottom.	  	  Fluoresence	  was	  read	  using	  a	  Spectramax	  M5	  microplate	  reader	  (Molecular	  Devices,	  Sunnydale,	  CA,	  USA)	  (Excitation	  wavelength	  540nm,	  Emission	  wavelength	  580nm).	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3.3	  	  Results	  
	  
3.3.1	  Hydrogel	  formation	  
Hydrogels	  were	  formed	  by	  copolymerization	  of	  4-­‐arm	  PEG	  Acrylate	  with	  PEG	  Dithiol	  in	  stoichiometrically	  balanced	  ratios.	  	  Cross-­‐links	  between	  monomers	  were	  formed	  by	  utilizing	  the	  Michael-­‐type	  addition	  reaction	  at	  37°C.	  	  For	  the	  crosslinking	  reaction	  to	  proceed,	  PEG4A	  was	  dissolved	  in	  PBS	  at	  pH	  7.4,	  whilst	  PEGDT	  was	  dissolved	  in	  PBS	  with	  1%	  triethanolamine	  at	  pH	  9.4.	  	  Upon	  mixing	  of	  the	  monomer	  solutions	  in	  a	  1.75ml	  glass	  vial,	  gelation	  was	  seen	  to	  occur	  within	  minutes	  as	  demonstrated	  by	  absence	  of	  flow	  when	  the	  vial	  was	  inverted	  (Figure	  3-­‐12).	  	  PEG	  hydrogels	  were	  successfully	  formed	  at	  weight/volume	  concentrations	  of	  5%,	  10%,	  20%	  and	  30%.	  	  PEG	  monomers	  were	  not	  found	  to	  dissolve	  completely	  in	  solution	  at	  concentrations	  above	  30%,	  thus	  the	  formation	  of	  hydrogels	  at	  a	  higher	  concentration	  was	  not	  attempted.	  	  	  
PEG-­‐peptide	  hydrogels	  were	  formed	  by	  the	  copolymerization	  of	  PEG4A	  and	  CCRGDSCC	  peptide	  in	  stoichiometrically	  balanced	  ratios.	  	  Cross-­‐links	  between	  monomers	  were	  formed	  by	  the	  Michael-­‐type	  addition	  reaction	  between	  the	  PEG	  acrylate	  groups	  and	  the	  free	  thiol	  groups	  on	  the	  peptide	  cysteine	  residues.	  	  For	  the	  crosslinking	  reaction	  to	  proceed,	  PEG4A	  was	  dissolved	  in	  PBS	  at	  pH	  7.4,	  whilst	  the	  CCRGDSCC	  peptide	  was	  dissolved	  in	  PBS	  with	  1%	  triethanolamine	  at	  pH	  9.4.	  Upon	  mixing	  of	  the	  monomer	  solutions	  in	  a	  1.75ml	  glass	  vial,	  at	  37°C	  gelation	  was	  seen	  to	  occur	  within	  minutes	  as	  demonstrated	  by	  absence	  of	  flow	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when	  the	  vial	  was	  inverted.	  	  PEG-­‐peptide	  hydrogels	  were	  successfully	  formed	  at	  weight/volume	  concentrations	  of	  5%,	  10%,	  20%	  and	  30%.	  
	  
	  
Figure	   3-­‐12:	   Formation	   of	   a	   PEG	   hydrogel	   in	   a	   glass	   vial.	   	   PEG4A	   and	   PEGDT	   (10%	   w/v	  concentrations)	   were	   mixed	   in	   stoichiometrically	   balanced	   ratios	   within	   a	   1.75ml	   glass	   vial.	  	  Gelation	   occurred	   within	   minutes	   as	   demonstrated	   by	   absence	   of	   flow	   when	   the	   vial	   was	  inverted.	  	  	  
	  
3.3.2	  Rheometry	  
The	  evolution	  of	  G’	  and	  G’’	  was	  used	  to	  monitor	  the	  viscoelastic	  properties	  of	  the	  hydrogel	  at	  37°C.	  	  The	  gelation	  point	  was	  defined	  as	  the	  point	  of	  crossover	  between	  G’	  and	  G”,	  and	  the	  gelation	  time	  measured	  as	  the	  time	  taken	  to	  reach	  the	  gelation	  point	  (Figure	  3-­‐13).	  	  Gelation	  time	  of	  the	  PEG	  hydrogel	  (PEG4A	  +	  PEGDT)	  depended	  upon	  the	  w/v	  concentration	  of	  the	  hydrogel	  precursors,	  with	  higher	  concentrations	  of	  hydrogel	  having	  a	  shorter	  gelation	  time	  (Figure	  3-­‐14).	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The	  gelation	  times	  for	  5%,	  10%,	  20%	  and	  30%	  hydrogels	  were	  352.1	  +/-­‐	  123.6	  s	  (mean	  +/-­‐SD),	  195.4	  +/-­‐	  41.6	  s,	  139.7	  +/-­‐	  14.3s,	  138.1	  +/-­‐	  29.0	  s	  respectively.	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  gelation	  times	  between	  different	  gel	  concentrations.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  gelation	  time	  at	  the	  p<0.05	  level	  [F(3,16)	  =	  12.32,	  p	  =	  0.0002].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  difference	  in	  gelation	  time	  between	  the	  5%	  hydrogel	  concentration	  group	  and	  the	  10%,	  20%	  and	  30%	  hydrogel	  concentration	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  
A	  10%	  PEG-­‐peptide	  hydrogel	  composed	  of	  PEG4A	  and	  CCRGDSCC	  peptide	  took	  212.6	  +/-­‐	  0.09	  s	  to	  reach	  the	  gelation	  point.	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Figure	   3-­‐13:	   	   Rheological	   analysis	   of	   a	   20%	   PEG	   hydrogel.	   	   Hydrogel	   precursors	   (PEG4A	   and	  PEGDT,	  20%	  w/v	  concentrations)	  were	  mixed	  and	  allowed	  to	  gel	  at	  37°C	  whilst	  undergoing	  small	  strain	  oscillatory	  shear	  measurements	  using	  a	  parallel	  plate	  configured	  rheometer.	  	  This	  allows	  measurement	   of	   the	   storage	  modulus	   (G’,	   red	   circles)	   and	   loss	  modulus	   (G”,	   blue	   circles)	   over	  time.	  	  The	  gelation	  point	  is	  taken	  as	  the	  point	  of	  crossover	  between	  G’	  and	  G”.	  	  The	  gelation	  time	  is	  the	  time	  taken	  to	  reach	  the	  gelation	  point.	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PEG	  hydrogels	  of	  varying	  w/v	  concentrations	  were	  subjected	  to	  increasing	  levels	  of	  strain	  (0.1	  to	  2.5)	  at	  constant	  frequency	  1Hz.	  	  PEG	  hydrogels	  of	  lower	  concentration	  were	  able	  to	  tolerate	  greater	  degrees	  of	  strain	  before	  loss	  of	  structure,	  as	  demonstrated	  by	  abrupt	  reduction	  in	  G’	  measurements	  (Figure	  3-­‐15).	  	  	  
The	  maximum	  G’	  was	  measured	  for	  hydrogels	  that	  had	  been	  allowed	  to	  crosslink	  overnight	  at	  37°C	  (Strain	  0.2,	  Frequency	  1Hz).	  	  Hydrogels	  with	  higher	  w/v	  concentrations	  tended	  to	  be	  stiffer,	  as	  G’	  increased	  with	  increasing	  concentrations	  of	  the	  hydrogel.	  	  The	  maximum	  G’	  of	  5%,	  10%,	  20%	  and	  30%	  hydrogels	  were	  805.32	  +/-­‐	  262.9	  Pa	  (mean	  +/-­‐	  SD),	  6888.3	  +/-­‐	  1758.7	  Pa,	  17246.7	  +/-­‐	  1235.2	  Pa,	  and	  34912	  +/-­‐	  9460.5	  Pa	  respectively	  (Figure	  3-­‐16).	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Figure	  3-­‐15:	   	   PEG	  hydrogel	   strain	   sweeps.	   	  Hydrogels	  were	  prepared	   from	   the	   combination	   of	  PEG4A	   and	   PEGDT	   in	   varying	   weight/volume	   concentrations	   (5%	   -­‐	   	   red	   circles,	   10%	   -­‐	   blue	  circles,	  20%	  -­‐	  clear	  squares,	  30%	  -­‐	  purple	  squares).	  	  Hydrogels	  were	  allowed	  to	  set	  overnight	  at	  37°C	   in	   circular	  moulds	   (2.5mm	  height,	   8mm	  diameter).	   	   Formed	  hydrogels	  were	   subjected	   to	  rheological	   analysis	   by	   increasing	   levels	   of	   rotational	   strain	   (10%	   to	   250%)	   at	   a	   constant	  frequency	  of	  1Hz.	  	  Loss	  of	  hydrogel	  structure	  can	  be	  seen	  by	  abrupt	  decrease	  in	  storage	  modulus	  (G’).	   	  Hydrogels	  of	  higher	  weight/volume	  concentrations	   lost	   their	  structure	  at	  a	   lower	   level	  of	  strain	  than	  less	  concentrated	  hydrogels.	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3.3.3	  Hydrogel	  swelling	  and	  degradation	  
Hydrogels	  of	  varying	  concentrations	  (5%,	  10%,	  20%,	  30%,	  n=4	  for	  each	  concentration)	  were	  made,	  weighed	  and	  immersed	  in	  PBS.	  	  Wet	  weights	  were	  measured	  at	  regular	  intervals	  until	  the	  gels	  had	  completely	  degraded.	  	  More	  concentrated	  gels	  were	  found	  to	  swell	  more	  by	  weight	  and	  to	  take	  longer	  to	  degrade	  than	  less	  concentrated	  gels	  (Figure	  3-­‐17).	  	  30%	  hydrogels	  took	  an	  average	  of	  22	  days	  to	  fully	  degrade.	  	  	  
	  
	  
Figure	   3-­‐17:	   	   Hydrogel	   swelling	   and	   degradation.	   	   300µl	   of	   PEG	   hydrogels	   (PEG4A	   +	   PEGDT)	  were	  formed	  in	  2ml	  eppendorf	   tubes	  at	  varying	  weight/volume	  concentrations	  (5%	  -­‐	  blue	   line,	  10%	   -­‐	   red	   line,	  20%	   -­‐	   green	   line,	  30%	   -­‐	  purple	   line,	  n=4	  each	  group).	   	  Once	   the	  gels	  had	  been	  allowed	  to	  set	  overnight	  they	  were	  immersed	  in	  1ml	  of	  PBS.	   	  At	  varying	  time	  points	  excess	  PBS	  was	  aspirated	  and	  the	  wet	  weight	  of	  the	  gels	  measured.	  	  Weights	  were	  expressed	  as	  a	  percentage	  of	  their	  original	  weight.	  	  Hydrogels	  of	  higher	  weight/volume	  concentrations	  swelled	  to	  a	  greater	  extent	  and	  took	  longer	  to	  degrade	  than	  lower	  concentration	  hydrogels.	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3.3.4	  Cell	  encapsulation	  within	  hydrogels.	  
RBMSCs	  were	  encapsulated	  with	  200µl	  hydrogels	  of	  varying	  concentrations	  (5%,	  10%,	  20%,	  n=3	  for	  each	  concentration).	  	  Cell	  viability	  was	  assessed	  using	  Alamar	  Blue	  reagent	  at	  timepoints	  of	  1	  day,	  3	  days,	  7	  days,	  and	  10days.	  	  Fluorescence	  values	  were	  normalized	  to	  values	  taken	  at	  day	  1.	  
Alamar	  blue	  fluorescence	  significantly	  increased	  compared	  with	  day	  one	  in	  all	  hydrogel	  samples	  ((Figure	  	  3-­‐18).	  	  For	  5%	  hydrogels	  the	  peak	  was	  reached	  at	  day	  3	  (602%	  +/-­‐	  30%;	  mean	  +/-­‐	  SD).	  For	  10%	  hydrogels	  the	  peak	  was	  reached	  at	  day	  10	  (457	  +/-­‐	  27%)	  and	  for	  20%	  hydrogels	  on	  day	  7	  (673	  +/-­‐	  7%).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  normalized	  alamar	  blue	  signals	  between	  different	  time	  points	  for	  the	  hydrogel	  groups.	  	  There	  was	  a	  significant	  difference	  found	  at	  the	  p<0.05	  level,	  with	  post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  confirming	  that	  all	  hydrogel	  groups	  demonstrated	  increased	  alamar	  blue	  signal	  compared	  with	  Day	  1	  .	  	  	  
Due	  to	  the	  different	  swelling	  and	  degradation	  properties	  of	  each	  type	  of	  hydrogel,	  comparisons	  were	  not	  made	  across	  hydrogels	  at	  the	  time	  points.	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Figure	  3-­‐18.	  	  Viability	  and	  proliferation	  of	  RBMSCs	  encapsulated	  within	  PEG	  hydrogels	  assessed	  by	  Alamar	  blue	  fluorescence	  (normalized	  to	  day	  1	  values).	  	  N=3	  for	  each	  column.	  	  D1	  =	  Day1,	  D3	  =	  Day3,	  D7	  =	  Day7,	  D10	  =	  Day10.	  	  All	  hydrogels	  exhibited	  significantly	  increased	  alamar	  blue	  fluorescence	  compared	  with	  day	  1	  timepoints	  (p<0.01)	  indicating	  cell	  proliferation.	  	  Comparisons	  of	  alamar	  blue	  fluorescence	  were	  not	  made	  between	  hydrogel	  types	  due	  to	  differences	  in	  swelling	  and	  degradation	  characteristics.	  	  Column	  values	  represent	  mean	  values,	  with	  error	  bars	  representing	  standard	  error	  means.	  	  *	  =	  p<0.05	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3.4	  Discussion	  
	  
3.4.1	  Hydrogel	  formation	  
A	  polyethylene	  glycol	  based	  hydrogel	  was	  synthesized	  using	  the	  Michael-­‐type	  addition	  reaction	  between	  acrylate	  and	  thiol	  side	  groups.	  	  	  
The	  reactivity	  between	  acrylate	  and	  thiol	  groups	  was	  also	  taken	  advantage	  of	  in	  the	  preparation	  of	  PEG-­‐peptide	  hydrogels,	  where	  short	  oligopeptides	  with	  free	  cysteine	  residues	  (containing	  thiol	  side	  groups)	  were	  used	  as	  the	  cross-­‐linking	  molecule.	  	  	  
The	  advantages	  of	  using	  this	  method	  of	  cross-­‐linking	  are	  that	  the	  reactions	  can	  occur	  rapidly	  within	  near	  physiological	  parameters	  of	  temperature	  and	  pH.	  	  Also,	  no	  chemical	  or	  irradiative	  initiators	  are	  required	  for	  the	  reaction.	  	  These	  factors	  make	  this	  reaction	  suitable	  for	  the	  targeted	  application	  of	  cardiac	  stem	  cell	  therapy.	  	  	  
It	  is	  important	  that	  transplanted	  cells	  are	  not	  damaged	  by	  the	  crosslinking	  reaction.	  	  The	  ability	  for	  these	  crosslinks	  to	  form	  at	  physiological	  pH	  and	  temperatures,	  plus	  the	  lack	  of	  free	  radical	  producing	  initiators	  bodes	  well	  for	  this	  application.	  	  The	  biocompatibility	  of	  these	  types	  of	  PEG	  hydrogels	  have	  already	  been	  demonstrated	  for	  several	  cell	  types	  including	  endothelial	  cells(Kraehenbuehl,	  Ferreira	  et	  al.	  2009),	  fibroblasts(Lutolf,	  Lauer-­‐Fields	  et	  al.	  2003),	  and	  embryonic	  carcinoma	  cells(Kraehenbuehl,	  Zammaretti	  et	  al.	  2008).	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It	  is	  also	  important	  that	  therapeutic	  proteins	  delivered	  within	  the	  hydrogel	  are	  also	  not	  damaged	  or	  altered	  by	  the	  cross-­‐linking	  reaction.	  	  Previous	  work	  has	  demonstrated	  that	  the	  rate	  of	  reaction	  between	  PEG	  acrylate	  groups	  with	  thiol	  containing	  compounds	  proceeds	  at	  a	  much	  faster	  rate	  than	  with	  the	  amine	  groups	  that	  are	  found	  in	  proteins(Elbert,	  Pratt	  et	  al.	  2001).	  	  Similarly,	  acrylate	  and	  thiol	  groups	  did	  not	  bind	  successfully	  to	  the	  cysteine	  groups	  found	  in	  natural	  proteins	  such	  as	  albumin	  in	  physiological	  conditions,	  possibly	  due	  to	  steric	  hinderence.	  Therefore	  any	  therapeutic	  proteins	  within	  the	  hydrogel	  are	  unlikely	  to	  be	  altered	  by	  potential	  reactions	  with	  the	  PEG	  monomers.	  	  	  
Previous	  work	  has	  demonstrated	  the	  ability	  of	  these	  hydrogels	  to	  act	  as	  a	  drug	  or	  protein	  delivery	  system,	  allowing	  continual	  and	  delayed	  release	  over	  time.	  	  This	  has	  been	  shown	  for	  molecules	  such	  as	  thymosin	  β4(Kraehenbuehl,	  Ferreira	  et	  al.	  2009),	  albumin(Elbert,	  Pratt	  et	  al.	  2001),	  bone	  morphogenetic	  protein(Lutolf,	  Weber	  et	  al.	  2003),	  human	  growth	  hormone(van	  de	  Wetering,	  Metters	  et	  al.	  2005).	  	  The	  delivery	  of	  therapeutic	  proteins	  will	  also	  play	  a	  key	  part	  in	  any	  successful	  tissue	  engineering	  strategy	  for	  the	  heart.	  	  	  
The	  Michael-­‐addition	  reaction	  can	  also	  be	  exploited	  further	  in	  order	  to	  covalently	  bind	  specific	  peptides	  to	  the	  hydrogel	  structure.	  	  This	  can	  be	  in	  the	  form	  of	  cross-­‐linking	  peptides,	  such	  as	  the	  matrix-­‐metalloproteinase	  sensitive	  sequence	  GPQG-­‐IWGQ,	  thus	  allowing	  cell-­‐dependent	  degradation	  of	  the	  hydrogel	  for	  cell	  invasion	  purposes(Lutolf,	  Lauer-­‐Fields	  et	  al.	  2003).	  	  Pendant	  peptides	  can	  also	  be	  bound	  to	  the	  PEG	  monomers	  such	  as	  the	  integrin	  binding	  sequence	  RGD	  to	  improve	  cellular	  adhesion,	  or	  other	  pro-­‐survival	  molecules	  such	  as	  vascular	  endothelial	  growth	  factor	  (VEGF)(Seliktar,	  Zisch	  et	  al.	  2004).	  	  An	  alternative	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approach	  was	  demonstrated	  by	  combining	  an	  MMP	  sensitive	  sequence	  with	  a	  fluorescent	  protein	  marker,	  which	  may	  thus	  allow	  cell	  dependent	  release	  of	  therapeutic	  molecules(Seliktar,	  Zisch	  et	  al.	  2004).	  
The	  use	  of	  a	  PEG	  hydrogel	  crosslinked	  by	  the	  Michael	  addition	  reaction	  therefore	  should	  provide	  a	  cell	  compatible	  and	  easily	  modifiable	  backbone	  for	  any	  tissue	  regenerative	  strategy.	  	  	  
	  
3.4.2	  Rheology	  
The	  ability	  to	  control	  the	  mechanical	  properties	  of	  the	  hydrogel	  is	  important,	  and	  is	  a	  factor	  that	  has	  been	  largely	  overlooked	  in	  cell	  therapy	  work	  so	  far.	  	  The	  infarcted	  myocardium	  undergoes	  a	  multitude	  of	  changes	  including	  the	  inflammatory	  response	  that	  leads	  to	  the	  breakdown	  of	  extracellular	  matrix	  and	  thus	  increasing	  the	  compliance	  of	  the	  infarct	  scar(Holmes,	  Borg	  et	  al.	  2005).	  	  This	  in	  turn	  can	  lead	  to	  infarct	  thinning,	  ventricular	  dilatation	  and	  both	  systolic	  and	  diastolic	  dysfuction.	  	  In	  the	  long	  term,	  fibrotic	  changes	  increase	  the	  scar	  stiffness	  leading	  to	  a	  long	  cycle	  of	  ventricular	  remodeling	  and	  worsening	  cardiac	  failure.	  	  Understanding	  the	  mechanics	  of	  myocardial	  infarction	  is	  of	  great	  importance	  and	  it	  follows	  that	  the	  mechanical	  properties	  of	  any	  injected	  material	  will	  have	  an	  effect	  upon	  myocardial	  function.	  	  The	  effect	  of	  hydrogel	  stiffness	  on	  myocardial	  function	  was	  investigated	  recently	  in	  an	  ovine	  model,	  which	  demonstrated	  that	  following	  infarction,	  injected	  hydrogels	  of	  a	  higher	  stiffness	  were	  associated	  with	  improved	  measures	  of	  cardiac	  output(Ifkovits,	  Tous	  et	  al.	  2010).	  	  However,	  the	  mechanical	  properties	  of	  hydrogels	  also	  have	  a	  large	  effect	  upon	  cellular	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differentiation(Engler,	  Sen	  et	  al.	  2006)	  and	  function(Engler,	  Carag-­‐Krieger	  et	  al.	  2008)	  with	  suggestions	  that	  both	  cardiomyogenic	  differentiation	  and	  function	  is	  best	  preserved	  with	  a	  matrix	  that	  mimics	  the	  natural	  mechanics	  of	  normal	  cardiac	  muscle.	  	  Recent	  analysis	  of	  cardiac	  muscle	  using	  Atomic	  Force	  Microscopy	  (AFM)	  has	  shown	  normal	  myocardium	  to	  have	  an	  elastic	  modulus	  of	  18kPa	  and	  infarcted	  myocardium	  to	  have	  an	  elastic	  modulus	  of	  55kPa(Berry,	  Engler	  et	  al.	  2006).	  	  Although	  the	  rheological	  analysis	  performed	  measures	  shear	  modulus,	  it	  is	  possible	  to	  estimate	  the	  corresponding	  elastic	  modulus	  (E)	  assuming	  a	  Poisson’s	  ratio	  (µ)	  of	  0.5	  (a	  reasonable	  assumption	  for	  crosslinked	  gels)	  using	  the	  equation	  E	  =	  2G’(1+µ)(Elbert,	  Pratt	  et	  al.	  2001).	  	  This	  leads	  to	  estimates	  of	  elastic	  modulus	  of	  2.4kPa,	  20.7kPa.	  51.7kPa	  and	  104.7kPa	  for	  the	  5%,	  10%,	  20%	  and	  30%	  PEG	  hydrogels	  respectively.	  	  Thus	  it	  would	  seem	  possible	  to	  synthesize	  hydrogels	  over	  a	  range	  of	  stiffness	  to	  match	  either	  normal	  or	  infarcted	  myocardium.	  	  This	  property	  is	  important	  for	  further	  tissue	  regenerative	  strategies.	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3.4.3	  Hydrogel	  swelling	  and	  degradation	  	  	  
Hydrogels	  were	  found	  to	  swell	  and	  degrade	  over	  time	  when	  placed	  in	  PBS.	  	  The	  ability	  to	  take	  up	  fluid	  and	  swell	  is	  a	  well	  established	  characteristic	  of	  many	  hydrogel	  networks	  and	  some	  hydrogels	  are	  known	  to	  take	  up	  thousands	  of	  times	  their	  dry	  weight	  in	  water(Hoffman	  2002).	  	  This	  process	  typically	  takes	  place	  in	  several	  stages,	  with	  water	  first	  hydrating	  polar	  hydrophilic	  groups	  (primary	  bound	  water)	  and	  next	  interacting	  with	  exposed	  hydrophobic	  groups	  (secondary	  bound	  water).	  	  The	  water	  interacting	  with	  the	  hydrophilic	  and	  hydrophobic	  components	  of	  a	  hydrogel	  is	  called	  the	  total	  bound	  water.	  	  Following	  this,	  the	  hydrogel	  network	  continues	  to	  absorb	  water	  due	  to	  osmotic	  forces	  (free	  water),	  which	  is	  opposed	  by	  the	  hydrogel	  crosslinks,	  leading	  to	  an	  elastic	  network	  retraction	  force.	  	  This	  gives	  the	  hydrogel	  an	  equilibrium	  swelling	  level.	  	  	  	  	  
Degradation	  was	  thought	  to	  occur	  via	  hydrolytic	  cleavage	  of	  the	  ester	  bond	  formed	  between	  acrylate	  and	  thiol	  groups(Elbert	  and	  Hubbell	  2001,	  Seliktar,	  Zisch	  et	  al.	  2004).	  	  Degradation	  occurred	  between	  8	  and	  22	  days	  when	  hydrogels	  were	  left	  in	  PBS.	  	  Although	  the	  use	  of	  other	  side	  groups	  such	  as	  vinyl	  sulfone	  groups	  are	  known	  to	  produce	  more	  stable	  bonds	  when	  reacted	  with	  thiol	  side	  groups(Seliktar,	  Zisch	  et	  al.	  2004),	  degradation	  of	  the	  hydrogel	  is	  a	  desired	  property	  in	  the	  case	  of	  cell	  delivery	  strategies(Davis,	  Hsieh	  et	  al.	  2005).	  	  This	  allows	  transplanted	  cells	  to	  move,	  develop	  cell-­‐cell	  and	  cell-­‐matrix	  interactions,	  which	  may	  be	  required	  for	  tissue	  regeneration.	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3.4.4	  Cell	  Viability	  and	  encapsulation	  within	  hydrogels	  
Alamar	  blue	  is	  a	  resazurin	  based	  blue	  dye	  that	  is	  reduced	  during	  the	  redox	  reactions	  in	  cell	  metabolism	  to	  pink	  coloured	  and	  highly	  fluorescent	  resorufin.	  	  It	  is	  used	  commonly	  as	  a	  marker	  of	  cell	  metabolism	  and	  thus	  viability.	  	  As	  each	  type	  of	  hydrogel	  swelled	  and	  degraded	  at	  different	  rates,	  it	  was	  felt	  that	  this	  would	  affect	  the	  delivery	  of	  Alamar	  blue	  to	  the	  cells,	  and	  thus	  the	  fluorescent	  signal.	  	  It	  was	  therefore	  not	  appropriate	  to	  directly	  compare	  fluorescent	  signals	  across	  different	  hydrogel	  groups.	  	  	  
Using	  Alamar	  Blue	  fluorescence	  as	  a	  marker	  of	  cell	  viability,	  5%,	  10%	  and	  20%	  hydrogels	  were	  found	  to	  maintain	  viable	  cells	  up	  to	  a	  time	  point	  of	  10	  days.	  	  Furthermore	  Alamar	  Blue	  fluorescence	  significantly	  increased	  with	  time,	  indicating	  that	  the	  hydrogels	  may	  also	  allow	  cell	  proliferation.	  	  Maintenance	  of	  viable	  cells	  and	  allowing	  cell	  proliferation	  are	  certainly	  key	  characteristics	  necessary	  for	  any	  tissue	  regenerative	  strategy.	  	  	  
	  
3.5	  Summary	  
This	  data	  broadly	  supports	  the	  use	  of	  a	  PEG	  based	  hydrogel,	  crosslinked	  by	  the	  Michael	  Addition	  reaction	  between	  acrylate	  and	  thiol	  side	  groups,	  as	  a	  backbone	  for	  future	  cardiac	  tissue	  regeneration	  strategies.	  	  The	  hydrogel	  in	  question	  is	  available	  as	  a	  solution,	  crosslinking	  upon	  mixing	  within	  a	  clinically	  relevant	  timeframe.	  	  This	  allows	  injection	  and	  application	  to	  minimally	  invasive	  techniques.	  	  The	  hydrogel	  is	  also	  degradable,	  and	  supports	  cell	  survival	  and	  proliferation.	  	  Importantly	  it	  is	  also	  easily	  tunable	  to	  match	  the	  physical	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properties	  of	  target	  tissue	  which	  is	  important	  for	  mechanically	  active	  tissues	  such	  as	  myocardium.	  	  Finally,	  the	  PEG	  backbone	  is	  easily	  modifiable,	  with	  the	  ability	  to	  bond	  cysteine	  tagged	  peptides,	  thus	  allowing	  future	  modification	  to	  aid	  cell-­‐matrix	  interactions	  and	  incorporation	  of	  survival	  factors.	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The	  effects	  of	  intramyocardial	  hydrogel	  injections	  on	  the	  healthy	  heart	  
	  
4.1	  Introduction	  
The	  heart	  is	  highly	  dependent	  upon	  mechanics	  for	  its	  function.	  	  Changes	  to	  the	  mechanical	  properties	  of	  the	  myocardium	  can	  have	  huge	  effects	  upon	  cardiac	  function	  and	  lead	  to	  devastating	  clinical	  consequences.	  	  Myocardial	  infarction	  leads	  to	  a	  continuing	  cycle	  of	  cardiac	  failure	  not	  simply	  due	  to	  loss	  of	  cardiomyocyte	  function	  in	  the	  infarcted	  zone,	  but	  also	  due	  to	  the	  massive	  mechanical	  changes	  that	  occur	  in	  the	  myocardium	  following	  infarction(Holmes,	  Borg	  et	  al.	  2005).	  	  As	  described	  by	  Holmes	  et	  al.	  there	  are	  four	  distinct	  phases	  following	  a	  myocardial	  infarction	  that	  can	  be	  defined	  by	  changes	  in	  myocardial	  mechanical	  properties(Holmes,	  Borg	  et	  al.	  2005).	  	  Firstly	  in	  the	  acute	  ischaemia	  stage,	  the	  infarcted	  zone	  behaves	  as	  a	  passive	  elastic	  material	  with	  increased	  compliance.	  	  This	  is	  followed	  by	  a	  stage	  of	  myocardial	  necrosis,	  where	  compliance	  reduces	  and	  the	  infarcted	  zone	  begins	  to	  stiffen.	  	  Infarct	  zone	  stiffness	  reaches	  a	  peak	  in	  the	  phase	  of	  myocardial	  fibrosis,	  followed	  by	  the	  stage	  of	  remodeling	  where	  scar	  stiffness	  reduces	  slightly.	  	  Each	  of	  these	  changes	  in	  the	  mechanical	  properties	  of	  the	  infarct	  zone	  is	  associated	  with	  an	  effect	  upon	  ventricular	  function	  and	  geometry.	  
Injection	  of	  cells,	  biomaterials	  or	  a	  combination	  into	  the	  infarct	  or	  peri-­‐infarct	  zone	  is	  a	  common	  experimental	  method	  within	  the	  field	  of	  tissue	  engineering	  research(Christman,	  Fok	  et	  al.	  2004,	  Christman,	  Vardanian	  et	  al.	  2004,	  Christman,	  Fang	  et	  al.	  2005,	  Dai,	  Wold	  et	  al.	  2005,	  Davis,	  Hsieh	  et	  al.	  2005,	  Leor,	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Amsalem	  et	  al.	  2005,	  Christman	  and	  Lee	  2006,	  Hsieh,	  Davis	  et	  al.	  2006,	  Jawad,	  Ali	  et	  al.	  2007,	  Jiang,	  Wang	  et	  al.	  2008).	  	  The	  aims	  of	  this	  research	  are	  usually	  to	  demonstrate	  cardiac	  tissue	  regeneration	  and	  therefore	  improved	  cardiac	  function.	  	  Many	  of	  these	  studies	  demonstrate	  positive	  benefits	  upon	  cardiac	  function	  as	  measured	  by	  outcomes	  such	  as	  ejection	  fraction	  (EF).	  	  This	  includes	  studies	  of	  cell	  injection	  as	  well	  as	  studies	  with	  purely	  acellular	  material	  injections.	  	  Therefore	  whether	  the	  positive	  effect	  on	  cardiac	  function	  is	  truly	  due	  to	  cardiac	  regeneration	  can	  be	  questioned.	  	  As	  the	  myocardium	  is	  so	  dependent	  upon	  its	  mechanical	  properties	  for	  effective	  function,	  it	  is	  possible	  that	  the	  injection	  of	  material	  into	  the	  myocardial	  wall	  affects	  the	  mechanical	  properties	  of	  the	  myocardium	  enough	  to	  cause	  changes	  in	  cardiac	  function.	  
This	  question	  was	  elegantly	  answered	  by	  Wall	  et	  al.	  	  in	  their	  finite	  element	  (FE)	  model	  of	  myocardial	  infarction,	  where	  they	  simulated	  the	  effects	  of	  biomaterial	  injection	  upon	  ventricular	  geometry	  and	  function(Wall,	  Walker	  et	  al.	  2006).	  	  They	  found	  that	  small	  injections	  of	  a	  non-­‐contractile	  material	  into	  the	  ventricular	  wall	  following	  infarction	  could	  significantly	  reduce	  wall	  fibre	  stress	  and	  change	  ventricular	  geometry	  enough	  to	  cause	  changes	  in	  ventricular	  function	  when	  measured	  by	  outcomes	  such	  as	  EF.	  	  They	  commented	  that	  reducing	  wall	  stress	  was	  potentially	  a	  clinically	  significant	  finding	  due	  to	  the	  fact	  that	  elevated	  stresses	  in	  the	  infarct	  border	  zone	  may	  contribute	  significantly	  to	  cardiac	  remodeling	  following	  myocardial	  infarction.	  	  However	  the	  apparent	  improvement	  in	  ventricular	  contractility	  as	  measured	  by	  EF	  may	  be	  a	  result	  of	  changes	  to	  ventricular	  geometry	  as	  opposed	  to	  true	  cardiac	  regeneration.	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A	  further	  FE	  model	  was	  demonstrated	  by	  Kortsmit	  et	  al.	  (Kortsmit,	  Davies	  et	  al.)	  who	  investigated	  this	  question	  in	  more	  detail	  by	  applying	  4	  separate	  infarct	  models	  to	  represent	  the	  4	  stages	  of	  myocardial	  mechanical	  change	  following	  infarction	  as	  described	  by	  Holmes	  et	  al.	  	  (Holmes,	  Borg	  et	  al.	  2005).	  	  They	  also	  found	  that	  hydrogel	  injections	  led	  to	  a	  reduction	  in	  myocardial	  fibre	  stress	  in	  their	  infarct	  models,	  as	  well	  as	  an	  apparent	  increase	  in	  apparent	  left	  ventricular	  function	  as	  measured	  by	  stroke	  volume	  (SV)	  and	  EF.	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4.2	  Methods	  
	  
4.2.1	  Langendorff	  model	  
Five	  hearts	  from	  adult	  male	  Sprague	  Dawley	  rats	  were	  used	  to	  set	  up	  the	  Langendorff	  circuit	  as	  described	  in	  section	  2.3.4.	  	  Once	  the	  heart	  was	  stabilized	  and	  beating	  successfully	  on	  the	  circuit,	  wires	  were	  introduced	  into	  the	  posterior	  surface	  of	  the	  heart,	  allowing	  continuous	  and	  real	  time	  readings	  of	  the	  ECG	  signal.	  	  	  
For	  three	  experiments,	  the	  left	  ventricular	  pressure	  was	  also	  measured.	  	  This	  was	  achieved	  through	  the	  use	  of	  a	  water	  filled	  catheter,	  tipped	  with	  a	  balloon.	  	  A	  pressure	  transducer	  (Millar	  Instruments,	  Houston,	  Texas,	  USA)	  was	  introduced	  down	  the	  catheter,	  with	  the	  tip	  placed	  within	  the	  balloon.	  	  A	  hole	  was	  cut	  into	  the	  left	  atrium,	  and	  the	  catheter	  with	  balloon	  introduced	  into	  the	  left	  ventricle	  via	  the	  mitral	  valve	  (Figure	  4-­‐1).	  	  The	  balloon	  was	  filled	  with	  water	  until	  a	  variable	  pressure	  signal	  could	  be	  measured	  that	  corresponded	  with	  systole	  and	  diastole.	  	  	  	  	  
Following	  set	  up	  of	  ECG	  and	  pressure	  reading	  equipment,	  the	  system	  was	  allowed	  to	  settle	  for	  3-­‐5	  minutes.	  	  	  
A	  20%	  PEG	  hydrogel	  was	  prepared	  by	  mixing	  4-­‐armed	  PEG	  acrylate	  and	  PEG	  dithiol	  as	  described	  in	  section	  3.2.1.	  	  An	  Evans	  blue	  solution	  was	  added	  to	  the	  mixture	  to	  a	  final	  concentration	  of	  2%.	  	  Using	  a	  28G	  needle,	  150µl	  of	  the	  hydrogel	  was	  injected	  into	  the	  anterior	  left	  ventricular	  wall	  and	  allowed	  to	  gel	  in	  situ	  (figure	  4-­‐2).	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Following	  the	  injection,	  the	  heart	  was	  monitored	  for	  10	  minutes	  to	  measure	  heart	  rate,	  number	  of	  arrythmias	  and	  left	  ventricular	  pressure.	  	  Left	  ventricular	  pressures	  following	  injection	  were	  expressed	  as	  a	  percentage	  of	  baseline	  (pre-­‐injection)	  pressure.	  	  	  
Following	  completion	  of	  the	  study,	  hearts	  were	  sectioned	  in	  the	  short	  axis	  using	  a	  heart	  cutting	  matrix,	  and	  frozen	  in	  optimal	  cutting	  temperature	  (OCT)	  compound	  as	  described	  in	  section	  2.5.	  	  10µM	  sections	  were	  taken	  to	  examine	  spread	  of	  the	  evans	  blue	  dye	  throughout	  the	  myocardium.	  	  As	  a	  control	  2	  hearts	  were	  set	  up	  on	  the	  langendorff	  circuit	  and	  received	  injections	  of	  150µl	  2%	  evans	  blue	  dye	  without	  hydrogel.	  	  	  
	  
	  
Figure	  4-­‐1.	  	  The	  Langendorff	  heart	  with	  ECG	  and	  left	  ventricular	  pressure	  measurements.	  	  The	  heart	  is	  attached	  to	  the	  Langendorff	  circuit	  via	  a	  perfusion	  catheter	  introduced	  retrogradely	  to	  the	  aortic	  root,	  where	  it	  is	  tied	  in	  place.	  	  ECG	  wires	  are	  attached	  to	  the	  posterior	  surface	  of	  the	  heart.	  	  The	  pressure	  transducer	  is	  introduced	  into	  the	  left	  ventricle	  via	  an	  incision	  made	  in	  the	  left	  atrium.	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Figure	  4-­‐2:	   	   Injection	  of	  PEG	  hydrogel	   into	  the	  Langendorff	  heart.	   	  150	  µl	  of	  20%	  PEG	  hydrogel	  (PEG4A	   +	   PEGDT)	  with	   2%	   evans	   blue	   dye	  was	   injected	   into	   the	   left	   ventricular	  wall.	   	   Effects	  upon	  ECG	  tracings	  and	  left	  ventricular	  pressure	  measurements	  were	  recorded.	  	  
	  
4.2.2	  In	  vivo	  hydrogel	  injection	  and	  Pressure-­‐Volume	  Loop	  analysis	  
Four	  rats	  underwent	  20%	  PEG	  hydrogel	  injection	  (150µl)	  as	  described	  in	  section	  2.3.6.	  	  One	  week	  later	  the	  same	  rats	  underwent	  pressure-­‐volume	  loop	  analysis	  as	  described	  in	  section	  2.3.7.	  	  Five	  age-­‐matched	  rats	  underwent	  pressure-­‐volume	  loop	  analysis	  without	  hydrogel	  injection	  as	  controls.	  	  	  
Outcomes	  measured	  included	  left	  ventricular	  end	  systolic	  and	  diastolic	  volumes	  (ESV	  and	  EDV),	  stroke	  volume	  (SV)	  and	  ejection	  fraction	  (EF).	  	  End	  systolic	  and	  end	  diastolic	  pressure	  volume	  relationships	  (ESPVR	  and	  EDPVR)	  were	  measured	  by	  continual	  measurement	  during	  temporary	  occlusion	  of	  the	  inferior	  vena	  cava	  (IVC).	  	  All	  data	  was	  recorded	  using	  Powerlabs	  data	  acquisition	  systems	  and	  Labchart	  software	  (Millar	  Systems,	  Houston,	  Texas,	  USA).	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4.2.3	  In	  vivo	  hydrogel	  injection	  and	  Cardiac	  MRI	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4.3	  Results	  
	  
4.3.1	  Langendorff	  model	  
The	  Langendorff	  model	  with	  injection	  of	  20%	  PEG	  hydrogel	  into	  the	  left	  ventricular	  wall	  was	  performed	  with	  5	  hearts.	  	  All	  5	  cases	  underwent	  ECG	  recordings.	  	  3	  cases	  also	  underwent	  left	  ventricular	  pressure	  measurements.	  	  	  
Following	  injection	  of	  20%	  PEG	  hydrogel,	  ECG	  tracings	  revealed	  no	  evidence	  of	  ectopy	  or	  arrythmia	  in	  any	  hearts	  during	  recording.	  	  There	  was	  no	  significant	  change	  in	  heart	  rate	  following	  hydrogel	  injection	  with	  the	  average	  heart	  rate	  prior	  to	  hydrogel	  injection	  being	  125	  beats	  per	  minute	  (bpm)	  +/-­‐	  22bpm,	  and	  the	  heart	  rate	  post	  injection	  being	  127bpm	  +/-­‐	  26bpm	  (p=0.9)	  (Figure	  4-­‐3).	  	  	  
Left	  ventricular	  pressure	  measurements	  also	  revealed	  no	  significant	  change	  following	  injection	  (p=0.64),	  with	  the	  mean	  post-­‐injection	  left	  ventricular	  pressures	  averaging	  93%	  (+/-­‐	  25%)	  of	  pre-­‐injection	  pressures.	  (Figure	  4-­‐4)	  	  	  
Inspection	  of	  the	  sections	  taken	  from	  Langendorff	  hearts	  revealed	  qualitatively	  a	  greater	  amount	  of	  Evans	  blue	  staining	  in	  hydrogel	  injected	  hearts	  compared	  with	  control	  injected	  hearts	  (Figure	  4-­‐5)	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Figure	  4-­‐3:	  	  The	  effects	  of	  PEG	  hydrogel	  injection	  on	  heart	  rate	  in	  the	  Langendorff	  model.	  	  150µl	  of	  20%	  PEG	  hydrogel	  (PEG4A	  +	  PEGDT)	  were	  injected	  into	  the	  left	  ventricular	  wall	  in	  a	  Langendorff	  heart.	  	  Continual	  heart	  rate	  recordings	  were	  measured	  prior	  and	  following	  hydrogel	  injections.	  	  The	  average	  heart	  rate	  prior	  to	  hydrogel	  injection	  was	  125	  beats	  per	  minute	  (bpm)	  +/-­‐	  22bpm,	  and	  the	  heart	  rate	  post	  injection	  was	  127bpm	  +/-­‐	  26bpm	  (p=0.9)	  
	  
Figure	  4-­‐4:	  	  The	  effects	  of	  20%	  PEG	  hydrogel	  injection	  on	  mean	  left	  ventricular	  pressure	  in	  the	  Langendorff	  Model.	  	  Post-­‐injection	  pressures	  are	  expressed	  as	  a	  percentage	  of	  pre-­‐injection	  pressures	  due	  to	  large	  variability	  in	  pre-­‐injection	  pressure	  measurements.	  	  Post-­‐injection	  pressures	  averaged	  93%	  +/-­‐25%	  of	  pre-­‐injection	  pressures	  (p=0.64).	  




Figure	  4-­‐5.	  	  Cardiac	  sections	  taken	  from	  Langendorff	  hearts.	  	  (A)	  mid-­‐ventricular	  section	  from	  a	  hydrogel	  injected	  group.	  	  (B)	  mid-­‐ventricular	  section	  from	  a	  control	  injected	  group.	  	  There	  is	  increased	  appearance	  of	  myocardial	  staining	  by	  Evans	  Blue	  in	  the	  hydrogel	  injected	  group	  compared	  with	  the	  control	  injected	  group.	  	  	  
	  
4.3.2	  In	  Vivo	  hydrogel	  Injection	  and	  Pressure-­‐Volume	  Loop	  Analysis	  
Four	  rats	  received	  150µl	  injections	  of	  20%	  PEG	  hydrogel	  into	  the	  left	  ventricular	  wall,	  and	  had	  PV	  loop	  measurements	  a	  week	  later.	  	  5	  normal	  rats	  (age-­‐matched)	  underwent	  PV	  loop	  measurement	  as	  controls.	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The	  injected	  group	  were	  found	  to	  have	  significant	  increases	  in	  both	  average	  end	  systolic	  volume	  (ESV)	  and	  end	  diastolic	  volume	  (EDV)	  compared	  with	  age-­‐matched	  controls	  (ESV:	  166.9	  +/-­‐	  44.1µl	  	  vs	  74.9	  +/-­‐	  28.3µl,	  p	  =	  0.02;	  EDV	  228.0	  +/-­‐	  40.2µl	  vs	  147.7	  +/-­‐	  19.4µl,	  p	  =	  0.02)	  (Figure	  4-­‐6)	  
End	  systolic	  pressure	  (ESP)	  and	  end	  diastolic	  pressure	  (EDP)	  were	  not	  significantly	  different	  in	  the	  injected	  and	  control	  groups	  (ESP:	  98.5	  +/-­‐	  26.0	  mmHg	  vs	  118.4	  +/-­‐	  28.9	  mmHg,	  p	  =	  0.27;	  EDP:	  5.6	  +/-­‐	  1.9	  mmHg	  vs	  22.1	  +/-­‐	  23.4	  mmHg,	  p	  =	  0.19)	  (Figure	  4-­‐6).	  	  	  
There	  was	  no	  significant	  difference	  in	  stroke	  volume	  between	  the	  injected	  and	  control	  groups	  (82.6	  +/-­‐	  31.8µl	  vs	  89.8	  +/-­‐	  26.2µl)	  and	  although	  there	  was	  a	  trend	  towards	  a	  reduction	  in	  ejection	  fraction	  in	  the	  injected	  group,	  this	  did	  not	  quite	  reach	  statistical	  significance	  (35.2	  +/-­‐	  13.0%	  vs	  56.6	  +/-­‐	  14.7%,	  p=0.054)	  (Figure	  4-­‐7).	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Figure	  4-­‐6:	  Pressure	  Volume	  Loop	  measurements	  of	  left	  ventricular	  volume	  and	  pressure.	  	  150µl	  of	  20%	  PEG	  hydrogels	  	  (PEG4A	  +	  PEGDT)	  were	  injected	  in	  50µl	  aliquots	  into	  the	  left	  ventricular	  wall.	   	  PV	   loop	  measurements	  were	  taken	  1	  week	   later.	  The	   injection	  group	  were	   found	  to	  have	  significant	   increases	   in	  both	  end	  systolic	  volume	  and	  end	  diastolic	  volume	  compared	  with	  age-­‐matched	   controls	   (A).End	   systolic	   pressure	   and	   end	   diastolic	   pressure	   were	   not	   significantly	  different	  in	  the	  injected	  and	  control	  groups	  (B).	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Figure	  4-­‐7:	  Pressure	  Volume	  Loop	  measurements	  of	   left	  ventricular	  stroke	  volume	  and	  ejection	  fraction.	  	  150µl	  of	  20%	  PEG	  hydrogels	  	  (PEG4A	  +	  PEGDT)	  were	  injected	  in	  50µl	  aliquots	  into	  the	  left	  ventricular	  wall.	   	  PV	  loop	  measurements	  were	  taken	  1	  week	  later.	  There	  was	  no	  significant	  difference	  in	  stroke	  volume	  between	  the	  injected	  and	  control	  groups	  (A)	  and	  although	  there	  was	  a	   trend	   towards	   a	   reduction	   in	   ejection	   fraction	   in	   the	   injected	   group,	   this	   did	  not	   quite	   reach	  statistical	  significance	  (B).	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Figure	  4-­‐8:	   	  Measurement	  of	   the	  End-­‐Systolic	  and	  End-­‐Diastolic	  pressure	  volume	  relationships.	  	  Experimental	  data	  demonstrated	  for	  a	  rat	  from	  the	  20%	  PEG	  hydrogel	  injection	  group.	  	  Transient	  occlusion	  of	  the	  inferior	  vena	  cava	  (IVC)	  during	  pressure	  volume	  loop	  measurements	  produce	  a	  series	  of	   loops	  as	  shown	  above.	   	  Fitting	  a	   line	  to	  the	  successive	  end	  systolic	  points	  (red	  circles)	  and	  end	  diastolic	  points	  (green	  circles)	  allows	  measurement	  of	  the	  end	  systolic	  pressure	  volume	  relationship	  (ESPVR	  –	  red	  dashed	  line)	  and	  end	  diastolic	  pressure	  volume	  relationship	  (EDPVR-­‐	  green	  dashed	  line).	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4.3.3	  In	  Vivo	  hydrogel	  Injection	  and	  Cardiac	  MRI	  
3	  Rats	  underwent	  10%	  PEG	  hydrogel	  injections	  into	  the	  left	  ventricular	  wall,	  with	  2	  further	  rats	  having	  saline	  injections	  as	  control.	  	  Cardiac	  MRI	  was	  performed	  1-­‐2	  days	  later.	  
End	  systolic	  and	  end	  diastolic	  volume	  did	  not	  differ	  significantly	  between	  the	  two	  groups	  (figure	  4-­‐9).	  	  Average	  end	  diastolic	  volume	  was	  412µl	  +/-­‐	  24µl	  (mean	  +/-­‐	  SD)	  and	  400µl	  +/-­‐	  54	  µl	  for	  the	  saline	  injected	  and	  hydrogel	  injected	  groups	  respectively.	  	  	  
Ejection	  fraction	  was	  also	  similar	  between	  groups,	  with	  the	  saline	  injected	  group	  averaging	  73%	  +/-­‐	  5%,	  and	  the	  hydrogel	  injected	  group	  averaging	  78%	  +/-­‐	  11%	  (figure	  4-­‐10).	  
There	  were	  no	  significant	  differences	  in	  stroke	  volume	  between	  the	  saline	  injected	  and	  hydrogel	  injected	  groups,	  with	  measurements	  of	  298	  µl	  +/-­‐	  3µl	  and	  310µl	  +/-­‐	  58	  µl	  respectively	  (figure	  4-­‐11).	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Figure	  4-­‐9	  	  End	  diastolic	  and	  systolic	  volumes	  for	  saline	  injected	  and	  hydrogel	  injected	  groups.	  	  There	  were	  no	  significant	  differences	  between	  groups.	  	  	  
	  
Figure	  4-­‐10.	  	  Average	  Ejection	  Fraction	  for	  Saline	  Injected	  and	  Hydrogel	  Injected	  groups.	  	  There	  were	  no	  significant	  differences	  found	  between	  groups.	  







Figure	  4-­‐11.	  	  Average	  Stroke	  volume	  for	  Saline	  Injected	  and	  Hydrogel	  Injected	  groups.	  	  There	  were	  no	  significant	  differences	  found	  between	  groups.	  
	  
	   141	  
	  










	   142	  
4.4	  Discussion	  
Many	  groups	  investigating	  cellular	  therapies	  to	  treat	  heart	  failure	  following	  myocardial	  infarction	  have	  combined	  the	  use	  of	  biomaterial	  scaffolds	  along	  with	  cells.	  	  Typically	  the	  aims	  of	  the	  biomaterial	  scaffold	  are	  to	  increase	  transplanted	  cell	  retention,	  and	  to	  support	  the	  transplanted	  cell	  population	  with	  adhesion	  molecules	  and/or	  soluble	  factors,	  which	  could	  improve	  the	  survival	  of	  transplanted	  cells.	  	  By	  meeting	  these	  goals,	  the	  belief	  is	  that	  cellular	  therapy	  will	  be	  more	  successful	  in	  achieving	  myocardial	  regeneration,	  and	  thus	  improving	  cardiac	  function	  and	  clinical	  outcomes.	  	  	  
However,	  injection	  of	  completely	  acellular	  biomaterials	  has	  also	  been	  shown	  to	  improve	  measures	  of	  cardiac	  function	  following	  myocardial	  infarction,	  implying	  that	  beneficial	  effects	  do	  not	  completely	  depend	  upon	  the	  presence	  of	  transplanted	  cells	  in	  regenerative	  strategies.	  	  	  
Although	  biomaterials	  can	  be	  designed	  to	  carry	  bioactive	  molecules	  and	  thus	  have	  a	  biological	  effect	  even	  without	  the	  presence	  of	  cells,	  the	  simulation	  studies	  carried	  out	  by	  Wall	  et	  al.(Wall,	  Walker	  et	  al.	  2006)	  and	  Kortsmit	  et	  al.	  (Kortsmit,	  
Davies	  et	  al.)	  	  have	  shown	  that	  biomaterials	  may	  have	  a	  beneficial	  effect	  purely	  due	  to	  mechanical	  effects	  associated	  with	  their	  presence.	  	  In	  their	  simulations,	  they	  demonstrated	  that	  the	  injection	  of	  small	  volumes	  of	  material	  around	  the	  infarct	  zone	  can	  cause	  significant	  changes	  in	  terms	  of	  ventricular	  geometry	  and	  reducing	  wall	  fibre	  stress	  .	  	  These	  changes	  may	  in	  turn	  explain	  the	  apparent	  benefits	  seen	  in	  measures	  of	  cardiac	  output	  such	  as	  ejection	  fraction.	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Several	  in	  vivo	  studies	  have	  shown	  a	  beneficial	  effect	  of	  simple	  hydrogel	  injections	  following	  myocardial	  infarction.	  	  As	  reported	  earlier,	  the	  use	  of	  collagen	  (Dai,	  Wold	  et	  al.	  2005),	  alginates	  (Landa,	  Miller	  et	  al.	  2008),	  hyaluronic	  acid	  (Ifkovits,	  Tous	  et	  al.	  2010),	  and	  completely	  synthetic	  gels	  (Jiang,	  Wang	  et	  al.	  2008)	  (Wang,	  Wu	  et	  al.	  2009)	  (Dobner,	  Bezuidenhout	  et	  al.	  2009)	  for	  intramyocardial	  injections	  following	  myocardial	  infarction	  in	  a	  variety	  of	  animal	  models	  have	  led	  to	  improvements	  in	  measures	  of	  cardiac	  function.	  	  However,	  the	  studies	  done	  by	  Dobner	  et	  al.	  demonstrated	  that	  these	  beneficial	  effects	  could	  only	  be	  temporary	  as	  an	  initial	  improvement	  in	  left	  ventricular	  end-­‐diastolic	  diameter	  had	  disappeared	  by	  the	  13	  week	  time	  point.	  	  	  	  	  	  
The	  aims	  of	  this	  series	  of	  experiments	  were	  to	  further	  investigate	  how	  the	  injection	  of	  biomaterials	  could	  affect	  measures	  of	  ventricular	  geometry	  and	  cardiac	  function.	  	  It	  was	  decided	  to	  investigate	  the	  effects	  of	  injection	  upon	  a	  normal	  non-­‐infarcted	  heart,	  to	  demonstrate	  any	  detrimental	  effects	  upon	  cardiac	  function	  as	  a	  result	  of	  changes	  in	  myocardial	  mechanical	  properties.	  	  	  A	  20%	  PEG	  hydrogel	  was	  chosen	  for	  the	  first	  sets	  of	  experiments	  using	  the	  Langendorff	  model	  and	  in-­‐vivo	  pressure	  volume	  loop	  measurements,	  as	  our	  previous	  work	  has	  shown	  that	  this	  has	  approximately	  the	  same	  stiffness	  as	  infarcted	  tissue	  (Section	  3.4.2),	  thus	  increasing	  the	  chances	  of	  demonstrating	  an	  effect.	  
Using	  the	  Langendorff	  model	  it	  was	  possible	  to	  measure	  the	  electrical	  effects	  of	  hydrogel	  injection	  upon	  a	  non-­‐infarcted	  heart,	  as	  well	  as	  limited	  left	  ventricular	  pressure	  data.	  	  Our	  results	  showed	  no	  significant	  effects	  upon	  heart	  rate	  following	  hydrogel	  injection	  and	  no	  evidence	  of	  ectopy	  or	  arrhythmia	  following	  injection.	  	  This	  is	  an	  important	  safety	  point,	  especially	  given	  the	  pro-­‐arrhythmic	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nature	  of	  myocardial	  infarction,	  and	  reports	  from	  clinical	  trials	  of	  increased	  arrhythmogenesis	  following	  skeletal	  myoblast	  transfer	  for	  cardiac	  failure(Menasche,	  Alfieri	  et	  al.	  2008).	  	  	  
Data	  regarding	  left	  ventricular	  pressure	  were	  limited	  primarily	  due	  to	  the	  drawbacks	  of	  the	  Langendorff	  model	  and	  pressure	  measurement	  apparatus.	  	  No	  significant	  differences	  were	  found	  in	  left	  ventricular	  pressure	  following	  hydrogel	  injection.	  	  However,	  post-­‐injection	  pressures	  had	  to	  be	  expressed	  as	  percentages	  of	  pre-­‐injection	  pressures	  due	  to	  the	  large	  amount	  of	  variability	  in	  pressure	  measurement.	  	  The	  Langendorff	  model	  removes	  the	  heart	  from	  the	  normal	  physiological	  environment,	  including	  removing	  its	  attachment	  to	  the	  circulatory	  system.	  	  Therefore	  the	  only	  way	  to	  measure	  ventricular	  pressure	  was	  to	  set	  up	  an	  artificial	  system	  whereby	  the	  ventricle	  contracted	  around	  a	  fluid	  filled	  balloon,	  containing	  a	  pressure	  sensor.	  	  This	  method	  was	  very	  dependent	  upon	  balloon	  positioning	  and	  amount	  of	  fluid	  within	  the	  balloon,	  and	  led	  to	  large	  variations	  in	  measurements.	  	  	  
Examination	  of	  sections	  from	  the	  Langendorff	  hearts	  demonstrated	  that	  qualitatively	  there	  was	  more	  Evans	  blue	  staining	  in	  hydrogel	  injected	  hearts	  than	  controls.	  	  This	  would	  imply	  that	  the	  hydrogel	  allowed	  more	  retention	  of	  injected	  Evans	  Blue	  dye	  within	  the	  myocardium	  compared	  with	  injections	  without	  hydrogel.	  	  This	  further	  supports	  the	  method	  of	  improving	  cellular	  retention	  with	  hydrogel	  injections.	  	  	  
In	  vivo	  pressure	  volume	  loop	  analysis	  allowed	  measurements	  of	  cardiac	  parameters	  in	  a	  more	  accurate	  and	  physiological	  fashion.	  	  	  	  Injection	  of	  150µl	  of	  20%	  hydrogel	  resulted	  in	  significant	  changes	  in	  ventricular	  geometry	  as	  shown	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by	  increases	  in	  both	  end	  diastolic	  and	  end	  systolic	  left	  ventricular	  volumes	  after	  1	  week.	  	  These	  geometrical	  measures	  are	  often	  used	  as	  markers	  of	  ventricular	  remodeling	  and	  cardiac	  failure.	  	  It	  would	  appear	  from	  these	  results	  that	  hydrogel	  injection	  can	  stretch	  the	  ventricular	  wall	  with	  corresponding	  increases	  in	  chamber	  size.	  	  	  
Left	  ventricular	  systolic	  and	  diastolic	  pressures	  were	  not	  significantly	  affected	  by	  hydrogel	  injection.	  	  These	  measures	  would	  only	  be	  expected	  to	  fall	  in	  severe	  or	  end	  stage	  cardiac	  failure.	  
Stroke	  volume	  and	  ejection	  fraction	  are	  used	  commonly	  in	  clinical	  practice	  as	  a	  measure	  of	  ventricular	  function.	  	  Although	  both	  measures	  did	  not	  show	  statistically	  significant	  change	  following	  hydrogel	  injection,	  ejection	  fraction	  did	  fall	  from	  56.6%	  to	  35.2%	  with	  a	  p	  value	  of	  	  0.054.	  	  It	  is	  possible	  that	  increasing	  the	  number	  of	  rats	  in	  the	  experiment	  may	  have	  allowed	  this	  result	  to	  reach	  significance.	  	  A	  fall	  in	  ejection	  fraction	  would	  also	  be	  expected	  in	  this	  case,	  due	  to	  the	  aforementioned	  increase	  in	  ventricular	  chamber	  size	  whilst	  maintaining	  the	  same	  stroke	  volume	  (ejection	  fraction	  =	  stroke	  volume	  /	  end	  diastolic	  volume).	  
Measurement	  of	  the	  ESPVR	  allows	  analysis	  of	  the	  inherent	  contractile	  or	  inotropic	  status	  of	  the	  myocardium,	  independent	  of	  loading	  conditions.	  	  There	  were	  no	  significant	  differences	  in	  the	  ESPVR	  between	  the	  injected	  and	  control	  groups,	  indicating	  that	  injection	  of	  the	  hydrogel	  did	  not	  alter	  the	  inotropic	  state	  of	  the	  ventricle.	  	  	  Measurement	  of	  the	  EDPVR	  allows	  analysis	  of	  ventricular	  compliance	  and	  thus	  diastolic	  function.	  	  Although	  the	  results	  did	  not	  quite	  reach	  statistical	  significance,	  there	  was	  a	  trend	  towards	  an	  increase	  in	  the	  EDPVR	  in	  the	  injected	  group.	  	  Further	  experimental	  numbers	  may	  allow	  this	  trend	  to	  gain	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statistical	  significance.	  	  This	  trend	  is	  commonly	  seen	  in	  models	  of	  cardiac	  failure	  following	  myocardial	  infarction(Lyon,	  MacLeod	  et	  al.	  2009).	  	  	  The	  PEG	  hydrogel	  that	  was	  injected	  into	  this	  model	  was	  of	  20%	  concentration,	  with	  an	  estimated	  elastic	  modulus	  of	  51.7kPa	  (see	  above).	  	  This	  is	  very	  similar	  in	  stiffness	  to	  infarcted	  myocardium,	  which	  was	  measured	  by	  atomic	  force	  microscopy	  to	  have	  an	  elastic	  modulus	  of	  55kPa(Berry,	  Engler	  et	  al.	  2006).	  	  In	  essence	  therefore,	  by	  injecting	  this	  hydrogel	  into	  the	  myocardium	  we	  have	  introduced	  a	  volume	  of	  stiff	  non-­‐contractile	  material	  that	  may	  simulate	  infarcted	  tissue.	  	  This	  effect	  may	  have	  caused	  the	  resultant	  changes	  in	  EDPVR	  to	  mimic	  those	  of	  cardiac	  failure.	  	  
Pressure	  volume	  loop	  analysis	  demonstrated	  therefore	  that	  stiff	  hydrogel	  injections	  into	  the	  myocardial	  wall	  could	  affect	  ventricular	  geometry	  and	  measures	  of	  function	  as	  suggested	  by	  Wall	  and	  Kortsmit,	  even	  in	  the	  non-­‐infarcted	  heart.	  
The	  next	  set	  of	  experiments	  involved	  injection	  of	  a	  10%	  PEG	  hydrogel,	  previously	  demonstrated	  to	  have	  a	  stiffness	  similar	  to	  healthy	  non-­‐infarcted	  myocardium	  (section	  3.4.2).	  	  This	  was	  compared	  with	  rats	  that	  had	  intramyocardial	  saline	  injections	  as	  a	  control.	  	  Cardiac	  MRI	  was	  used	  to	  measure	  ventricular	  geometry	  and	  function	  1	  –	  2	  days	  following	  injection,	  as	  it	  is	  widely	  accepted	  clinically	  as	  being	  a	  excellent	  high	  resolution	  and	  non-­‐invasive	  method	  of	  cardiac	  assessment.	  	  	  
No	  significant	  differences	  were	  found	  between	  saline	  and	  hydrogel	  injected	  groups	  in	  measures	  of	  ventricular	  geometry	  (end	  diastolic	  and	  end	  systolic	  volumes),	  or	  ventricular	  function	  (stroke	  volume	  and	  ejection	  fraction).	  	  If	  compared	  with	  previously	  published	  data	  on	  sham	  operated	  Sprague	  Dawley	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rats(Stuckey,	  Carr	  et	  al.	  2008),	  these	  results	  were	  also	  very	  similar	  (figure	  4-­‐12).	  	  These	  results	  demonstrate	  that	  injection	  of	  a	  10%	  PEG	  hydrogel	  does	  not	  have	  short-­‐term	  detrimental	  effects	  upon	  normal	  cardiac	  geometry	  and	  function,	  and	  may	  therefore	  be	  safe	  for	  use	  in	  further	  experiments.	  
This	  series	  of	  experiments	  utilized	  a	  variety	  of	  different	  methods	  to	  assess	  cardiac	  function	  as	  well	  as	  using	  differing	  time	  points.	  	  It	  is	  important	  to	  highlight	  the	  differences	  between	  the	  models	  and	  how	  the	  methods	  used	  may	  have	  affected	  outcomes.	  	  As	  discussed	  previously,	  the	  ex-­‐vivo	  Langendorff	  set	  up	  is	  compromised	  by	  its	  detachment	  from	  the	  circulatory	  and	  neuro-­‐endocrine	  system,	  meaning	  that	  results	  are	  dependent	  upon	  the	  myocardial	  response	  alone,	  without	  any	  other	  important	  physiological	  input.	  	  The	  functioning	  of	  the	  cardiovascular	  system	  as	  a	  whole	  is	  dependent	  upon	  a	  multitude	  of	  feedback	  loops,	  and	  the	  generation	  of	  meaningful	  data	  may	  be	  questioned	  once	  the	  heart	  has	  been	  removed	  from	  these	  feedback	  systems.	  	  Similarly,	  responses	  from	  the	  Langendorff	  set	  up	  can	  be	  time	  dependent,	  as	  the	  myocardium	  will	  continually	  deteriorate,	  giving	  only	  a	  limited	  time	  window	  for	  usable	  data	  collection.	  	  	  
In	  vivo	  Pressure-­‐Volume	  loop	  measurement	  allows	  assessment	  of	  cardiac	  function	  in	  a	  more	  physiological	  setting,	  meaning	  that	  results	  can	  be	  more	  easily	  extrapolated	  to	  the	  fully	  functional	  cardiovascular	  system	  compared	  with	  the	  Langendorff	  model.	  	  However,	  critics	  of	  the	  system	  will	  correctly	  point	  out	  that	  Pressure-­‐Volume	  loop	  measurement	  is	  an	  invasive	  procedure,	  and	  injury	  to	  the	  myocardium	  by	  introduction	  of	  the	  PV	  catheter	  may	  have	  an	  effect	  upon	  left	  ventricular	  function.	  	  Similarly,	  the	  need	  for	  open	  chest	  surgery	  may	  have	  effects	  upon	  thoracic	  pressures	  further	  affecting	  your	  results.	  	  The	  time	  point	  used	  for	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this	  set	  of	  experiments	  was	  1	  week.	  	  According	  to	  our	  previous	  work,	  a	  20%	  PEG	  hydrogel	  would	  not	  be	  expected	  to	  fully	  degrade	  until	  approximately	  2-­‐3	  weeks,	  and	  therefore	  it	  was	  assumed	  that	  at	  a	  time	  point	  of	  1	  week,	  the	  hydrogel	  would	  still	  be	  present	  in	  the	  myocardium	  and	  exerting	  an	  effect.	  	  	  
Cardiac	  MRI	  is	  widely	  used	  in	  humans	  for	  the	  clinical	  assessment	  of	  cardiac	  function,	  and	  provides	  excellent	  high-­‐resolution	  images	  of	  the	  heart	  throughout	  the	  cardiac	  cycle.	  	  Being	  a	  completely	  non-­‐invasive	  technique	  it	  allows	  assessment	  of	  cardiac	  function	  in	  a	  true	  physiological	  environment	  without	  the	  caveats	  of	  either	  the	  Langendorff	  or	  Pressure-­‐Volume	  loop	  methods.	  	  As	  it	  is	  also	  less	  operator-­‐dependent	  than	  the	  other	  two	  models,	  reproducibility	  is	  improved	  and	  variation	  reduced.	  	  Out	  of	  all	  the	  methods	  used	  in	  this	  series	  of	  experiments,	  cardiac	  MRI	  can	  be	  thought	  of	  as	  the	  most	  accurate	  measure	  of	  cardiac	  function.	  
	  
4.5	  Summary	  
Previously	  published	  finite	  element	  model	  simulations	  have	  suggested	  that	  injections	  of	  biomaterial	  into	  the	  left	  ventricular	  wall	  following	  an	  infarct	  may	  have	  significant	  effects	  upon	  ventricular	  geometry	  and	  function.	  	  This	  has	  been	  supported	  by	  several	  in	  vivo	  studies	  demonstrating	  the	  beneficial	  effects	  of	  hydrogel	  injection	  upon	  cardiac	  function	  following	  myocardial	  infarction.	  
This	  series	  of	  experiments	  demonstrates	  that	  injection	  of	  a	  stiff	  hydrogel	  (approximating	  an	  infarct)	  may	  also	  adversely	  affect	  measures	  of	  ventricular	  geometry	  and	  function	  in	  a	  normal	  non-­‐infarcted	  heart.	  	  	  	  Injections	  of	  a	  more	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The	  Protective	  effects	  of	  Erythropoietin	  
	  
5.1	  Introduction	  
Human	  erythropoietin	  (Epo)	  is	  a	  165	  amino	  acid	  protein	  hormone	  that	  is	  primarily	  produced	  in	  the	  kidney,	  by	  the	  renal	  tubular	  interstitium(Brines	  and	  Cerami	  2008).	  	  It	  has	  a	  well	  understood	  role	  in	  regulating	  erythropoiesis,	  and	  maintains	  erythrocyte	  mass	  by	  preventing	  apoptosis	  of	  erythrocyte	  precursors(Brines	  and	  Cerami	  2006).	  	  Epo	  production	  is	  normally	  induced	  in	  response	  to	  hypoxia,	  which	  activates	  transcription	  of	  the	  Epo	  gene(Jelkmann	  2007).	  	  Plasma	  concentrations	  of	  Epo	  are	  normally	  in	  the	  low	  picomolar	  range(Jelkmann	  2007),	  and	  controlled	  by	  a	  classical	  negative	  feedback	  loop,	  whereby	  hypoxia	  is	  detected	  by	  the	  kidney,	  which	  stimulates	  Epo	  production,	  resulting	  in	  an	  increase	  in	  erythrocyte	  number	  and	  oxygen	  delivery	  to	  the	  kidney,	  thus	  dampening	  Epo	  production(Brines	  and	  Cerami	  2008).	  	  The	  ability	  of	  Epo	  to	  raise	  erythrocyte	  number	  has	  led	  to	  its	  widespread	  clinical	  use	  in	  the	  treatments	  of	  anaemia	  secondary	  to	  renal	  failure,	  chemotherapy	  and	  AIDS(Cheetham,	  Smith	  et	  al.	  1998).	  
The	  classical	  Epo	  receptor	  (EPOR)2	  is	  a	  homodimer	  that	  is	  present	  on	  the	  cell	  membrane	  of	  erythrocytic	  progenitor	  cells	  in	  the	  bone	  marrow(Brines,	  Patel	  et	  al.	  2008).	  	  However,	  observations	  that	  (EPOR)2	  was	  also	  expressed	  by	  other	  cell	  types	  including	  endothelial	  cells(Anagnostou,	  Lee	  et	  al.	  1990)	  and	  within	  the	  central	  nervous	  system(Digicaylioglu,	  Bichet	  et	  al.	  1995)	  has	  led	  to	  a	  wider	  appreciation	  of	  Epo‘s	  potential	  function.	  	  Epo	  has	  been	  found	  to	  be	  produced	  by	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almost	  every	  tissue	  studied,	  when	  put	  under	  conditions	  of	  hypoxia	  or	  metabolic	  stress(Brines	  and	  Cerami	  2008).	  	  This	  locally	  produced	  Epo	  interacts	  with	  a	  locally	  upregulated	  receptor	  composed	  of	  a	  single	  unit	  of	  EPOR	  combined	  with	  the	  beta	  common	  receptor	  (βcR)(Brines,	  Grasso	  et	  al.	  2004,	  Brines,	  Patel	  et	  al.	  2008).	  	  Through	  action	  on	  this	  receptor,	  an	  understanding	  of	  the	  role	  of	  Epo	  as	  an	  autocrine	  tissue-­‐protective	  molecule	  has	  emerged,	  with	  Epo	  playing	  a	  role	  of	  antagonist	  to	  the	  normal	  biological	  process	  of	  apoptosis	  following	  metabolic	  stress	  and	  tissue	  injury(Brines	  and	  Cerami	  2006,	  Brines	  and	  Cerami	  2008).	  	  In	  this	  manner,	  Epo	  has	  demonstrated	  a	  remarkable	  tissue	  protective	  effect	  in	  preclinical	  models	  of	  neuronal(Grasso,	  Sfacteria	  et	  al.	  2004),	  retinal(Mowat,	  Gonzalez	  et	  al.),	  renal(Nakazawa,	  Nishino	  et	  al.	  ,	  Brines	  and	  Cerami	  2006),	  and	  cardiac	  injury(Hanlon,	  Fu	  et	  al.	  2005).	  	  	  
Investigations	  of	  the	  use	  of	  Epo	  for	  cardiac	  protection	  have	  been	  ongoing	  since	  2003,	  when	  it	  was	  demonstrated	  that	  Epo	  was	  protective	  against	  hypoxia-­‐induced	  apoptosis	  in	  isolated	  rat	  cardiomyocytes(Calvillo,	  Latini	  et	  al.	  2003).	  	  Further	  in-­‐vivo	  studies	  of	  cardiac	  ischaemia	  also	  demonstrated	  benefits	  in	  terms	  of	  cardiomyocyte	  loss	  by	  apoptosis(Cai,	  Manalo	  et	  al.	  2003,	  Calvillo,	  Latini	  et	  al.	  2003,	  Tramontano,	  Muniyappa	  et	  al.	  2003),	  infarct	  size(Moon,	  Krawczyk	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2006),	  and	  left	  ventricular	  function(Calvillo,	  Latini	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2006).	  	  Most	  recently	  Epo	  has	  been	  used	  in	  human	  clinical	  trials	  to	  evaluate	  its	  effect	  following	  myocardial	  infarction(Ludman,	  Yellon	  et	  al.	  ,	  Najjar,	  Rao	  et	  al.	  ,	  Prunier,	  Biere	  et	  al.).	  	  Although	  beneficial	  effects	  have	  been	  minimal	  in	  human	  trials,	  questions	  still	  remain	  unanswered	  regarding	  the	  optimum	  timing	  and	  dosing	  strategies	  to	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try	  and	  match	  the	  benefits	  seen	  from	  pre-­‐clinical	  experiments(Talan,	  Ahmet	  et	  al.).	  
Epo	  is	  a	  strong	  candidate	  for	  use	  in	  a	  cardiac	  tissue	  regeneration	  strategy	  for	  several	  reasons.	  	  Epo	  is	  already	  in	  current	  clinical	  use	  and	  its	  potential	  side	  effects	  are	  already	  well	  understood,	  making	  potential	  translation	  to	  the	  clinic	  a	  more	  straightforward	  path.	  	  Also,	  the	  tissue	  protective	  effect	  of	  Epo	  can	  be	  beneficial	  for	  both	  native	  myocardium	  following	  injury	  (which	  is	  already	  well	  established	  from	  pre-­‐clinical	  models),	  as	  well	  as	  potentially	  for	  supporting	  transplanted	  cells,	  which	  will	  also	  be	  subject	  to	  a	  potentially	  noxious	  environment.	  	  	  
The	  aims	  of	  the	  current	  experiment	  were	  to	  test	  Epo	  as	  a	  protective	  factor	  using	  










	   154	  
5.2	  Methods	  
5.2.1	  Cell	  culture	  
Rat	  bone	  marrow	  stromal	  cells	  (RBMCs)	  were	  isolated	  from	  adult	  rat	  femurs	  as	  described	  in	  section	  2.2.1.1.	  	  RBMCs	  from	  passage	  3-­‐4	  were	  used	  for	  experiments.	  	  	  
Induced	  pluripotent	  stem	  cell-­‐derived	  cardiomyocytes	  were	  thawed	  and	  plated	  into	  96	  well	  plates	  as	  described	  in	  section	  2.2.2.1.	  	  Cell	  cultures	  were	  used	  for	  the	  experiments	  7-­‐10	  days	  after	  plating.	  	  	  
	  
5.2.2	  Erythropoietin	  and	  RBMCs	  
RBMCs	  were	  plated	  into	  24	  well	  plates	  at	  a	  density	  of	  100,000	  cells	  per	  well.	  	  Cultures	  were	  left	  overnight	  to	  allow	  cell	  attachment	  to	  the	  plate	  surface.	  	  The	  following	  day,	  media	  was	  exchanged	  for	  serum	  free	  media	  (containing	  	  α-­‐MEM,	  1%	  Penicillin/Streptomycin	  and	  1%	  L-­‐Glutamine)	  and	  left	  for	  24	  hours.	  	  	  
For	  the	  injury	  model,	  cultures	  were	  washed	  once	  with	  PBS,	  and	  hydrogen	  peroxide	  (diluted	  in	  serum	  free	  media	  to	  give	  0.3%,	  0.03%,	  0.005%	  weight/volume	  hydrogen	  peroxide)	  added	  to	  cultures	  for	  30	  minutes.	  	  Following	  this,	  the	  hydrogen	  peroxide	  was	  removed,	  wells	  washed	  twice	  with	  PBS,	  and	  serum	  free	  media	  replaced.	  	  	  
For	  erythropoietin	  experiments,	  cultures	  were	  incubated	  for	  4	  hours	  with	  erythropoietin	  (0.1u/ml,	  1u/ml	  and	  10u/ml)	  prior	  to	  hydrogen	  peroxide	  injury.	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Control	  cultures	  for	  erythropoietin	  without	  hydrogen	  peroxide	  injury	  were	  also	  prepared.	  	  All	  wells	  were	  prepared	  in	  triplicate.	  
At	  the	  end	  of	  the	  experiment,	  cultures	  were	  stained	  for	  live	  and	  dead	  cells	  by	  covering	  with	  Calcein	  AM,	  and	  Ethidium	  homodimer	  (10µl	  in	  5ml	  sterile	  PBS,	  Invitrogen),	  and	  incubated	  for	  15	  minutes	  at	  37°C.	  	  Cultures	  were	  washed	  twice	  again	  with	  sterile	  PBS	  and	  imaged	  using	  fluorescent	  microscopy.	  	  	  
	  
5.2.3	  Erythropoietin	  and	  iPS-­‐CM	  
A	  dose	  response	  curve	  was	  prepared	  by	  plating	  iPS-­‐CM	  in	  opaque	  white-­‐walled	  96	  well	  plates.	  	  Cells	  were	  exposed	  to	  increasing	  concentrations	  of	  Epo	  (0u/ml,	  0.1u/ml,	  1u/ml,	  10uml)	  for	  6	  hours.	  	  Cultures	  were	  kept	  in	  an	  incubator	  at	  37°C.	  	  All	  samples	  were	  prepared	  in	  triplicate.	  	  At	  the	  end	  of	  the	  experiment	  cell	  viability	  was	  measured	  using	  Cell-­‐Titer	  Glo	  (Promega)	  according	  to	  the	  manufacturers	  protocol.	  	  	  	  In	  brief	  the	  Cell-­‐Titer	  reagent	  was	  added	  to	  culture	  wells	  at	  an	  equal	  volume	  to	  cell	  culture	  media.	  	  The	  plate	  was	  placed	  on	  an	  orbital	  shaker	  for	  2	  minutes	  and	  left	  at	  room	  temperature	  for	  a	  further	  10	  minutes.	  	  The	  luminescent	  signal	  from	  the	  culture	  wells	  was	  read	  using	  a	  SpectraMax	  M5	  plate	  reader	  (Molecular	  Devices,	  Sunnydale,	  California,	  USA).	  	  	  
A	  doxorubicin	  injury	  model	  was	  used	  for	  the	  iPS-­‐CM.	  	  Increasing	  concentrations	  of	  doxorubicin	  (0µM,	  0.001µM.	  0.01µM,	  0.1µM,	  1µM)	  were	  added	  to	  iPS-­‐CM	  cultures	  in	  96	  well	  plates,	  with	  or	  without	  the	  presence	  of	  EPO	  (1u/ml,	  either	  given	  at	  the	  same	  time	  as	  injury	  or	  for	  3	  hours	  prior	  to	  injury).	  	  Cultures	  were	  left	  in	  an	  incubator	  at	  37°C	  for	  6	  hours.	  	  All	  samples	  were	  prepared	  in	  triplicate.	  	  At	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the	  end	  of	  the	  experiment,	  cell	  viability	  was	  measured	  using	  the	  Cell-­‐Titer	  Glo	  assay	  as	  described	  above.	  	  	  
	  
5.3	  Results	  	  	  	  	  	  	  	  	  
	  
5.3.1	  Erythropoietin	  and	  RBMCs	  
5.3.1.1	  Hydrogen	  Peroxide	  Injury	  Model	  
A	  hydrogen	  peroxide	  injury	  model	  was	  used	  with	  the	  RBMC	  cultures,	  and	  Live/Dead	  (Calcein	  AM	  and	  Ethidium	  Homodimer)	  stain	  used	  to	  assess	  cell	  injury	  (Figure	  5-­‐1	  and	  5-­‐2).	  	  	  
Control	  cultures	  demonstrated	  green-­‐stained	  live	  cells	  that	  were	  nicely	  spread	  upon	  the	  tissue	  culture	  plastic.	  	  There	  were	  very	  few	  red	  stained	  dead	  cells.	  	  Injury	  with	  0.005%	  hydrogen	  peroxide	  for	  30	  minutes	  had	  no	  appreciable	  difference	  to	  the	  cell	  culture	  appearance.	  	  Injury	  with	  0.03%	  hydrogen	  peroxide	  resulted	  in	  an	  increase	  in	  the	  number	  of	  red	  stained	  dead	  cells,	  with	  the	  remaining	  green	  stained	  live	  cells	  appearing	  condensed	  and	  irregular	  in	  appearance.	  	  Injury	  with	  0.3%	  hydrogen	  peroxide	  on	  the	  cell	  cultures	  had	  a	  similar	  appearance.	  	  Following	  this	  result,	  0.03%	  hydrogen	  peroxide	  was	  chosen	  as	  the	  injury	  model	  for	  the	  erythropoietin	  experiments.	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Figure	  5-­‐1	  	  Hydrogen	  Peroxide	  Dose	  Response	  Assay.	  	  Increasing	  concentrations	  of	  hydrogen	  peroxide	  (0.005%,	  0.03%,	  0.3%)	  were	  added	  to	  RBMC	  cultures	  for	  30	  minutes.	  	  Control	  cultures	  had	  no	  hydrogen	  peroxide	  added	  to	  them.	  	  Cultures	  were	  stained	  with	  Live/Dead	  stain	  (Calcein	  AM	  and	  Ethidium	  Homodimer).	  	  Scale	  bars	  =	  1.0mm	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Figure	  5-­‐2.	  	  Hydrogen	  Peroxide	  Dose	  Response	  Assay.	  	  Close	  up	  views	  of	  combination	  (Live/Dead)	  images.	  	  A	  –	  Control,	  	  B	  -­‐	  0.005%,	  	  	  C	  –	  0.03%,	  	  D	  –	  0.3%.	  	  Scale	  bars	  =	  1.0mm	  
	  
5.3.1.2	  Erythropoietin	  Concentration-­‐Response	  and	  Hydrogen	  Peroxide	  Injury	  
RBMC	  cultures	  were	  incubated	  for	  4	  hours	  with	  increasing	  doses	  of	  erythropoietin	  prior	  to	  30	  minutes	  injury	  with	  or	  without	  0.03%	  hydrogen	  peroxide	  (Figure	  5-­‐3,	  5-­‐4	  and	  5-­‐5).	  
0.1u/ml,	  and	  1u/ml	  of	  Epo	  without	  hydrogen	  peroxide	  demonstrated	  very	  similar	  appearances	  to	  negative	  control	  cultures	  with	  well	  spread	  green	  stained	  live	  cells	  on	  the	  tissue	  culture	  plastic	  and	  very	  few	  red	  stained	  dead	  cells.	  	  10u/ml	  Epo	  resulted	  in	  condensed	  and	  irregular	  green	  stained	  live	  cells,	  with	  few	  red	  stained	  dead	  cells.	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Figure	  5-­‐3.	  	  Erythropoietin	  Concentration-­‐Response	  for	  RBMSCs.	  	  RBMC	  cultures	  were	  incubated	  with	  increasing	  doses	  of	  erythropoietin	  (0.1u/ml.	  1u/ml.	  10u/ml)	  for	  4	  hours.	  	  Negative	  control	  cultures	  had	  no	  erythropoietin.	  	  Cultures	  were	  stained	  with	  Live/Dead	  stain	  (Calcein	  AM	  and	  Ethidium	  Homodimer).	  	  Scale	  bars	  =	  200µm	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Figure	  5-­‐4.	  	  Erythropoietin	  with	  Hydrogen	  Peroxide	  Injury.	  	  RBMC	  cultures	  were	  incubated	  for	  4	  hours	  with	  increasing	  concentrations	  of	  erythropoietin	  (0.1u/ml,	  1u/ml,	  10u/ml).	  	  Hydrogen	  Peroxide	  (0.03%)	  was	  added	  for	  30	  minutes.	  	  Negative	  control	  cultures	  were	  RBMC	  cultures	  alone	  without	  erythropoietin	  or	  hydrogen	  peroxide	  injury.	  	  Positive	  cultures	  had	  hydrogen	  peroxide	  injury	  alone.	  	  Cultures	  were	  stained	  with	  Live/Dead	  stain	  (Calcein	  AM	  and	  Ethidium	  Homodimer).	  	  Scale	  bars	  =	  200µm	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Figure	  5-­‐5:	  	  Erythropoietin	  with	  Hydrogen	  Peroxide	  Injury.	  	  Close	  up	  views	  of	  combination	  images	  (Live/Dead).	  	  A	  –	  Negative	  control	  (RBMC	  cultures	  alone),	  	  B	  –	  Positive	  control	  (0.03%	  Hydrogen	  Peroxide	  injury),	  	  C	  –	  0.1u/ml	  erythropoietin	  +	  Hydrogen	  Peroxide	  Injury,	  	  D	  -­‐	  1u/ml	  erythropoietin	  +	  Hydrogen	  Peroxide	  Injury,	  	  E	  -­‐	  10u/ml	  erythropoietin	  +	  Hydrogen	  Peroxide	  Injury.	  	  Scale	  bars	  =	  200µm	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5.3.2	  Erythropoietin	  and	  iPS-­‐CM	  
5.3.2.1	  Erythropoietin	  Concentration-­‐Response	  
iPS-­‐CM	  cultures	  were	  exposed	  to	  increasing	  concentrations	  of	  Epo	  (0.1u/ml,	  1u/ml,	  10u/ml)	  for	  6	  hours	  at	  37°C	  (Figure	  5-­‐6).	  	  Cell	  viability	  was	  assessed	  using	  the	  Cell	  Titer	  Glo	  assay	  (Promega)	  whereby	  the	  luminescent	  signal	  correlates	  with	  cellular	  viability,	  and	  results	  were	  normalised	  against	  control	  cultures.	  
Doses	  of	  0.1u/ml	  and	  1u/ml	  of	  Epo	  had	  no	  significant	  effect	  upon	  cell	  viability	  with	  luminescent	  signals	  reaching	  100.7%	  +/-­‐	  13.4%	  (mean	  +/-­‐	  SD),	  and	  101.9%	  +/-­‐	  10.7%,	  of	  control	  values	  respectively.	  	  However	  a	  dose	  of	  10u/ml	  Epo	  significantly	  reduced	  cell	  viability	  down	  to	  28.4%	  +/-­‐	  0.8%	  (p<0.01).	  	  As	  a	  result	  of	  this	  experiment,	  1u/ml	  Epo	  was	  used	  in	  the	  subsequent	  doxorubicin	  injury	  experiments.	  	  	  
	  
5.3.2.2	  Erythropoietin	  and	  Doxorubicin	  Injury	  on	  iPS-­‐CM	  cultures	  
Doxorubicin	  was	  added	  to	  iPS-­‐CM	  cultures	  in	  increasing	  concentrations	  (0.01µM,	  0.1µM,	  0.3µM,	  1µM)	  for	  6	  hours	  with	  or	  without	  the	  presence	  of	  1u/ml	  Epo	  (Figure	  5-­‐7).	  	  Cell	  viability	  was	  assessed	  using	  the	  Cell	  Titer	  Glo	  assay	  (Promega)	  whereby	  the	  luminescent	  signal	  correlates	  with	  cellular	  viability,	  and	  results	  were	  normalised	  against	  control	  cultures.	  
Increasing	  doxorubicin	  concentrations	  resulted	  in	  a	  drop	  in	  cell	  viability	  compared	  with	  control	  cultures.	  	  0.01µM	  doxorubicin	  resulted	  in	  cell	  viability	  of	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91.0%	  +/-­‐	  7.7%,	  with	  0.1µM,	  0.3µM,	  and	  1µM	  doxorubicin	  resulting	  in	  cell	  viability	  levels	  of	  4.9%	  +/-­‐1.2%,	  0.2%	  +/-­‐	  0.02%,	  and	  0.03%	  +-­‐/-­‐	  0.02%	  respectively.	  	  The	  presence	  of	  1u/ml	  Epo	  resulted	  in	  significantly	  higher	  cell	  viability	  at	  doxorubicin	  concentrations	  of	  0.1µM	  (15.3%	  +/-­‐	  0.7%,	  p<0.01),	  and	  0.3µM	  (2.7%	  +/-­‐	  1.3%,	  p<0.05).	  
	  
Figure	  5-­‐6:	  Erythropoietin	  dose	  response	  for	  iPS-­‐CM.	  	  Increasing	  concentrations	  of	  erythropoietin	  were	  added	  to	  iPS-­‐CM	  cultures	  for	  6	  hours.	  	  Control	  cultures	  received	  no	  erythropoietin.	  	  Cell	  viability	  was	  assessed	  using	  the	  Cell-­‐Titer	  Glo	  Assay	  (Promega),	  where	  the	  luminescent	  signal	  correlates	  with	  cell	  viability.	  	  Results	  were	  normalised	  against	  control	  cultures.	  	  Error	  bars	  represent	  standard	  deviations.	  	  Experiments	  were	  repeated	  in	  triplicates.	  	  	  **	  =	  p<0.01	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Figure	  5-­‐7:	  	  Effect	  of	  erythropoietin	  on	  Doxorubicin	  induced	  injury	  of	  iPS-­‐CM.	  	  iPS-­‐CM	  cultures	  were	  	  exposed	  to	  increasing	  concentrations	  of	  doxorubicin	  for	  6	  hours	  with	  or	  without	  the	  presence	  of	  1u/ml	  erythropoietin.	  	  Cell	  viability	  was	  assessed	  using	  the	  Cell-­‐Titer	  Glo	  Assay	  (Promega),	  where	  the	  luminescent	  signal	  correlates	  with	  cell	  viability.	  	  Results	  were	  normalised	  against	  control	  cultures.	  	  Error	  bars	  represent	  standard	  deviations.	  	  Experiments	  were	  repeated	  in	  triplicates.	  	  	  **	  =	  p<0.01	  	  *=	  p<0.05	  
	  
This	  experiment	  was	  then	  repeated	  with	  the	  iPS-­‐CM	  cultures	  being	  pre-­‐incubated	  with	  1u/ml	  EPO	  for	  3	  hours	  prior	  to	  doxorubicin	  injury	  (figure	  5-­‐8).	  	  The	  presence	  of	  EPO	  demonstrated	  a	  protective	  effect	  against	  injury	  again	  at	  doxorubicin	  concentrations	  of	  0.1µM	  (18.4%	  +/-­‐	  1.3%	  vs.	  4.6%	  +/-­‐	  0.2%,	  p<0.01)	  and	  0.3µM	  (0.6%	  +/-­‐	  0.1%	  vs.	  0.3%	  +/-­‐	  0.02%,	  p<0.01).	  	  EPO	  also	  had	  a	  
	   166	  
slight	  protective	  effect	  at	  1µM	  doxorubicin	  (0.05%	  +/-­‐	  0.007%	  vs	  0.03%	  +/-­‐	  0.02%,	  p<0.05).	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5.4	  Discussion	  
Over	  the	  past	  15	  years,	  erythropoietin	  has	  received	  increasing	  attention	  with	  regards	  to	  its	  tissue	  protective	  properties(Brines	  and	  Cerami	  2006).	  	  One	  of	  the	  areas	  most	  heavily	  investigated	  has	  been	  the	  protective	  effects	  of	  Epo	  on	  cardiac	  tissue,	  especially	  in	  regard	  to	  ischaemic	  injury(Riksen,	  Hausenloy	  et	  al.	  2008).	  	  The	  mechanisms	  of	  Epo’s	  tissue	  protective	  effects	  are	  thought	  to	  be	  due	  to	  its	  activation	  of	  specific	  intracellular	  pathways	  including	  protein	  kinase	  C	  (PKC)	  activation,	  and	  the	  PI3K/Akt	  pathway,	  which	  serves	  to	  control	  apoptosis	  by	  several	  routes	  such	  as	  the	  inhibition	  of	  pro-­‐apoptotic	  B-­‐cell	  lymphoma	  (Bcl-­‐2)	  proteins	  BAD	  and	  BAX,	  caspase	  inhibition,	  and	  inhibition	  of	  the	  mitochondrial	  permeability	  transition	  pore	  (mPTP)(Hausenloy	  and	  Yellon	  2004,	  Hanlon,	  Fu	  et	  al.	  2005,	  Riksen,	  Hausenloy	  et	  al.	  2008).	  	  	  	  	  
Results	  from	  pre-­‐clinical	  studies	  investigating	  the	  tissue	  protective	  effects	  of	  Epo	  have	  been	  extremely	  promising,	  and	  although	  clinical	  trials	  have	  yet	  to	  demonstrate	  this	  degree	  of	  benefit,	  Epo	  still	  has	  promising	  potential	  in	  the	  field	  of	  cardioprotection.	  	  For	  these	  reasons,	  Epo	  is	  a	  strong	  candidate	  for	  a	  tissue	  regenerative	  strategy	  that	  aims	  to	  treat	  cardiac	  injury.	  	  The	  aims	  of	  this	  current	  study	  were	  to	  investigate	  if	  Epo	  also	  had	  protective	  effects	  upon	  two	  cell	  types	  that	  may	  be	  suitable	  for	  cell	  therapy	  –	  bone	  marrow	  cells	  and	  induced	  pluripotent	  stem	  cell	  derived	  cardiomyocytes.	  
For	  the	  rat	  bone	  marrow	  stromal	  cell	  cultures,	  a	  hydrogen	  peroxide	  injury	  model	  was	  used.	  	  Hydrogen	  peroxide	  is	  one	  of	  the	  main	  oxidant	  species	  produced	  in	  cardiac	  tissues	  during	  ischaemia-­‐reperfusion	  injury,	  and	  is	  thought	  to	  be	  an	  important	  cause	  of	  cellular	  damage(Josephson,	  Silverman	  et	  al.	  1991).	  	  Calcein	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AM	  was	  used	  to	  stain	  live	  cells,	  as	  it	  is	  quickly	  converted	  to	  green	  fluorescent	  calcein	  after	  hydrolysis	  by	  living	  cell	  intracellular	  esterases.	  	  Dead	  cells	  were	  stained	  with	  ethidium	  homodimer,	  which	  is	  able	  to	  enter	  dead	  cells	  due	  to	  disruption	  of	  their	  plasma	  membranes,	  and	  bind	  to	  DNA.	  	  Exposing	  RBMC	  cultures	  to	  hydrogen	  peroxide	  for	  30	  minutes	  at	  concentrations	  of	  0.03%	  or	  greater	  resulted	  in	  an	  obvious	  change	  in	  morphology	  to	  living	  cells.	  	  They	  became	  condensed	  and	  irregular	  in	  shape,	  as	  opposed	  to	  the	  well	  spread	  appearance	  seen	  in	  control	  cultures.	  	  Dead	  cell	  staining	  was	  limited,	  which	  may	  be	  due	  to	  the	  very	  short	  time	  span	  of	  hydrogen	  peroxide	  injury,	  or	  due	  to	  the	  effects	  of	  cell	  detatchment	  and	  wash	  out	  during	  the	  staining	  procedure.	  	  The	  presence	  of	  1u/ml	  Epo	  restored	  live	  cell	  morphology	  almost	  back	  to	  normal	  demonstrating	  the	  protective	  effects	  of	  Epo	  upon	  RBMCs.	  	  Interestingly	  high	  doses	  of	  Epo	  (10u/ml)	  also	  resulted	  in	  the	  appearance	  of	  cellular	  injury,	  implying	  that	  high	  Epo	  concentrations	  may	  in	  fact	  be	  harmful	  to	  RBMC	  populations.	  	  	  
A	  doxorubicin	  injury	  model	  was	  utilised	  for	  iPS-­‐CM	  experiments.	  	  Doxorubicin	  is	  a	  widely	  used	  chemotherapeutic	  agent,	  often	  utilised	  in	  the	  treatment	  of	  breast	  and	  bladder	  cancer,	  Hodgkin’s	  lymphomas	  and	  acute	  leukaemia(Takemura	  and	  Fujiwara	  2007).	  	  However,	  it	  has	  a	  severe	  side	  effect	  of	  cardiac	  toxicity,	  which	  can	  lead	  to	  a	  form	  of	  cardiomyopathy(Takemura	  and	  Fujiwara	  2007).	  	  Its	  mechanism	  of	  injury	  includes	  the	  formation	  of	  reactive	  oxygen	  species,	  lipid	  peroxidation,	  inhibition	  of	  DNA	  and	  protein	  synthesis,	  and	  induction	  of	  cardiomyocyte	  apoptosis(Yao,	  Xu	  et	  al.	  ,	  Takemura	  and	  Fujiwara	  2007).	  	  Doxorubicin	  is	  therefore	  often	  used	  as	  a	  model	  of	  in	  vivo	  cardiac	  injury,	  in	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particular	  for	  the	  production	  of	  cardiomyopathy	  models(Ma,	  Zhang	  et	  al.).	  	  To	  assess	  iPS-­‐CM	  injury,	  the	  Cell-­‐Titer	  Glo	  assay	  was	  used.	  	  This	  luminescent	  assay	  allows	  a	  measure	  of	  viable	  cell	  number	  based	  on	  the	  quantification	  of	  the	  amount	  of	  ATP	  present	  in	  cell	  culture,	  which	  is	  used	  as	  an	  indicator	  of	  metabolically	  active	  and	  thus	  viable	  cells.	  
EPO	  demonstrated	  a	  significantly	  protective	  effect	  on	  iPS-­‐CM	  from	  doxorubicin	  injury	  at	  0.1µM	  and	  0.3µM	  concentrations.	  	  However	  pre-­‐incubation	  with	  EPO	  for	  3	  hours	  seemed	  to	  have	  very	  minimal	  additional	  effects	  on	  cellular	  injury.	  	  This	  result	  may	  be	  explained	  by	  observations	  that	  the	  tissue	  protective	  effect	  of	  Epo	  stem	  from	  action	  upon	  a	  specific	  receptor	  that	  combines	  an	  EPOR	  monomer	  and	  the	  beta	  common	  receptor	  (βcR)(Ueba,	  Brines	  et	  al.	  ,	  Brines,	  Grasso	  et	  al.	  2004,	  Brines,	  Patel	  et	  al.	  2008).	  	  This	  receptor	  is	  not	  normally	  present	  in	  tissues,	  but	  is	  upregulated	  with	  injury	  and	  metabolic	  stress.	  	  Therefore	  incubation	  with	  Epo	  prior	  to	  injury	  may	  be	  unlikely	  to	  confer	  any	  additional	  benefits.	  	  	  
As	  seen	  with	  the	  RMBC	  cultures,	  high	  doses	  of	  EPO	  alone	  resulted	  in	  a	  significant	  fall	  in	  cell	  viability,	  implying	  cell	  injury	  or	  death.	  	  This	  could	  potentially	  cause	  problems	  for	  in	  vivo	  studies	  where	  injection	  of	  high	  concentrations	  of	  EPO	  in	  myocardial	  infarction	  models	  may	  cause	  further	  cardiomyocyte	  injury	  with	  a	  further	  detrimental	  effect	  upon	  function.	  	  Therefore	  for	  further	  studies	  the	  concentration	  of	  EPO	  injections	  was	  kept	  to	  a	  maximum	  of	  1u/ml	  to	  avoid	  induction	  of	  injury.	  	  	  
It	  has	  previously	  been	  shown	  that	  synthesis	  of	  specific	  short	  peptide	  sequences	  derived	  from	  the	  tertiary	  structure	  of	  Epo	  are	  able	  to	  deliver	  tissue	  protection	  through	  the	  EPOR-­‐βcR	  receptor,	  without	  activation	  of	  the	  normal	  (EPOR)2	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receptor	  and	  subsequent	  erythropoietic	  pathways(Brines,	  Patel	  et	  al.	  2008).	  	  This	  is	  important	  for	  future	  work	  as	  these	  peptides	  are	  able	  to	  deliver	  the	  tissue	  protective	  effects	  of	  Epo	  without	  the	  common	  adverse	  effects	  of	  Epo	  treatment	  such	  as	  hypertension	  and	  thrombosis(Ueba,	  Brines	  et	  al.).	  
	  
5.5	  Summary	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Establishing	  the	  in	  vivo	  rat	  model	  of	  Myocardial	  Infarction	  
	  
6.1	  Introduction	  
Myocardial	  Infarction	  and	  subsequent	  heart	  failure	  represent	  one	  of	  the	  greatest	  causes	  of	  mortality	  and	  morbidity	  worldwide.	  	  Advances	  in	  therapy	  for	  myocardial	  infarction	  and	  heart	  failure	  have	  the	  potential	  of	  significantly	  impacting	  upon	  global	  health,	  and	  as	  a	  result,	  research	  in	  this	  area	  is	  incredibly	  active.	  
Part	  of	  the	  overall	  research	  strategy	  into	  treatment	  of	  diseases	  includes	  finding	  the	  appropriate	  animal	  model	  on	  which	  to	  trial	  new	  therapies	  prior	  to	  clinical	  use	  on	  humans.	  	  	  
The	  rat	  has	  been	  the	  animal	  model	  of	  choice	  for	  more	  than	  a	  century	  of	  cardiovascular	  research(Goldman	  and	  Raya	  1995).	  	  Many	  different	  models	  of	  cardiac	  disease	  have	  been	  developed	  and	  used	  for	  thousands	  of	  experiments.	  	  The	  reasons	  for	  the	  popularity	  of	  the	  rat	  are	  several,	  including	  the	  reduced	  purchasing	  and	  housing	  costs	  as	  well	  as	  the	  increased	  ease	  of	  handling	  when	  using	  a	  small	  rodent	  model.	  	  	  
The	  rat	  model	  of	  myocardial	  infarction	  is	  typically	  created	  via	  the	  ligation	  of	  the	  left	  anterior	  descending	  (LAD)	  artery	  close	  to	  its	  origin.	  	  This	  was	  first	  described	  in	  1946	  by	  Heimburger(Heimburger	  1946)	  and	  again	  in	  1954	  by	  Johns	  and	  Olsen(Johns	  and	  Olson	  1954).	  	  The	  model	  was	  adapted	  and	  refined	  at	  Harvard	  University	  from	  the	  1970’s	  to	  1980’s(Pfeffer,	  Pfeffer	  et	  al.	  1979,	  Fletcher,	  Pfeffer	  et	  al.	  1980,	  Spadaro,	  Fishbein	  et	  al.	  1980,	  Fletcher,	  Pfeffer	  et	  al.	  1981,	  Fletcher,	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Pfeffer	  et	  al.	  1982,	  Pfeffer,	  Pfeffer	  et	  al.	  1984)	  which	  forms	  the	  basis	  of	  the	  current	  rat	  myocardial	  infarction	  model.	  	  This	  model	  has	  been	  used	  in	  the	  investigation	  of	  many	  different	  therapies	  with	  a	  good	  early	  example	  being	  the	  use	  of	  the	  angiotensin-­‐converting	  enzyme	  inhibitor	  (ACEi)	  Captopril	  as	  a	  treatment	  for	  cardiac	  failure(Pfeffer,	  Pfeffer	  et	  al.	  1985,	  Pfeffer,	  Pfeffer	  et	  al.	  1987).	  	  	  These	  results	  led	  directly	  to	  successful	  human	  clinical	  trials(Pfeffer,	  Pfeffer	  et	  al.	  1987)	  and	  incorporation	  of	  Captopril	  into	  clinical	  practice	  	  	  
The	  initial	  findings	  from	  these	  early	  studies	  still	  apply	  to	  the	  model	  today.	  	  The	  effective	  induction	  of	  myocardial	  infarction	  is	  variable,	  resulting	  in	  a	  variety	  of	  infarct	  sizes.	  	  Initial	  infarct	  size	  classifications	  were	  divided	  into	  small	  (4-­‐30%),	  moderate	  (31-­‐46%)	  and	  large	  (>47%)(Pfeffer,	  Pfeffer	  et	  al.	  1979),	  with	  early	  mortality	  being	  typically	  caused	  by	  fatal	  ventricular	  arrythmias(Curtis,	  Macleod	  et	  al.	  1987).	  	  Rats	  with	  small	  infarcts	  below	  30%	  in	  size	  were	  found	  to	  have	  no	  detectable	  impairment	  of	  left	  ventricular	  function,	  whilst	  moderate	  infarcts	  between	  31%	  and	  46%	  had	  normal	  baseline	  function	  with	  detectable	  ventricular	  impairment	  upon	  temporary	  outflow	  occlusion.	  	  Large	  infarcts	  over	  47%	  in	  size	  had	  measurable	  ventricular	  impairment	  in	  the	  resting	  state.	  	  	  	  
Although	  ligation	  of	  the	  LAD	  artery	  in	  rats	  does	  not	  exactly	  compare	  with	  the	  pathophysiology	  of	  myocardial	  infarction	  in	  humans,	  following	  myocardial	  infarction	  in	  the	  rat,	  remodeling	  occurs	  in	  a	  similar	  fashion	  to	  human	  pathology,	  with	  fibrosis	  and	  thinning	  of	  the	  infarcted	  zone	  and	  progressive	  left	  ventricular	  dilatation,	  with	  increases	  in	  chamber	  volume	  up	  to	  81%	  compared	  with	  normal	  age	  matched	  controls(Olivetti,	  Capasso	  et	  al.	  1991).	  	  This	  can	  lead	  to	  approximately	  a	  nine-­‐times	  increase	  in	  diastolic	  wall	  stress.	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6.2	  Methods	  
	  
6.2.1	  Experimental	  Groups	  
Male	  Sprague	  Dawley	  (SD)	  rats	  and	  male	  nude	  rats	  underwent	  general	  anaesthesia	  and	  LAD	  artery	  ligation	  to	  induce	  myocardial	  infarction	  as	  described	  in	  section	  2.3.9.	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6.2.2	  Planimetry	  
The	  hearts	  from	  group	  1	  rats	  were	  excised	  for	  histological	  analysis.	  	  In-­‐vivo	  fixation	  and	  heart	  explantation	  were	  performed	  as	  described	  in	  section	  2.5.	  
Explanted	  hearts	  were	  flash	  frozen	  in	  liquid	  nitrogen	  for	  twenty	  seconds,	  partially	  thawed	  and	  placed	  in	  a	  coronal	  cardiac	  sectioning	  matrix	  (Zivic	  Laboratories).	  	  The	  hearts	  were	  sliced	  into	  biventricular	  sections	  perpendicular	  to	  the	  long	  axis	  of	  the	  heart	  extending	  from	  apex	  to	  atrioventricular	  groove,	  generating	  on	  average	  5	  to	  6	  2mm	  thick	  coronal	  sections	  (Figure	  6-­‐1).	  	  	  
Cardiac	  sections	  were	  placed	  between	  2	  clear	  microscope	  slides	  and	  images	  captured	  using	  a	  Hewlett-­‐Packard	  6200C	  scanner	  (Figure	  6-­‐2).	  	  Planimetry	  of	  the	  captured	  images	  was	  performed	  using	  Image	  J	  software	  (NIH).	  
The	  planimetry	  protocol	  was	  performed	  based	  upon	  previously	  described	  methods(Pfeffer,	  Pfeffer	  et	  al.	  1987).	  	  For	  each	  section,	  the	  endocardial	  and	  epicardial	  circumference	  of	  the	  infarct	  zone	  was	  measured.	  	  This	  could	  easily	  be	  identified	  visually	  as	  the	  pale	  thinned	  part	  of	  the	  left	  ventricular	  wall.	  	  The	  total	  endocardial	  and	  epicardial	  infarct	  lengths	  were	  calculated	  by	  adding	  up	  the	  individual	  values	  for	  each	  section.	  	  This	  was	  followed	  by	  measurement	  of	  the	  endocardial	  and	  epicardial	  circumference	  of	  the	  left	  ventricle	  in	  each	  section.	  	  Endocardial	  and	  epicardial	  infarct	  sizes	  were	  calculated	  as	  a	  percentage	  by	  dividing	  total	  endocardial	  and	  epicardial	  infarct	  lengths	  	  by	  the	  total	  endocardium	  and	  epicardium	  lengths	  respectively.	  	  Final	  infarct	  size	  was	  calculated	  as	  an	  average	  of	  the	  endocardial	  and	  epicardial	  infarct	  sizes.	  (figure	  6-­‐3).	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Figure	  6-­‐2:	  	  	  A	  typical	  series	  of	  cardiac	  sections	  prepared	  for	  planimetry.	  	  In	  this	  series	  the	  large	  infarct	  can	  be	  seen	  as	  the	  pale	  thinned	  area	  of	  tissue	  that	  has	  in	  this	  case	  involved	  the	  majority	  of	  the	  lower	  part	  of	  the	  left	  ventricle.	  Scale	  bar	  =	  1cm	  
	  
Figure	  6-­‐3:	  	  Planimetry	  –	  how	  to	  calculate	  infarct	  size.	  	  (A)	  The	  endocardial	  (yellow	  line)	  and	  epicardial	  (blue	  line)	  infarct	  lengths	  are	  measured	  for	  each	  section.	  	  (B)	  The	  left	  ventricular	  endocardial	  (green	  line)	  and	  epicardial	  (orange	  line)	  circumferences	  are	  measured.	  	  The	  infarct	  size	  is	  calculated	  as	  an	  average	  of	  the	  endocardial	  and	  epicardial	  infarct	  proportions	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (total	  infarct	  length/ventricular	  circumference).	  Scale	  bar	  =	  1cm	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6.2.3	  Cardiac	  MRI	  
Cardiac	  MRI	  was	  performed	  as	  per	  the	  protocol	  described	  in	  section	  2.4.1.	  	  Infarct	  size	  was	  calculated	  using	  late	  gadolinium	  enhancement	  scans.	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6.3	  Results	  
	  
6.3.1	  Operative	  Mortality	  
A	  total	  of	  51	  rats	  underwent	  LAD	  ligation	  to	  induce	  myocardial	  infarction.	  	  Overall	  early	  mortality	  was	  41.2%	  with	  group	  1	  having	  a	  33%	  mortality	  rate,	  group	  2	  having	  50%	  mortality,	  and	  group	  3	  having	  33%	  mortality	  (figure	  6-­‐4).	  	  Early	  mortality	  was	  secondary	  to	  either	  ventricular	  arrythmia	  that	  did	  not	  respond	  to	  cardiac	  massage,	  or	  anaesthetic	  difficulties	  associated	  with	  mechanical	  ventilation.	  	  There	  were	  no	  late	  deaths	  (later	  than	  24	  hours	  post	  infarction)	  in	  any	  group.	  	  	  
Figure	  6-­‐4:	  	  	  Flowchart	  demonstrating	  animal	  numbers,	  survival	  and	  infarct	  size	  category	  in	  each	  study	  group.	  	  Nil	  =	  no	  infarct	  found.	  Small	  =	  Infarct	  up	  to	  29%.	  Med	  =	  Medium	  infarct	  from	  30-­‐46%.	  Large	  =	  Infarct	  size	  47%	  or	  greater.	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6.3.2	  Successful	  infarction	  
Infarction	  was	  induced	  successfully	  overall	  in	  90%	  of	  cases,	  with	  3	  rats	  in	  total	  not	  showing	  evidence	  of	  infarction	  on	  planimetry	  or	  MRI.	  	  Group	  1	  had	  a	  successful	  infarction	  rate	  of	  80%	  (2	  out	  of	  10	  surviving	  rats	  showed	  no	  signs	  of	  infarction),	  group	  2	  had	  an	  infarction	  rate	  of	  91.7%	  (1	  out	  of	  12	  surviving	  rats	  showed	  no	  signs	  of	  infarction)	  and	  group	  3	  had	  an	  infarction	  rate	  of	  100%	  (all	  8	  surviving	  rats	  showed	  evidence	  of	  infarction).	  
	  
6.3.3	  Infarct	  size	  
Group	  1	  had	  infarct	  size	  calculated	  by	  planimetry,	  4	  weeks	  following	  myocardial	  infarction.	  	  Group	  2	  had	  infarct	  size	  calculated	  by	  late	  gadolinium	  enhancement	  on	  MRI	  scan	  between	  1	  day	  and	  4	  weeks	  post	  infarction.	  	  Group	  3	  had	  infarct	  size	  calculated	  by	  late	  gadolinium	  enhancement	  on	  MRI	  scan	  at	  day	  1-­‐2	  post	  infarction	  (figure	  6-­‐5).	  	  	  
The	  infarct	  size	  criteria	  described	  by	  Pfeffer(Pfeffer,	  Pfeffer	  et	  al.	  1979)	  (Small	  infarct	  =	  1-­‐29%,	  Medium	  infarct	  =	  30-­‐46%,	  Large	  infarct	  =	  47%	  or	  greater)	  was	  used	  to	  grade	  infarct	  sizes.	  	  Group	  1	  had	  20%	  rats	  with	  no	  infarct	  (2	  rats	  out	  of	  10),	  40%	  small	  infarcts	  (4	  rats	  out	  of	  10),	  30%	  medium	  infarcts	  (3	  rats	  out	  of	  10)	  and	  10%	  large	  infarcts	  (1	  rat	  out	  of	  10).	  	  Group	  2	  had	  8.3%	  rats	  with	  no	  infarct	  (1	  rat	  out	  of	  12),	  83.3%	  small	  infarcts	  (10	  rats	  out	  of	  12),	  8.3%	  medium	  infarcts	  (1	  rat	  out	  of	  12)	  and	  0%	  large	  infarcts	  (0	  rats).	  	  Group	  3	  had	  12.5%	  small	  infarcts	  (1	  rats	  out	  of	  8),	  75%	  medium	  infarcts	  (6	  rats	  out	  of	  8),	  and	  12.5%	  large	  infarcts	  (2	  rats	  out	  of	  8).	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The	  average	  infarct	  size	  as	  calculated	  by	  planimetry	  or	  MRI	  was	  23.7%	  +/-­‐	  16.0%	  (Mean	  +/-­‐	  SD)	  for	  group	  1,	  18.3%	  +/-­‐	  9.1%	  for	  group	  2,	  and	  36.2%	  +/-­‐	  7.3%	  for	  group	  3	  (Figure	  6-­‐6).	  
	  
Figure	  6-­‐5:	  	  Infarct	  size	  in	  surviving	  rats	  from	  Group	  1	  (blue	  diamonds),	  Group	  2	  (Red	  Squares),	  and	  Group	  3	  (Green	  Triangles).	  	  Small	  infarctions	  were	  classified	  as	  being	  up	  to	  29%	  in	  size,	  Medium	  infarctions	  from	  30-­‐46%	  in	  size	  and	  Large	  infarctions	  greater	  than	  47%	  in	  size.	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Figure	  6-­‐6:	  	  Average	  infarct	  size	  by	  study	  group.	  	  Bars	  represent	  standard	  deviation.	  
	  
6.3.4	  Ejection	  Fraction	  
Left	  ventricular	  ejection	  fraction	  was	  measured	  by	  cardiac	  MRI	  for	  a	  subset	  of	  rats	  from	  group	  2	  (7	  rats	  out	  of	  10)	  and	  all	  of	  group	  3	  (8	  rats)	  (figure	  6-­‐7).	  	  Group	  2	  had	  an	  average	  ejection	  fraction	  of	  55.4%	  +/-­‐	  10.6%	  (mean	  +/-­‐	  SD).	  	  Group	  3	  had	  a	  significantly	  lower	  average	  ejection	  fraction	  of	  45.4%	  +/-­‐	  7.8%	  (p<0.05).	  	  The	  control	  group,	  which	  had	  no	  myocardial	  infarction	  had	  an	  average	  ejection	  fraction	  of	  69.8%	  +/-­‐	  1.1%.	  
There	  was	  a	  correlation	  between	  increasing	  infarct	  size	  and	  reducing	  ejection	  fraction	  with	  an	  R-­‐squared	  value	  of	  0.67	  (figure	  6-­‐8)	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Figure	  6-­‐7:	  	  Average	  ejection	  fraction	  as	  measured	  by	  cardiac	  MRI.	  	  Points	  represent	  mean	  averages,	  and	  error	  bars	  represent	  standard	  deviations.	  	  (p<0.05)
	  
Figure	  6-­‐8:	  	  The	  correlation	  between	  infarct	  size	  and	  ejection	  fraction.	  	  Ejection	  fraction	  decreases	  as	  infarct	  size	  increases.	  	  R-­‐squared	  value	  =	  0.67	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6.4	  Discussion	  
Establishing	  an	  animal	  model	  for	  the	  investigation	  of	  novel	  therapies	  for	  disease	  is	  an	  important	  step	  in	  any	  research	  pathway.	  	  One	  of	  the	  most	  important	  aspects	  of	  any	  animal	  model	  must	  be	  consistency.	  	  Large	  variations	  in	  an	  animal	  model	  will	  lead	  to	  a	  correspondingly	  large	  variation	  in	  responses	  to	  therapy,	  making	  experimental	  results	  difficult	  to	  interpret.	  	  	  
The	  rat	  has	  been	  used	  as	  the	  animal	  of	  choice	  for	  cardiovascular	  research	  for	  decades.	  	  The	  rat	  has	  relatively	  few	  collateral	  vessels	  in	  the	  heart.	  	  Maxwell	  et	  al.	  used	  radiolabelled	  microspheres	  to	  study	  collateral	  flow	  following	  coronary	  ligation	  in	  animals,	  and	  reported	  only	  6.1%	  of	  non-­‐ischaemic	  flow	  in	  the	  rat	  is	  via	  collateral	  vessels(Maxwell,	  Hearse	  et	  al.	  1987).	  	  Therefore,	  ligation	  of	  the	  LAD	  should	  result	  in	  reproducible	  ischaemic	  zones,	  making	  it	  one	  of	  the	  best-­‐suited	  species	  for	  study	  of	  myocardial	  infarction.	  	  	  
Despite	  the	  anatomical	  advantages	  of	  the	  rat	  species,	  there	  is	  still	  considerable	  variation	  brought	  in	  to	  the	  rat	  model	  of	  myocardial	  infarction	  due	  to	  the	  need	  for	  surgical	  intervention.	  	  The	  procedure	  to	  induce	  myocardial	  infarction	  is	  complex	  and	  can	  be	  affected	  significantly	  by	  both	  anaesthetic	  and	  surgical	  complications.	  	  As	  with	  any	  surgical	  procedure,	  there	  is	  a	  learning	  curve	  that	  is	  required	  before	  consistent	  results	  can	  be	  expected.	  	  	  
The	  ability	  to	  induce	  an	  infarct	  is	  key	  in	  the	  rat	  myocardial	  infarction	  model.	  	  Early	  studies	  of	  this	  model	  by	  Pfeffer	  et	  al.	  demonstrated	  only	  a	  49%	  success	  rate	  in	  producing	  myocardial	  infarction.	  	  In	  the	  current	  study,	  group	  1	  demonstrated	  an	  80%	  success	  rate,	  group	  2	  a	  91.7	  %	  success	  rate,	  and	  group	  3	  a	  100%	  success	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rate,	  with	  an	  overall	  success	  rate	  of	  90%.	  	  This	  demonstrates	  a	  excellent	  rate	  of	  infarction,	  and	  evidences	  the	  effect	  of	  the	  learning	  curve,	  as	  infarction	  rates	  improved	  with	  each	  successive	  experimental	  group.	  
Another	  key	  factor	  in	  producing	  the	  rat	  myocardial	  infarction	  model	  is	  the	  variability	  of	  the	  size	  of	  infarction.	  	  Again	  the	  effect	  of	  the	  surgical	  learning	  curve	  can	  be	  seen	  in	  the	  current	  study,	  with	  intra-­‐group	  variation	  highest	  in	  group	  1	  (SD=16.0%),	  lower	  in	  group	  2	  (SD	  =	  9.1%)	  and	  lowest	  of	  all	  in	  group	  3	  (SD	  =	  7.3%).	  	  This	  demonstrates	  increasing	  consistency	  of	  the	  surgical	  technique,	  resulting	  in	  smaller	  variations	  in	  infarct	  size.	  	  	  
The	  final	  size	  of	  infarct	  is	  also	  crucial	  to	  the	  model	  as	  this	  can	  have	  great	  effects	  upon	  myocardial	  function,	  and	  thus	  may	  also	  affect	  responses	  to	  therapy(Pfeffer,	  Pfeffer	  et	  al.	  1979,	  Pfeffer,	  Pfeffer	  et	  al.	  1984).	  	  This	  has	  to	  be	  counterbalanced	  against	  mortality,	  as	  larger	  infarcts	  are	  associated	  with	  higher	  mortality	  rates.	  	  The	  key	  to	  this	  model	  is	  the	  production	  of	  infarcts	  that	  have	  a	  definite	  impact	  upon	  cardiac	  function,	  whilst	  maintaining	  an	  acceptable	  mortality	  rate.	  	  In	  the	  current	  study,	  group	  3	  was	  shown	  to	  have	  the	  greatest	  infarct	  size	  (36.2%	  +/-­‐	  7.3%).	  	  Mortality	  rates	  for	  group	  3	  were	  also	  acceptable	  at	  33.3%	  in	  comparison	  with	  published	  literature	  quoting	  mortality	  rates	  of	  40-­‐50%(Pfeffer,	  Pfeffer	  et	  al.	  1979,	  Pfeffer,	  Pfeffer	  et	  al.	  1984).	  
Cardiac	  function	  was	  investigated	  by	  MRI,	  with	  measurements	  of	  left	  ventricular	  ejection	  fraction	  for	  rats	  from	  groups	  2	  and	  3.	  	  This	  demonstrated	  a	  clear	  relationship	  between	  left	  ventricular	  impairment	  and	  infarct	  size,	  with	  ejection	  fraction	  falling	  as	  infarct	  size	  increased.	  	  A	  correlation	  was	  established	  between	  the	  two	  variables,	  with	  R-­‐squared	  value	  equaling	  0.67.	  	  If	  results	  were	  grouped	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according	  to	  Pfeffers	  original	  classification,	  rats	  with	  no	  infarction,	  small	  infarction,	  and	  medium	  sized	  infarctions	  had	  ejection	  fractions	  of	  69.6%	  +/-­‐	  1.14%	  (mean	  +/-­‐	  SD),	  55.8%	  +/-­‐	  7.22%,	  and	  44.7	  +/-­‐	  8.36%	  respectively,	  with	  statistical	  significance	  across	  all	  group	  comparisons	  (p<0.05).	  
This	  result	  supports	  the	  original	  reports	  by	  Pfeffer	  et	  al.	  that	  cardiac	  function	  is	  related	  to	  infarct	  size.	  	  	  However,	  Pfeffer	  et	  al.	  reported	  that	  only	  large	  infarcts	  above	  47%	  in	  size	  resulted	  in	  impairment	  in	  baseline	  cardiac	  function,	  with	  medium	  infarctions	  demonstrating	  impairment	  only	  upon	  temporary	  aortic	  occlusion	  and	  small	  infarcts	  demonstrating	  no	  cardiac	  impairment	  at	  all.	  	  Our	  study	  demonstrates	  that	  even	  small	  infarctions	  of	  less	  than	  30%	  can	  result	  in	  significant	  impairment	  of	  left	  ventricular	  ejection	  fraction.	  	  It	  is	  likely	  that	  the	  excellent	  tissue	  resolution	  and	  non-­‐invasiveness	  of	  cardiac	  MRI	  has	  allowed	  the	  detection	  of	  these	  effects.	  
	  
6.5	  Summary	  
In	  summary	  this	  study	  has	  demonstrated	  the	  successful	  establishment	  of	  a	  rat	  model	  of	  myocardial	  infarction	  by	  ligation	  of	  the	  left	  anterior	  descending	  artery.	  	  Infarcts	  were	  induced	  reliably,	  and	  average	  infarction	  size	  in	  the	  final	  group	  of	  rats	  was	  measured	  as	  36.2%	  +/-­‐	  7.3%,	  with	  significant	  impairment	  of	  left	  ventricular	  ejection	  fraction	  (45.4%	  +/-­‐	  7.8%).	  	  These	  results	  imply	  that	  nude	  rats	  can	  be	  used	  myocardial	  infarction,	  and	  that	  aiming	  for	  a	  moderate	  sized	  infarct	  produces	  a	  significant	  detrimental	  effect	  upon	  measures	  of	  cardiac	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Myocardial	  Infarction	  (MI)	  and	  its	  consequences	  of	  cardiac	  failure	  are	  tremendously	  important	  causes	  of	  global	  death	  and	  ill	  health(Roger,	  Go	  et	  al.	  ,	  Levy,	  Kenchaiah	  et	  al.	  2002,	  Roger,	  Weston	  et	  al.	  2004,	  Allender,	  Peto	  et	  al.	  2008).	  	  The	  medical	  field	  has	  spent	  decades	  of	  research	  aimed	  at	  the	  prevention	  and	  treatment	  of	  this	  clinical	  event.	  	  Many	  incredible	  advances	  have	  been	  made,	  especially	  within	  the	  realms	  of	  pharmacological	  therapies	  and	  now	  new	  revascularisation	  strategies	  to	  treat	  those	  who	  have	  suffered	  an	  MI.	  	  However,	  despite	  all	  these	  advances,	  there	  has	  never	  been	  a	  way	  to	  cure	  the	  fundamental	  pathology	  behind	  MI	  –	  the	  death	  and	  loss	  of	  functioning	  myocardium.	  	  	  
Although	  cardiomyocytes	  have	  recently	  been	  found	  to	  have	  the	  potential	  to	  proliferate	  (Bergmann,	  Bhardwaj	  et	  al.	  2009),	  the	  central	  problem	  is	  that	  this	  rate	  of	  proliferation	  is	  very	  slow	  and	  woefully	  inadequate	  to	  react	  to	  sizeable	  injury	  (Kajstura,	  Rota	  et	  al.	  2012,	  Senyo,	  Steinhauser	  et	  al.	  2013).	  	  Therefore,	  no	  matter	  how	  the	  body	  tries	  to	  heal	  itself,	  and	  repair	  damage,	  the	  myocardium	  that	  is	  lost	  from	  an	  MI	  will	  always	  become	  fibrotic,	  stiff	  scar	  that	  is	  non-­‐functional	  (Holmes,	  Borg	  et	  al.	  2005).	  	  This	  pathological	  problem	  has	  always	  been	  up	  to	  this	  point	  unassailable,	  with	  even	  the	  best	  therapies	  only	  prolonging	  the	  inevitable.	  
The	  field	  of	  regenerative	  medicine	  has	  brought	  hope	  to	  this	  important	  healthcare	  area,	  with	  many	  studies	  now	  showing	  that	  there	  may	  be	  the	  potential	  to	  reverse	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this	  damage	  and	  cure	  the	  previously	  incurable(Leor,	  Amsalem	  et	  al.	  2005,	  Christman	  and	  Lee	  2006,	  Jawad,	  Ali	  et	  al.	  2007).	  	  Advances	  particularly	  within	  the	  field	  of	  stem	  cell	  technology	  and	  biomaterials	  has	  given	  us	  the	  tools	  that	  may	  allow	  us	  to	  grow	  and	  replace	  damaged	  tissues	  –	  so	  called	  tissue	  engineering.	  
As	  our	  understanding	  of	  this	  area	  deepens,	  so	  does	  the	  realisation	  that	  there	  are	  still	  many	  obstacles	  to	  be	  overcome	  before	  an	  effective	  solution	  can	  be	  found.	  	  It	  is	  extremely	  unlikely	  that	  researchers	  will	  find	  a	  “magic	  bullet”	  –	  a	  single	  simple	  solution	  to	  this	  incredibly	  complex	  and	  multi-­‐factorial	  problem.	  	  	  
The	  pathological	  processes	  behind	  MI	  and	  cardiac	  failure	  are	  dependent	  upon	  a	  multitude	  of	  interacting	  processes,	  including	  cell	  death,	  inflammation,	  mechanical	  disruption	  and	  hormonal	  changes(Holmes,	  Borg	  et	  al.	  2005).	  	  It	  is	  likely	  therefore	  that	  any	  successful	  treatment	  strategy	  will	  also	  have	  to	  involve	  a	  multitude	  of	  processes.	  	  Research	  so	  far	  has	  been	  guided	  by	  the	  “three	  pillars	  of	  tissue	  engineering”	  –	  being	  cells,	  scaffolds,	  and	  stimulating	  biomolecules.	  	  Attention	  will	  have	  to	  be	  paid	  to	  each	  of	  these	  to	  develop	  a	  well-­‐rounded	  treatment	  strategy	  for	  cardiac	  regeneration.	  	  	  	  	  	  
Yamanaka	  et	  al.	  first	  described	  the	  development	  of	  induced-­‐pluripotent	  stem	  cells	  (iPS)(Takahashi	  and	  Yamanaka	  2006),	  opening	  up	  a	  whole	  new	  field	  of	  stem	  cell	  research.	  	  The	  use	  of	  iPS	  in	  tissue	  regeneration	  strategies	  is	  incredibly	  exciting	  due	  to	  the	  potential	  for	  unlimited	  production	  and	  expansion	  of	  specific	  cell	  populations,	  whilst	  avoiding	  many	  of	  the	  immunological	  and	  ethical	  problems	  associated	  with	  embryonic	  stem	  cells(Yoshida	  and	  Yamanaka	  ,	  Yamanaka	  2009).	  	  Although	  researchers	  are	  still	  investigating	  the	  similarities	  and	  differences	  between	  iPS	  and	  the	  better	  understood	  embryonic	  equivalents,	  it	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is	  clear	  to	  many	  that	  iPS	  therapy	  is	  the	  future	  of	  cell	  therapy	  for	  cardiac	  disease10.	  	  	  
Breakthroughs	  in	  the	  field	  of	  biomaterial	  scaffolds	  are	  also	  being	  made	  on	  a	  regular	  basis.	  	  Increasingly	  complex	  and	  bioactive	  materials	  can	  now	  be	  manufactured,	  allowing	  specific	  tailoring	  of	  mechanical	  properties	  as	  well	  as	  designing	  specific	  biomaterial-­‐cell	  interactions	  to	  promote	  survival	  and	  healing	  on	  a	  cellular	  and	  molecular	  level(Place,	  Evans	  et	  al.	  2009).	  	  Material	  mechanical	  properties	  have	  been	  shown	  to	  influence	  infarct	  healing(Kortsmit,	  Davies	  et	  al.	  ,	  Wall,	  Walker	  et	  al.	  2006,	  Ifkovits,	  Tous	  et	  al.	  2010),	  as	  well	  as	  cellular	  function(Engler,	  Sen	  et	  al.	  2006,	  Engler,	  Carag-­‐Krieger	  et	  al.	  2008),	  demonstrating	  the	  need	  to	  pay	  attention	  to	  every	  aspect	  of	  scaffold	  design.	  	  In	  this	  current	  series	  of	  experiments	  we	  have	  described	  the	  creation	  of	  an	  injectable	  biomaterial	  scaffold	  based	  on	  a	  polyethylene	  glycol	  (PEG)	  backbone.	  	  This	  material	  has	  been	  engineered	  specifically	  to	  mimic	  the	  mechanical	  properties	  of	  healthy	  myocardium,	  thus	  potentially	  providing	  support	  not	  only	  to	  the	  infarcted	  heart,	  but	  also	  to	  transplanted	  cardiac	  cells.	  
A	  multitude	  of	  signaling	  molecules	  and	  survival	  factors	  have	  been	  investigated	  as	  a	  therapy	  for	  cardiac	  failure.	  	  As	  described	  by	  Laflamme	  et	  al.(Laflamme,	  Chen	  et	  al.	  2007)	  it	  may	  even	  be	  necessary	  to	  provide	  a	  pro-­‐survival	  cocktail	  involving	  several	  factors	  at	  once,	  in	  order	  to	  achieve	  the	  desired	  effect.	  	  The	  aims	  of	  these	  factors	  are	  two-­‐fold.	  	  Firstly	  they	  can	  serve	  to	  affect	  the	  resident	  cells	  –	  promoting	  survival	  within	  the	  infarct	  and	  also	  activating	  or	  recruiting	  cells	  to	  aid	  with	  cardiac	  regeneration.	  	  Secondly,	  they	  serve	  a	  function	  for	  transplanted	  cells	  –	  helping	  to	  create	  an	  environment	  whereby	  exogenous	  cells	  can	  survive	  long	  
	   193	  
enough	  to	  fulfill	  their	  specific	  role	  in	  tissue	  regeneration,	  be	  that	  via	  direct	  or	  paracrine	  effects.	  	  The	  use	  of	  erythropoietin	  (Epo)	  within	  this	  series	  of	  experiments	  was	  targeted	  to	  try	  and	  address	  both	  strategies.	  	  Epo	  has	  already	  been	  shown	  in	  many	  experiments	  to	  be	  a	  potential	  therapy	  post-­‐MI	  as	  it	  can	  reduce	  cardiac	  cell	  death	  and	  improve	  cardiac	  function(Brines,	  Grasso	  et	  al.	  2004,	  Hausenloy	  and	  Yellon	  2004,	  Brines	  and	  Cerami	  2006,	  Brines	  and	  Cerami	  2008).	  	  We	  have	  also	  shown	  in	  the	  current	  series	  of	  experiments	  (see	  Chapter	  5)	  that	  Epo	  has	  a	  protective	  effect	  upon	  iPSC-­‐derived	  cardiomyoctes,	  a	  potential	  source	  of	  cell	  therapy.	  	  Therefore	  Epo	  potentially	  may	  be	  an	  important	  factor	  in	  any	  multifaceted	  therapeutic	  strategy.	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7.2	  Methods	  
7.2.1	  Hydrogel	  preparation	  and	  materials	  
A	  10%	  PEG	  hydrogel	  was	  prepared	  using	  4-­‐Armed	  PEG	  acrylate	  and	  PEG	  dithiol	  as	  described	  in	  section	  3.2.1.	  	  To	  create	  a	  final	  hydrogel	  concentration	  of	  10%,	  a	  20%	  4-­‐Armed	  PEG	  acrylate	  solution	  was	  made.	  	  150µl	  of	  this	  was	  diluted	  with	  150µl	  of	  cell	  suspension	  just	  prior	  to	  injection	  to	  form	  a	  10%	  4-­‐Armed	  PEG	  acrylate	  solution.	  	  The	  appropriate	  amount	  of	  10%	  PEG	  dithiol	  was	  added	  to	  this	  mixture	  just	  prior	  to	  injection	  to	  initiate	  the	  gelling	  process.	  	  The	  final	  mixure	  was	  drawn	  up	  into	  a	  1ml	  syringe	  and	  intramyocardial	  injections	  delivered	  through	  a	  27G	  needle.	  	  	  
For	  experiments	  involving	  erythropoietin	  –	  this	  was	  purchased	  as	  a	  powder	  from	  Sigma	  Aldrich,	  and	  dissolved	  in	  CDI	  maintenance	  media	  immediately	  before	  commencing	  experiments.	  	  This	  preparation	  was	  used	  to	  create	  the	  4-­‐Armed	  PEG	  acrylate	  solutions	  for	  hydrogel	  experiments.	  	  The	  mixtures	  were	  prepared	  to	  give	  a	  final	  concentration	  of	  Epo	  within	  the	  hydrogels	  of	  1u/ml.	  
	  
7.2.2	  Cell	  culture	  
Induced-­‐pluripotent	  stem	  cell	  derived	  cardiomyocytes	  (iPS-­‐CM)	  were	  purchased	  from	  Cellular	  Dynamics	  Inc.	  and	  cultured	  as	  described	  in	  section	  2.2.2.1.	  	  Cells	  were	  plated	  at	  a	  density	  of	  60,000	  cells	  per	  cm2	  into	  gelatin	  coated	  T75	  flasks,	  and	  kept	  in	  culture	  for	  7-­‐8	  days	  prior	  to	  injection.	  	  This	  allowed	  cultures	  to	  form	  a	  spontaneously	  beating	  syncitium	  of	  cardiomyocytes.	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On	  the	  morning	  of	  experiments,	  cultures	  were	  washed	  twice	  with	  phosphate	  buffered	  saline	  (PBS)	  and	  trypsinised	  for	  2-­‐3	  minutes	  using	  0.5%	  trypsin	  at	  37°C.	  	  Trypsin	  was	  neutralized	  with	  5x	  volume	  of	  CDI	  maintenance	  media	  containing	  serum.	  	  The	  resultant	  cell	  suspension	  was	  pipetted	  gently	  to	  break	  up	  cell	  clusters	  and	  detach	  any	  remaining	  cells,	  before	  being	  transferred	  to	  a	  centrifuge	  tube,	  and	  centrifuged	  for	  5	  minutes	  at	  500rpm.	  	  The	  supernatant	  was	  removed	  and	  the	  resultant	  cell	  pellet	  resuspended	  in	  5ml	  of	  CDI	  maintenance	  medium.	  	  Viable	  cell	  counts	  were	  measured	  using	  trypan	  blue	  exclusion	  and	  a	  haemocytometer.	  	  The	  cell	  suspension	  was	  centrifuged	  again	  for	  5	  minutes	  at	  500rpm	  and	  the	  resultant	  cell	  pellet	  resuspended	  in	  CDI	  maintenance	  media	  to	  a	  concentration	  of	  6	  –	  7	  million	  cells	  per	  ml.	  	  150µl	  of	  this	  suspension	  containing	  approximately	  1	  million	  cells	  was	  mixed	  with	  150µl	  of	  20%	  4-­‐Armed	  PEG	  Acrylate	  solution	  prior	  to	  injection.	  	  	  	  
	  
7.2.3	  Animal	  models	  
Seven	  week	  old	  male	  nude	  rats	  were	  purchased	  from	  Charles	  River	  Limited	  (Germany),	  housed	  2-­‐3	  to	  a	  cage	  and	  allowed	  to	  acclimatize	  for	  7	  days	  prior	  to	  experiments.	  
Rats	  were	  anaesthetized	  as	  described	  in	  section	  2.3.5,	  and	  underwent	  MI	  surgery	  as	  described	  in	  section	  2.3.9.	  	  	  Sham	  surgery	  was	  performed	  by	  passing	  a	  suture	  and	  needle	  through	  the	  myocardium	  without	  ligation.	  	  Following	  successful	  infarction,	  hydrogels,	  cells,	  or	  a	  hydrogel	  and	  cell	  mixture	  was	  injected	  by	  3	  x	  50µl	  injections	  around	  the	  infarct	  border	  zone.	  	  Following	  injection	  the	  chest	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cavity	  was	  closed	  as	  described	  in	  section	  2.3.6	  and	  the	  animal	  recovered	  as	  described	  in	  section	  2.3.5.	  	  	  
The	  experimental	  groups	  were	  as	  follows:	  
1) Sham	  control	  (Sham	  group)	  2) MI	  control	  (MI	  group)	  3) MI	  +10%	  PEG	  hydrogel	  (Gel	  group)	  4) MI	  +	  10%	  PEG	  hydrogel	  +	  Epo	  (Gel-­‐Epo	  group)	  5) MI	  +	  iPS-­‐CM	  (Cell	  group)	  6) MI	  +	  10%	  PEG	  hydrogel	  +	  iPS-­‐CM	  +	  Epo	  (Gel-­‐Cell-­‐Epo	  group)	  
	  
7.2.4	  Cardiac	  MRI	  
Cardiac	  MRI	  was	  performed	  as	  described	  in	  section	  2.4.1.	  	  Timepoints	  for	  MRI	  scanning	  were	  at	  1-­‐2	  days	  and	  again	  at	  8-­‐10	  weeks.	  	  Primary	  outcome	  measures	  were	  left	  ventricular	  chamber	  end-­‐diastolic	  and	  end-­‐systolic	  chamber	  volumes,	  stroke	  volume	  and	  ejection	  fraction.	  	  Infarct	  size	  was	  measured	  using	  delayed	  gadolinium	  enhancement	  and	  expressed	  as	  a	  percentage	  of	  the	  left	  ventricular	  myocardial	  area.	  	  Measurement	  of	  outcomes	  from	  MRI	  images	  was	  performed	  by	  an	  investigator	  blinded	  to	  the	  experimental	  groups.	  
	  
7.2.5	  Histology	  
Following	  the	  8-­‐10	  week	  MRI	  scan,	  hearts	  were	  fixed	  using	  10%	  formalin	  as	  described	  in	  section	  2.5.	  	  Hearts	  were	  subject	  to	  paraffin	  embedded	  sectioning,	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prior	  to	  staining	  with	  Massons	  trichrome	  stain	  or	  immunostaining.	  	  Immunostaining	  experiments	  were	  performed	  by	  Dr	  Mark	  Rocco.	  	  For	  immunostaining	  studies,	  negative	  control	  samples	  were	  taken	  from	  the	  MI	  group,	  and	  positive	  control	  samples	  were	  from	  human	  tissue	  taken	  from	  patients	  with	  dilated	  cardiomyopathy,	  as	  well	  as	  iPS-­‐CM	  grown	  on	  glass	  coverslips.	  	  Experimental	  samples	  were	  from	  the	  Cell	  and	  Gel-­‐Cell-­‐Epo	  groups,	  at	  day	  1	  (taken	  from	  rats	  that	  died	  during	  surgery),	  and	  from	  the	  Gel-­‐Cell-­‐Epo	  group	  taken	  at	  the	  end	  of	  the	  study	  (day	  77).	  	  
Images	  of	  the	  infarct	  zone	  (x4	  magnification)	  were	  analyzed	  using	  ImageJ	  software.	  	  This	  allowed	  measurement	  of	  infarct	  thickness	  (as	  in	  Chapter	  6),	  as	  well	  as	  measurement	  of	  the	  proportion	  of	  the	  infarct	  stained	  red	  by	  Massons	  Trichrome.	  	  This	  allowed	  calculation	  of	  the	  amount	  of	  muscle	  fibres	  present	  in	  the	  infarct	  zone.	  	  Fluorescence	  microscopy	  was	  used	  to	  image	  samples	  labeled	  with	  immunostaining.	  	  	  
	  
7.2.6	  Quantitative	  Polymerase	  Chain	  Reaction	  (qPCR)	  
qPCR	  experiments	  were	  performed	  by	  Dr	  Mark	  Rocco.	  	  As	  described	  in	  chapter	  2.6,	  frozen	  cardiac	  samples	  were	  subject	  to	  qPCR	  analysis.	  	  Infarct	  zones	  and	  remaining	  left	  ventricular	  areas	  were	  analyzed	  separately.	  	  Negative	  control	  samples	  were	  taken	  from	  the	  sham	  and	  MI	  groups.	  	  Experimental	  samples	  were	  from	  the	  Gel-­‐Cell-­‐Epo	  group,	  at	  day	  1	  (taken	  from	  rats	  that	  died	  during	  surgery),	  and	  at	  the	  end	  of	  the	  study	  (day	  77).	  	  Positive	  control	  samples	  used	  were	  human	  samples	  from	  patients	  with	  dilated	  cardiomyopathy.	  	  qPCR	  was	  performed	  	  for	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an	  assortment	  of	  early	  and	  late	  cardiac	  markers,	  including	  atrial	  natriuretic	  factor	  (ANF),	  myosin-­‐6	  (MYH6),	  myosin-­‐7	  (MYH7),	  and	  alpha-­‐1A	  and	  1B	  adrenergic	  receptors	  (ADRA1a	  and	  ADRA1b).	  
	  
7.2.7	  Statistical	  Analysis	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7.3	  Results	  
	  
7.3.1	  Experimental	  groups	  and	  survival	  rates	  
Sixty-­‐four	  male	  nude	  rats	  were	  operated	  on	  for	  this	  experiment.	  	  Each	  experimental	  group	  had	  12	  rats,	  except	  for	  the	  sham	  operated	  group,which	  had	  4	  rats.	  	  Figure	  7-­‐2	  outlines	  the	  experimental	  structure	  and	  survival	  rates	  per	  group.	  
All	  the	  rats	  in	  the	  sham	  operated	  group	  (n=4)	  survived	  surgery	  and	  follow	  up	  to	  the	  2nd	  MRI	  time	  point	  at	  8-­‐10	  weeks.	  	  In	  the	  MI	  group	  (n=12),	  8	  rats	  survived	  initial	  surgery	  (67%	  early	  survival	  rate)	  and	  successfully	  underwent	  MRI	  scan	  at	  the	  first	  MRI	  timepoint	  (day	  1-­‐2).	  	  One	  rat	  from	  this	  group	  died	  in	  the	  following	  weeks	  to	  give	  a	  final	  count	  of	  7	  rats	  undergoing	  a	  second	  MRI	  scan	  (58%	  late	  survival	  rate).	  	  In	  the	  Gel	  group	  (n=12),	  8	  rats	  survived	  initial	  surgery	  and	  underwent	  MRI	  scan	  at	  the	  early	  time	  point	  (67%	  early	  survival	  rate).	  	  Two	  rats	  died	  in	  the	  following	  weeks	  and	  6	  rats	  survived	  to	  undergo	  the	  second	  MRI	  scan	  (50%	  late	  survival	  rate).	  	  In	  the	  Gel-­‐Epo	  group	  (n=12)	  6	  rats	  survived	  surgery	  (50%	  early	  survival	  rate),	  and	  underwent	  early	  MRI	  scan.	  	  5	  rats	  survived	  to	  the	  second	  MRI	  time	  point	  (42%	  late	  survival	  rate).	  	  In	  the	  Cell	  group	  10	  rats	  survived	  initial	  surgery	  (83%	  early	  survival).	  	  One	  rat	  died	  prior	  to	  the	  first	  MRI	  scan	  and	  another	  two	  died	  before	  the	  second	  MRI	  scan	  leaving	  7	  rats	  surviving	  to	  the	  late	  time	  point	  (58%	  late	  survival	  rate).	  	  In	  the	  Gel-­‐Cell-­‐Epo	  group	  9	  rats	  survived	  initial	  surgery	  (75%	  early	  survival	  rate)	  with	  8	  rats	  surviving	  to	  the	  initial	  MRI	  scan	  and	  5	  rats	  surviving	  to	  the	  late	  MRI	  time	  point	  (42%	  late	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survival)	  (figure	  7-­‐3).	  	  Differences	  between	  groups	  were	  not	  significant	  by	  Chi-­‐Squared	  analysis	  (Fishers	  exact	  test).	  
Overall	  early	  survival	  for	  the	  experimental	  groups	  (excluding	  sham)	  was	  68%.	  	  Overall	  late	  survival	  was	  50%.	  
	  
Figure	  7-­‐2:	  	  Flowchart	  demonstrating	  experimental	  design	  and	  rat	  survival	  rates	  (in	  brackets).	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Figure	  7-­‐3:	  Chart	  describing	  early	  and	  late	  survival	  rates	  in	  experimental	  groups.	  Early	  survival	  was	  defined	  as	  surviving	  the	  initial	  surgical	  procedure.	  Late	  survival	  was	  determined	  as	  rats	  surviving	  to	  the	  2nd	  MRI	  time	  point	  at	  8-­‐10	  weeks.	  
	  
7.3.2	  Cardiac	  MRI	  
	  
7.3.2.1	  End	  Diastolic	  Volume	  
At	  the	  early	  MRI	  time	  point	  (1-­‐2	  days)	  the	  average	  End	  Diastolic	  Volume	  (EDV)	  in	  the	  sham	  control	  group	  was	  290	  µl	  +/-­‐	  45µl	  (mean	  +/-­‐	  SD).	  	  The	  MI	  control	  group	  had	  a	  higher	  average	  EDV	  of	  407µl	  +/-­‐	  51µl.	  	  The	  Gel	  (348µl	  +/-­‐	  66µl),	  Gel-­‐Epo	  (324µl	  +/-­‐	  49µl),	  Cell	  (328µl	  +/-­‐	  72µl)	  and	  Gel-­‐Cell-­‐Epo	  (327µl	  +/-­‐	  39µl)	  had	  average	  EDV	  values	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐4).	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A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  EDV	  values	  between	  groups	  at	  the	  early	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  early	  EDV	  at	  the	  p<0.05	  level	  [F(5,37)	  =	  3.142,	  p	  =	  0.0183].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  increase	  in	  early	  EDV	  in	  the	  MI	  control	  group	  compared	  with	  the	  sham	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  	  
	  
At	  the	  late	  MRI	  time	  point	  (8-­‐10	  weeks),	  average	  EDV	  was	  422µl	  +/-­‐	  36µl	  in	  the	  sham	  control	  group.	  	  The	  average	  late	  EDV	  in	  the	  MI	  control	  group	  was	  632µl	  +/-­‐	  65µl.	  	  The	  average	  late	  EDV	  in	  the	  Cell	  (649µl	  +/-­‐	  155µl)	  group	  was	  higher	  than	  the	  MI	  control	  group,	  with	  the	  average	  late	  EDV	  in	  the	  Gel	  (598µl	  +/-­‐	  89µl),	  Gel-­‐Epo	  (565µl	  +/-­‐	  146µl),	  and	  Gel-­‐Cell-­‐Epo	  (592µl	  +/-­‐	  60µl)	  groups	  lying	  in	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐5).	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7.3.2.2	  End	  Systolic	  Volume	  
At	  the	  early	  time	  point	  (day	  1-­‐2)	  the	  average	  End	  Systolic	  Volume	  (ESV)	  was	  88µl	  +/-­‐	  15µl	  in	  the	  Sham	  control	  group.	  	  This	  was	  increased	  in	  the	  MI	  control	  group	  at	  222µl	  +/-­‐	  44µl.	  	  The	  average	  early	  ESV	  in	  the	  Gel	  (194µl	  +/-­‐	  65µl),	  Gel-­‐Epo	  (151µl	  +/-­‐	  62µl),	  Cell	  (165µl	  +/-­‐	  55µl),	  and	  Gel-­‐Cell-­‐Epo	  (181µl+/-­‐	  34µl)	  groups	  lay	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐6).	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  ESV	  values	  between	  groups	  at	  the	  early	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  early	  ESV	  at	  the	  p<0.05	  level	  [F(5,37)	  =	  4.327,	  p	  =	  0.0034].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  increase	  in	  the	  MI	  control	  and	  Gel	  groups	  compared	  with	  the	  Sham	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  
	  
	  At	  the	  late	  time	  point	  (8-­‐10	  weeks)	  the	  average	  ESV	  in	  the	  Sham	  control	  group	  was	  101µl	  +/-­‐	  10µl.	  	  This	  was	  increased	  in	  the	  MI	  (334µl	  +/-­‐	  54µl)	  group.	  	  The	  average	  late	  ESV	  for	  the	  Gel	  (283µl	  +/-­‐	  85µl),	  Gel-­‐Epo	  (220µl	  +/-­‐	  135µl),	  Cell	  (298µl	  +/-­‐	  103µl),	  and	  Gel-­‐Cell-­‐Epo	  (272µl	  +/-­‐	  77µl)	  groups	  were	  in	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐7).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  ESV	  values	  between	  groups	  at	  the	  late	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  late	  ESV	  at	  the	  p<0.05	  level	  [F(5,28)	  =	  4.205,	  p	  =	  0.0056].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  increase	  in	  late	  
	   207	  
ESV	  in	  the	  MI	  control,	  Gel,	  and	  Cell	  groups	  compared	  with	  the	  Sham	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  	  
	  
	  
Figure	  7-­‐6:	  	  Graph	  to	  show	  End	  Systolic	  Volume	  (ESV)	  measured	  at	  the	  early	  time	  point	  (1-­‐2	  days)	  by	  cardiac	  MRI.	  	  Columns	  represent	  mean	  values,	  with	  error	  bars	  representing	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  	  *	  =	  Significant	  difference	  found	  between	  groups	  using	  Tukey’s	  multiple	  comparisons	  post-­‐hoc	  test	  following	  one-­‐way	  ANOVA.	  	  	  
	  
	  
































Figure	  7-­‐7:	  	  	  Graph	  to	  show	  End	  Systolic	  Volume	  (ESV)	  measured	  at	  the	  late	  time	  point	  (8-­‐10	  weeks)	  by	  cardiac	  MRI.	  	  Columns	  represent	  mean	  values,	  with	  error	  bars	  representing	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  	  *	  =	  Significant	  difference	  found	  between	  groups	  using	  Tukey’s	  multiple	  comparisons	  post-­‐hoc	  test	  following	  one-­‐way	  ANOVA.	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7.3.2.3	  %	  Area	  of	  Late	  Gadolinium	  Enhancement	  
At	  the	  early	  time	  point	  of	  1-­‐2	  days	  the	  average	  area	  of	  late	  gadolinium	  enhancement	  (expressed	  as	  a	  percentage	  of	  total	  left	  ventricular	  area	  -­‐	  %LGE)	  was	  3.2	  +/-­‐	  1.7%.	  	  This	  was	  increased	  to	  36.2%	  +/-­‐	  7.3%	  in	  the	  MI	  control	  group.	  	  The	  Gel	  (38.3%	  +/-­‐	  8.0%)	  and	  Cell	  (38.4%	  +/-­‐	  12.5%)	  groups	  had	  slightly	  higher	  %LGE	  signals	  than	  the	  MI	  control	  group,	  with	  the	  Gel-­‐Epo	  (29.1%	  +/-­‐	  9.3%)	  and	  Gel-­‐Cell-­‐Epo	  (37.0%	  +/-­‐	  8.1%)	  groups	  having	  %LGE	  signals	  slightly	  lower	  than	  the	  MI	  control	  group	  (table	  7.1	  and	  Figure	  7-­‐8).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  %LGE	  values	  between	  groups	  at	  the	  early	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  early	  %LGE	  at	  the	  p<0.05	  level	  [F(5,36)	  =	  11.05,	  p	  <	  0.0001].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  increase	  in	  early	  %LGE	  for	  all	  groups	  (MI	  control,	  Gel,	  Gel-­‐Epo,	  Cell,	  Gel-­‐Cell-­‐Epo)	  compared	  with	  the	  Sham	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  	  
At	  the	  late	  time	  point	  (week	  8-­‐10)	  the	  %	  area	  of	  LGE	  was	  1.4%	  +/-­‐	  1.1%	  in	  the	  sham	  operated	  group.	  	  This	  was	  higher	  in	  the	  MI	  control	  (27.1%	  +/-­‐	  4.4%)	  group.	  	  The	  average	  late	  %LGE	  was	  slightly	  higher	  in	  the	  Gel	  (28.3%	  /-­‐	  4.4%)	  group.	  	  The	  average	  late	  %LGE	  for	  the	  Gel-­‐Epo	  (16.7%	  +/-­‐	  7.2%),	  Cell	  (21.1%	  +/-­‐	  5.1%),	  and	  Gel-­‐Cell-­‐Epo	  (21.6%	  +/-­‐	  2.6%)	  groups	  were	  lower	  than	  the	  MI	  control	  group	  (table	  7.1	  and	  figure	  7-­‐9).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  the	  %LGE	  values	  between	  groups	  at	  the	  late	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	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Figure	  7-­‐9.	  	  Graph	  to	  show	  %	  Area	  of	  Late	  Gadolinium	  Enhancement	  (%LGE)	  measured	  at	  the	  late	  time	  point	  (8-­‐10	  weeks)	  by	  cardiac	  MRI.	  	  Columns	  represent	  mean	  values,	  with	  error	  bars	  representing	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  	  *	  =	  Significant	  difference	  found	  between	  groups	  using	  Tukey’s	  multiple	  comparisons	  post-­‐hoc	  test	  following	  one-­‐way	  ANOVA.	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7.3.2.4	  Stroke	  Volume	  
At	  the	  early	  time	  point	  (day	  1-­‐2)	  the	  average	  stroke	  volume	  (SV)	  in	  the	  Sham	  control	  group	  was	  202µl	  +/-­‐	  30µl,	  with	  the	  average	  SV	  in	  the	  MI	  control	  group	  being	  lower	  at	  185µl	  +/-­‐	  37µl.	  	  The	  Gel	  (156µl	  +/-­‐	  37µl),	  Gel-­‐Epo	  (172µl	  +/-­‐	  25µl),	  Cell	  (164µl	  +/-­‐	  35µl),	  and	  Gel-­‐Cell-­‐Epo	  (146µl	  +/-­‐	  29µl)	  had	  even	  lower	  average	  early	  SV	  values	  (table	  7.1	  and	  figure	  7-­‐10).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  SV	  between	  groups	  at	  the	  early	  time	  point.	  	  There	  was	  no	  significant	  difference	  found	  between	  groups	  for	  early	  SV	  at	  the	  p<0.05	  level	  [F(5,36)	  =	  2.245,	  p	  =	  0.0708].	  	  Post-­‐hoc	  analysis	  was	  therefore	  not	  conducted.	  	  	  
	  
At	  the	  late	  time	  point	  (8-­‐10	  weeks)	  the	  average	  SV	  in	  the	  Sham	  control	  group	  was	  321µl	  +/-­‐	  27µl,	  with	  the	  average	  SV	  in	  the	  MI	  control	  group	  being	  lower	  at	  298µl	  +/-­‐	  46µl.	  	  The	  Gel-­‐Epo	  (346µl	  +/-­‐	  20µl)	  and	  Cell	  (352µl	  +/-­‐	  65µl)	  groups	  had	  average	  late	  SV	  values	  greater	  than	  the	  Sham	  control,	  with	  the	  Gel	  (315µl	  +/-­‐	  72µl)	  and	  Gel-­‐Cell-­‐Epo	  (321µl	  +/-­‐	  27µl)	  groups	  having	  average	  late	  SV	  values	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐11).	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  SV	  between	  groups	  at	  the	  late	  time	  point.	  	  There	  was	  no	  significant	  difference	  found	  between	  groups	  for	  late	  SV	  at	  the	  p<0.05	  level	  [F(5,28)	  =	  1.011,	  p	  =	  0.4300].	  	  Post-­‐hoc	  analysis	  was	  therefore	  not	  conducted.	  	  	  
	  





































Figure	  7-­‐11:	  	  Graph	  to	  show	  Stroke	  Volume	  (SV)	  measured	  at	  the	  late	  time	  point	  (8-­‐10	  weeks)	  by	  cardiac	  MRI.	  	  Columns	  represent	  mean	  values,	  with	  error	  bars	  representing	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  	  No	  significant	  differences	  were	  found	  between	  groups	  using	  one-­‐way	  ANOVA.	  	  	  
	  
7.3.2.5	  Ejection	  Fraction	  
At	  the	  early	  time	  point	  (day	  1-­‐2)	  the	  ejection	  fraction	  (EF)	  in	  the	  Sham	  control	  group	  was	  69.8%	  +/-­‐	  1.1%.	  	  There	  was	  a	  reduction	  in	  EF	  in	  the	  MI	  control	  group	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(45.4%	  +/-­‐	  7.8%).	  	  The	  average	  early	  EF	  in	  the	  Gel	  (45.2%	  +/-­‐	  10.2%)	  and	  Gel-­‐Cell-­‐Epo	  (44.8	  +/-­‐	  8.4%)	  was	  similar	  to	  the	  MI	  control	  group,	  with	  the	  Gel-­‐Epo	  (54.6%	  +/-­‐	  12.6%)	  and	  Cell	  (50.6%	  +/-­‐	  8.9%)	  groups	  having	  early	  EF	  values	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐12)	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  EF	  between	  groups	  at	  the	  early	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  early	  EF	  at	  the	  p<0.05	  level	  [F(5,37)	  =	  5.443,	  p	  =	  0.0008].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  fall	  in	  early	  EF	  in	  the	  MI	  control,	  Gel,	  Cell,	  and	  Gel-­‐Cell-­‐Epo	  groups	  compared	  with	  the	  Sham	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  	  
	  
At	  the	  late	  time	  point	  (week	  8-­‐10)	  EF	  was	  76.2%	  +/-­‐	  0.9%	  in	  the	  Sham	  control	  group.	  	  This	  was	  reduced	  in	  the	  MI	  control	  group	  to	  47.3%	  +/-­‐	  6.1%.	  	  The	  Gel	  (53.1%	  +/-­‐	  10.5%),	  Gel-­‐Epo	  (63.5%	  +/-­‐	  11.6%),	  Cell	  (55.3%	  +/-­‐	  8.0%)	  and	  Gel-­‐Cell-­‐Epo	  (54.7%	  +/-­‐	  8.1%)	  groups	  had	  late	  EF	  values	  between	  the	  two	  control	  groups	  (table	  7.1	  and	  figure	  7-­‐13).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  EF	  between	  groups	  at	  the	  late	  time	  point.	  	  There	  was	  a	  significant	  difference	  found	  between	  groups	  for	  late	  EF	  at	  the	  p<0.05	  level	  [F(5,28)	  =	  7.106,	  p	  =	  0.0002].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  a	  significant	  fall	  in	  late	  EF	  in	  the	  MI	  control,	  Gel,	  Cell,	  and	  Gel-­‐Cell-­‐Epo	  groups	  compared	  with	  the	  Sham	  control	  group.	  	  The	  Gel-­‐Epo	  group	  was	  also	  found	  to	  have	  a	  significantly	  higher	  late	  EF	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compared	  with	  the	  MI	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	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Figure	  7-­‐14.	  	  Graph	  to	  show	  Ejection	  Fraction	  (EF)	  measured	  at	  the	  early	  (E)	  and	  late	  (L)	  time	  points.	  	  Columns	  represent	  mean	  values,	  with	  error	  bars	  representing	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  	  Statistical	  Analysis	  performed	  using	  a	  paired	  students	  t-­‐test.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  =	  p<0.05	  **	  =	  p<0.01	  
	  
	  





















E L E L E L E L E L
**
* *
	   221	  
7.3.3	  Histology	  
7.3.3.1	  Masson’s	  Trichrome	  
Three	  hearts	  from	  each	  group	  were	  subject	  to	  histological	  analysis	  following	  the	  late	  MRI	  time	  point	  (8-­‐10	  weeks).	  	  Sections	  were	  taken	  from	  the	  mid-­‐ventricular	  area	  of	  the	  heart,	  just	  below	  the	  point	  of	  LAD	  ligation.	  
Paraffin	  embedded	  sections	  were	  stained	  with	  Masson’s	  Trichrome	  stain	  to	  differentiate	  muscle	  (stained	  dark	  red)	  and	  collagen	  (stained	  light	  blue)	  fibres.	  
Within	  the	  experimental	  groups	  (MI,	  Gel,	  Gel-­‐Epo,	  Cell,	  Gel-­‐Cell-­‐Epo),	  it	  was	  easy	  to	  visualize	  the	  infarcted	  area	  at	  the	  late	  time	  point	  (figure	  7-­‐15	  and	  7-­‐16).	  	  This	  part	  of	  the	  left	  ventricular	  wall	  was	  greatly	  thinned	  compared	  with	  the	  normal	  left	  ventricular	  wall,	  and	  contained	  a	  large	  proportion	  of	  blue	  stained	  collagen	  fibres.	  	  Between	  the	  infarct	  zone	  and	  normal	  myocardium	  there	  was	  an	  area	  of	  transition,	  where	  blue	  stained	  collagen	  fibres	  could	  be	  seen	  interlacing	  with	  normal	  dark	  red	  staining	  muscle	  fibres.	  	  This	  was	  seen	  in	  stark	  comparison	  to	  sham	  operated	  animals,	  which	  had	  no	  evidence	  of	  ventricular	  wall	  thinning	  and	  only	  negligible	  amounts	  of	  stained	  collagen	  fibres.	  	  	  
The	  average	  infarct	  thickness	  for	  the	  MI	  control	  group	  was	  1.33mm	  +/-­‐	  0.27mm	  (mean	  +/-­‐	  SD).	  	  The	  average	  infarct	  thickness	  in	  the	  Gel	  (1.99mm	  +/-­‐	  0.34mm),	  Gel-­‐Epo	  (1.66mm	  +/-­‐	  0.37mm),	  Cell	  (1.92mm	  +/-­‐	  0.35mm)	  and	  Gel-­‐Cell-­‐Epo	  (1.98mm	  +/-­‐	  0.41mm)	  were	  all	  higher	  than	  the	  MI	  control	  group	  (table	  7.1	  and	  figure	  7-­‐17).	  	  	  
A	  one	  way	  ANOVA	  was	  conducted	  to	  compare	  infarct	  thickness	  between	  the	  MI	  control,	  Gel,	  Gel-­‐Epo,	  Cell	  and	  Gel-­‐Cell-­‐Epo	  groups.	  	  A	  significant	  difference	  was	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found	  for	  infarct	  thickness	  between	  groups	  	  at	  the	  p<0.05	  level	  [F(4,66)	  =	  7.019,	  p	  <	  0.0001].	  	  Post-­‐hoc	  analysis	  using	  Tukey’s	  multiple	  comparisons	  test	  demonstrated	  that	  the	  Gel,	  Gel-­‐Epo,	  Cell	  and	  Gel-­‐Cell-­‐Epo	  groups	  all	  had	  significantly	  thicker	  infarcts	  than	  the	  MI	  control	  group.	  	  No	  other	  significant	  differences	  were	  found	  between	  groups.	  	  	  
The	  proportion	  of	  the	  infarct	  scar	  containing	  muscle	  fibres	  (red	  stained)	  was	  measured	  using	  ImageJ.	  	  The	  infarct	  scar	  in	  the	  MI	  control	  group	  contained	  9.2%	  +/-­‐	  3.3%	  muscle	  fibres.	  	  The	  average	  muscle	  content	  in	  the	  Gel	  (22.69%	  +/-­‐	  10.09%),	  Gel-­‐Epo	  (18.12%	  +/-­‐	  10.53%),	  Cell	  (24.16%	  +/-­‐	  3.416%)	  and	  Gel-­‐Cell-­‐Epo	  (36.38%	  +/-­‐	  6.338%)	  groups	  were	  all	  higher	  than	  the	  MI	  control	  group	  (table	  7.1	  and	  figure	  7-­‐18).	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Figure	  7-­‐15:	  	  Masson’s	  Trichrome	  staining	  of	  mid-­‐ventricular	  cardiac	  sections	  (paraffin	  embedded)	  taken	  at	  the	  8-­‐10	  week	  time	  point.	  	  Collagen	  fibres	  stain	  light	  blue	  and	  muscle	  fibres	  stain	  red.	  	  The	  infarct	  zone	  can	  easily	  be	  seen	  as	  the	  thinned	  region	  of	  the	  left	  ventricular	  wall	  that	  contains	  large	  numbers	  of	  blue	  stained	  collagen	  fibres..	  	  Scale	  bar	  =	  1cm	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Figure	  7-­‐16:	  	  Magnified	  views	  (x4)	  of	  the	  infarct	  zones	  in	  representative	  samples	  of	  mid-­‐ventricular	  cardiac	  sections	  (paraffin	  embedded).	  	  Sections	  have	  been	  stained	  with	  Massons	  Trichrome.	  	  Collagen	  fibres	  stain	  light	  blue	  and	  muscle	  fibres	  stain	  red.	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7.3.3.2	  	  Immunohistochemistry	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  Figure	  7-­‐19.	  Immunohistochemistry	  of	  rat	  cardiac	  sections.	  	  1°α	  =	  primary	  antibody,	  	  2°α	  =	  secondary	  antibody	  	  
7.3.3.3	  	  Quantitative	  Polymerase	  Chain	  Reaction	  (qPCR)	  
	  qPCR	  analysis	  was	  carried	  out	  on	  frozen	  cardiac	  samples	  from	  the	  Gel-­‐Cell-­‐Epo	  group	   at	   day	   1	   (rats	   that	   died	   during	   surgery)	   and	   day	   77.	   Pre-­‐validated	  TaqMan®	  assays	  from	  Life	  TechnologiesTM	  were	  used	  for	  an	  assortment	  of	  early	  and	   late	   cardiac	   markers,	   including	   atrial	   natriuretic	   factor	   (ANF),	   myosin-­‐6	  (MYH6),	  myosin-­‐7	  (MYH7),	  and	  alpha-­‐1A	  and	  1B	  adrenergic	  receptors	  (ADRA1a	  and	  ADRA1b).	  The	  presence	  of	  human	  cardiac	  cells	  was	  not	  demonstrated	  within	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Figure	  7-­‐20:	  Quantitative	  Polymerase	  Chain	  Reaction	  Results.	  	  LV	  =	  Left	  ventricle.	  	  
Infarct	  =	  Myocardial	  infarct	  zone.	  	  DCM	  =	  Human	  patient	  sample	  with	  dilated	  cardiomyopathy.	  
ANF	  =	  Atrial	  Natriuretic	  Factor,	  MYH7	  =	  myosin	  7,	  ADRA1a	  =	  alpha	  1a	  adrenergic	  receptor
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! ! Sham! MI! Gel! Gel+Epo! Cell! Gel+Cell+Epo!
End!Diastolic!Volume!(EDV)!
Early! 290!+/-!45!µl! 407!+/-!51!µl! 348!+/-!66!µl! 324!+/-!49!µl! 328!+/-!72!µl! 327!+/-!39!µl!Late! 422!+/-!36!µl! 632!+/-!65!µl! 598!+/-!89!µl! 565!+/-!146!µl! 649!+/-!155!µl! 592!+/-!60!µl!
End!Systolic!Volume!(ESV)!
Early! 88!+/-!15!µl! 222!+/-!44!µl! 194!+/-!65!µl! 151!+/-!62!µl! 165!+/-!55!µl! 181!+/-!34!µl!Late! 101!+/-!10!µl! 334!+/-!54!µl! 283!+/-!85!µl! 220!+/-!135!µl! 298!+/-!103!µl! 272!+/-!77!µl!
%!Area!of!Late!Gadolinium!
Enhancement!(%LGE)!
Early! 3.2!+/-!1.7!%! 36.2!+/-!7.3!%! 38.3!+/-!8.0!%! 29.1!+/-!9.3!%! 38.4!+/-!12.5!%! 37.0!+/-!8.1!%!Late! 1.4!+/-!1.1!%! 27.1!+/-!4.4!%! 28.3!+/-!4.4!%! 16.7!+/-!7.2!%! 21.1!+/-!5.1!%! 21.6!+/-!2.6!%!
Stroke!Volume!(SV)!
Early! 202!+/-!30!µl! 185!+/-!37!µl! 156!+/-!37!µl! 172!+/-!25!µl! 164!+/-!35!µl! 146!+/-!29µl!Late! 321!+/-!27!µl! 298!+/-!46!µl! 315!+/-!72!µl! 346!+/-!20µl! 352!+/-!65!µl! 321!+/-!27!µl!
Ejection!Fraction!(EF)!
Early! 69.8!+/-!1.1!%! 45.4!+/-!7.8!%! 45.2!+/-!10.2!%! 54.6!+/-!12.6!%! 50.6!+/-!8.9!%! 44.8!+/-!8.4!%!Late! 76.2!+/-!0.9!%! 47.3!+/-!6.1!%! 53.1!+/-!10.5!%! 63.5!+/-!11.6!%! 55.3!+/-!8.0!%! 54.7!+/-!8.1!%!
Infarct!Thickness! ! N/A! 1.34!+/-!0.27!mm! 1.99!+/-!0.34!mm! 1.66!+/-!0.37!mm! 1.92!+/-!0.35!mm! 1.98!+/-!0.41mm!
Infarct!Muscle!Content! ! N/A! 9.2!+/-!3.3!%! 22.7!+/-!10.1!%! 18.1!+/-!10.5!%! 24.2!+/-!3.4!%! 36.4!+/-!6.3!%!!
Table!7.1:!!Summary!of!Results
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7.4	  Discussion	  
As	  described	  in	  earlier	  chapters,	  a	  successful	  tissue	  engineering	  strategy	  for	  the	  heart	  will	  most	  likely	  include	  aspects	  of	  all	  the	  ‘pillars’	  of	  tissue	  engineering.	  	  These	  are	  the	  use	  of	  biomaterials,	  cell	  therapy	  and	  soluble	  factors.	  	  In	  this	  current	  experiment	  a	  strategy	  was	  used	  that	  encompassed	  all	  three	  aspects	  of	  tissue	  engineering.	  	  For	  the	  biomaterial	  arm,	  the	  injectable	  PEG	  based	  hydrogel	  was	  used.	  	  This	  had	  been	  tailored	  to	  match	  the	  mechanical	  properties	  of	  healthy	  myocardium,	  was	  capable	  of	  gelling	  in	  situ	  within	  the	  myocardium	  after	  injection,	  could	  maintain	  live	  cells,	  and	  degraded	  within	  2	  weeks	  (see	  Chapter	  3).	  	  The	  hydrogel	  had	  also	  demonstrated	  absence	  of	  adverse	  effects	  when	  injected	  into	  normal	  hearts	  (see	  Chapter	  4)	  making	  it	  a	  suitable	  candidate	  for	  a	  tissue	  regeneration	  strategy.	  	  
The	  cellular	  component	  of	  the	  strategy	  comprised	  of	  induced	  pluripotent	  stem	  cell	  derived	  cardiomyoctes.	  	  This	  newly	  developed	  cell	  line	  has	  invigorated	  the	  field	  of	  cardiac	  tissue	  engineering	  due	  to	  the	  potential	  for	  unlimited	  cardiomyocyte	  production,	  along	  with	  the	  avoidance	  of	  ethical	  and	  immunological	  hurdles	  associated	  with	  other	  pluripotent	  stem	  cell	  sources.	  	  	  
Erythropoietin	  was	  selected	  as	  the	  final	  part	  of	  this	  strategy	  for	  several	  reasons.	  	  Firstly,	  epo	  was	  demonstrated	  to	  protect	  iPS-­‐CM	  from	  doxorubicin	  injury,	  a	  commonly	  used	  inducer	  of	  cardiomyocyte	  apoptosis	  (see	  Chapter	  5).	  	  Secondly,	  epo	  has	  also	  been	  shown	  to	  have	  significant	  tissue	  protective	  effects	  upon	  native	  myocardium	  following	  infarction(Cai,	  Manalo	  et	  al.	  2003,	  Calvillo,	  Latini	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2003,	  Tramontano,	  Muniyappa	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2006).	  	  Thirdly,	  as	  epo	  is	  already	  used	  clinically	  for	  the	  treatment	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of	  anaemia	  in	  cancer	  patients(Cheetham,	  Smith	  et	  al.	  1998),	  relative	  clinical	  safety	  can	  be	  implied	  upon	  its	  use.	  
The	  combination	  of	  these	  3	  therapeutic	  arms	  was	  used	  in	  a	  well-­‐characterized	  model	  of	  rat	  myocardial	  infarction.	  	  The	  aims	  of	  the	  study	  were	  to	  investigate	  the	  effects	  of	  these	  tissue	  engineering	  strategies	  upon	  measures	  of	  cardiac	  geometry	  and	  function	  following	  myocardial	  infarction.	  	  	  
	  
7.4.1	  Ventricular	  geometry	  
Ventricular	  geometry	  is	  often	  used	  as	  a	  marker	  for	  assessing	  cardiac	  failure,	  with	  the	  most	  commonly	  assessed	  measures	  being	  left	  ventricular	  end	  diastolic	  volume	  (EDV)	  and	  end	  systolic	  volume	  (ESV).	  	  Following	  myocardial	  infarction,	  both	  EDV	  and	  ESV	  are	  expected	  to	  increase.	  	  At	  first	  this	  is	  due	  to	  the	  loss	  of	  contractile	  function,	  and	  the	  effect	  of	  paradoxical	  systolic	  bulging(Holmes,	  Borg	  et	  al.	  2005).	  	  As	  time	  progresses,	  necrosis	  and	  inflammation	  leads	  to	  break	  down	  of	  extracellular	  matrix,	  along	  with	  infarct	  expansion	  and	  thinning	  secondary	  to	  increased	  myocardial	  wall	  stresses.	  	  The	  result	  is	  a	  significantly	  dilated	  left	  ventricle	  with	  both	  impaired	  systolic	  and	  diastolic	  function.	  	  	  
In	  the	  current	  experiment,	  myocardial	  infarction	  caused	  significant	  left	  ventricular	  dilatation,	  with	  significantly	  larger	  EDV	  and	  ESV	  values	  at	  both	  the	  early	  and	  late	  time	  points	  compared	  with	  the	  Sham	  control	  group.	  	  The	  effects	  of	  our	  interventions	  (Gel,	  Gel-­‐Epo,	  Cell,	  Gel-­‐Cell-­‐Epo	  groups)	  appeared	  to	  be	  insignificant	  compared	  with	  the	  MI	  control,	  and	  although	  most	  EDV	  and	  ESV	  
	   233	  
measurements	  had	  mean	  values	  lower	  than	  the	  MI	  control,	  there	  was	  no	  statistically	  significant	  difference	  found.	  	  	  	  
	  
7.4.2	  Infarct	  characteristics	  
Myocardial	  infarct	  size	  was	  measured	  using	  late	  gadolinium	  enhancement	  (LGE)	  on	  MRI.	  	  This	  was	  expressed	  as	  a	  percentage	  of	  overall	  left	  ventricular	  muscle	  area.	  	  Gadolinium	  is	  a	  commonly	  used	  MRI	  contrast	  agent,	  and	  is	  able	  to	  pass	  out	  of	  the	  circulation	  and	  accumulate	  in	  extracellular	  fluid	  volumes.	  	  Its	  use	  in	  myocardial	  injury	  stems	  from	  changes	  within	  injured	  myocardium	  that	  lead	  to	  an	  increased	  volume	  distribution	  and	  changes	  in	  ‘wash-­‐in’	  and	  ‘wash-­‐out’	  kinetics(Kim,	  Fieno	  et	  al.	  1999,	  Klein,	  Schmal	  et	  al.	  2007).	  	  These	  changes	  occur	  in	  both	  acute	  and	  chronic	  infarcts,	  and	  lead	  to	  a	  delayed	  enhancement	  effect	  upon	  the	  affected	  myocardial	  area.	  	  This	  combined	  with	  the	  excellent	  spatial	  resolution	  of	  MRI	  makes	  late	  gadolinium	  enhancement	  established	  as	  a	  gold	  standard	  method	  for	  assessing	  the	  degree	  of	  myocardial	  injury	  following	  myocardial	  infarction(Dall'Armellina,	  Karia	  et	  al.	  ,	  Kim,	  Wu	  et	  al.	  2000).	  
As	  expected,	  all	  groups	  that	  underwent	  infarction	  demonstrated	  a	  significantly	  greater	  %LGE	  signal	  compared	  with	  the	  Sham	  control	  at	  both	  early	  and	  late	  time	  points.	  	  At	  the	  late	  time	  point,	  the	  Gel-­‐Epo,	  Cell,	  and	  Gel-­‐Cell-­‐Epo	  groups	  appeared	  to	  have	  a	  smaller	  %LGE	  signal	  compared	  with	  the	  MI	  control	  group,	  although	  only	  the	  Gel-­‐Epo	  group	  demonstrated	  a	  statistically	  significant	  difference.	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Interestingly	  there	  was	  a	  drop	  in	  the	  %LGE	  signal	  between	  early	  and	  late	  timepoints	  for	  all	  groups.	  	  This	  effect	  of	  ‘infarct	  shrinking’	  is	  a	  well	  recognized	  one,	  and	  may	  be	  explained	  by	  the	  transition	  between	  myocardial	  necrotic	  tissue	  with	  associated	  oedema,	  to	  fibrotic	  scar	  along	  with	  the	  effects	  of	  compensatory	  ventricular	  hypertrophy(Reimer	  and	  Jennings	  1979,	  Kim,	  Fieno	  et	  al.	  1999).	  	  This	  is	  an	  important	  effect	  to	  note	  clinically,	  as	  LGE	  is	  often	  taken	  as	  a	  measure	  of	  irreversible	  myocardial	  damage(Kim,	  Wu	  et	  al.	  2000)	  whereas	  recent	  studies	  have	  demonstrated	  that	  acutely	  detected	  LGE	  does	  not	  necessarily	  equate	  with	  irreversible	  injury(Dall'Armellina,	  Karia	  et	  al.).	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7.4.3	  Ventricular	  systolic	  function	  
Following	  myocardial	  infarction,	  systolic	  function	  of	  the	  myocardium	  in	  invariably	  impeded,	  due	  to	  the	  immediate	  loss	  of	  contractile	  myocardium	  contributing	  to	  the	  ejection	  of	  blood	  with	  every	  systole.	  	  In	  an	  attempt	  to	  maintain	  cardiac	  output,	  the	  heart	  is	  able	  to	  compensate	  for	  this	  via	  several	  mechanisms.	  	  One	  of	  the	  most	  important	  is	  by	  increasing	  ventricular	  filling.	  	  As	  the	  ventricle	  fills	  with	  an	  increased	  volume	  of	  blood,	  this	  allows	  increased	  stretch	  of	  cardiac	  muscle	  fibres,	  resulting	  in	  an	  increased	  force	  of	  contraction	  –	  Starling’s	  law.	  	  Although	  this	  helps	  to	  maintain	  stroke	  volume,	  the	  necessary	  dilatation	  of	  the	  heart	  is	  reflected	  in	  a	  drop	  in	  ejection	  fraction,	  and	  the	  increased	  wall	  pressures	  can	  result	  in	  continued	  ventricular	  remodeling	  and	  eventual	  cardiac	  failure.	  	  	  
This	  effect	  was	  clearly	  seen	  in	  our	  MI	  model,	  where	  the	  MI	  control	  group	  demonstrated	  increasing	  ventricular	  volumes	  (EDV	  and	  ESV),	  whilst	  maintaining	  a	  SV	  similar	  to	  that	  of	  the	  Sham	  control	  group.	  	  However	  as	  expected	  EF	  fell	  significantly	  in	  the	  MI	  control	  group	  compared	  with	  Sham	  controls.	  	  Our	  interventions	  failed	  to	  show	  much	  benefit	  in	  average	  ejection	  fraction	  apart	  from	  the	  Gel-­‐Epo	  group,	  which	  demonstrated	  an	  EF	  significantly	  greater	  than	  the	  MI	  group	  by	  the	  late	  time	  point.	  	  This	  correlates	  well	  with	  the	  smaller	  %LGE	  signal	  (and	  therefore	  infarct	  size)	  seen	  in	  the	  Gel-­‐Epo	  group	  as	  well.	  	  	  
Paired	  analysis	  between	  the	  early	  and	  late	  time	  points	  demonstrated	  a	  stable	  EF	  for	  the	  MI	  control	  group.	  	  However,	  the	  Gel-­‐Epo,	  Cell,	  and	  Gel-­‐Cell-­‐Epo	  groups	  demonstrated	  a	  significant	  improvement	  in	  EF	  over	  the	  time	  course	  of	  the	  experiment.	  	  Taken	  together	  with	  the	  %LGE	  and	  Masson’s	  Trichrome	  data,	  this	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may	  represent	  either	  a	  successful	  preservation	  of	  native	  tissue	  or	  myocardial	  regeneration	  induced	  by	  our	  interventions.	  	  	  
	  
7.4.4	  Immunohistochemistry	  and	  qPCR	  
One	  of	  the	  fundamental	  questions	  remaining	  after	  the	  basic	  histology	  and	  cardiac	  MRI	  studies	  was	  whether	  the	  improvements	  seen	  in	  cardiac	  function,	  as	  well	  as	  the	  enhanced	  muscle	  fiber	  staining	  within	  the	  infarct,	  was	  a	  result	  of	  surviving	  human	  cardiomyocytes	  delivered	  during	  the	  experiment	  or	  simply	  a	  result	  of	  the	  native	  rat	  cells	  -­‐	  cardiomyocyte	  or	  otherwise?	  	  To	  address	  this	  question,	  we	  performed	  immunohistochemistry	  on	  the	  infarcted	  rat	  tissue	  sections.	  	  No	  evidence	  of	  human	  cells	  were	  found	  at	  either	  day	  1	  (in	  the	  Cell	  and	  Gel-­‐Cell-­‐Epo	  groups)	  or	  at	  day	  77	  (Gel-­‐Cell-­‐Epo	  groups).	  	  
As	  it	  was	  not	  possible	  to	  detect	  the	  injected	  human	  cells	  in	  the	  treatment	  groups	  using	  standard	  immunohistochemistry	  techniques,	  we	  next	  sought	  to	  use	  a	  much	  more	  sensitive	  technique	  –	  quantitative	  polymerase	  chain	  reaction	  (qPCR)	  –	  to	  search	  for	  an	  assortment	  of	  human	  early	  and	  late	  cardiac	  markers.	  	  Once	  again,	  no	  evidence	  of	  human	  cells	  could	  be	  found	  in	  the	  Gel-­‐Cell-­‐Epo	  group	  at	  both	  day	  1	  and	  day	  77.	  	  Therefore,	  taking	  the	  immunohistochemistry	  and	  qPCR	  results	  together,	  it	  could	  be	  concluded	  that	  the	  improvements	  in	  cardiac	  function	  and	  microstructure	  are	  likely	  due	  to	  paracrine	  effects	  –	  a	  phenomenon	  previously	  reported	  in	  the	  literature	  (Wollert	  and	  Drexler	  2005).	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7.4.5	  Study	  limitations	  
The	  early	  mortality	  in	  this	  experiment	  was	  32%,	  with	  a	  late	  mortality	  of	  50%.	  	  This	  mortality	  rate	  is	  within	  the	  range	  described	  in	  the	  literature,	  which	  quotes	  mortality	  rates	  from	  40-­‐50%(Pfeffer,	  Pfeffer	  et	  al.	  1979,	  Pfeffer,	  Pfeffer	  et	  al.	  1984).	  	  However,	  late	  mortality	  in	  particular	  was	  higher	  than	  desired	  and	  thus	  left	  some	  experimental	  groups	  with	  fewer	  animals	  than	  expected	  at	  the	  late	  time	  point,	  making	  the	  study	  potentially	  underpowered	  and	  subject	  to	  a	  type	  2	  statistical	  error.	  	  Although	  no	  significant	  differences	  were	  found	  in	  death	  rates	  between	  groups,	  3	  out	  of	  4	  experimental	  groups	  had	  higher	  mortality	  rates	  than	  the	  MI	  control	  group.	  	  This	  raises	  the	  possibility	  of	  late	  arrhythmia	  in	  these	  groups	  as	  a	  result	  of	  myocardial	  injections.	  	  The	  rat	  MI	  model	  is	  also	  by	  its	  nature	  highly	  variable	  and	  difficult	  to	  standardize.	  	  This	  may	  have	  been	  evident	  in	  several	  comparisons	  where	  intervention	  group	  measurements	  fell	  between	  the	  Sham	  and	  MI	  control	  group	  values,	  with	  no	  significant	  differences	  found.	  	  	  	  	  
Our	  results	  from	  immunohistochemistry	  and	  qPCR	  analysis	  could	  not	  demonstrate	  the	  presence	  of	  human	  cells	  at	  either	  day	  1	  or	  day	  77.	  	  Although	  paracrine	  mechanisms	  may	  explain	  how	  injections	  of	  human	  cells	  could	  help	  to	  improve	  cardiac	  function	  without	  the	  long-­‐term	  survival	  of	  transplanted	  cells,	  the	  inability	  to	  confirm	  the	  presence	  of	  human	  cells	  at	  day	  1	  was	  surprising.	  	  Immunohistochemical	  analysis	  was	  performed	  on	  very	  thin	  cardiac	  sections	  so	  that	  it	  is	  possible	  that	  the	  sections	  analyzed	  missed	  areas	  of	  cell	  injection,	  as	  these	  areas	  were	  not	  marked	  intra-­‐operatively.	  	  qPCR	  would	  have	  been	  expected	  to	  pick	  up	  the	  presence	  of	  even	  minute	  numbers	  of	  human	  cells	  within	  the	  myocardium,	  however	  these	  results	  were	  also	  negative.	  	  It	  is	  possible	  that	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differences	  in	  the	  process	  of	  tissue	  fixation	  may	  account	  for	  these	  negative	  findings.	  	  Day	  1	  cardiac	  samples	  were	  taken	  from	  animals	  that	  had	  died	  during	  surgery,	  and	  therefore	  did	  not	  undergo	  in-­‐vivo	  tissue	  fixation.	  	  Similarly,	  the	  fact	  that	  these	  animals	  had	  died	  during	  surgery	  may	  have	  introduced	  selection	  bias,	  where	  death	  during	  surgery	  may	  have	  occurred	  secondary	  to	  complications	  such	  as	  accidental	  intra-­‐ventricular	  hydrogel	  injection	  as	  opposed	  to	  intra-­‐myocardial	  injection.	  	  This	  would	  potentially	  explain	  animal	  death	  due	  to	  intravascular	  hydrogel	  emboli,	  as	  well	  as	  explain	  the	  lack	  of	  human	  cells	  within	  the	  myocardium	  at	  that	  time	  point.	  	  	  
The	  use	  of	  human	  derived	  iPS-­‐CM	  in	  a	  rat	  model	  of	  MI	  may	  also	  have	  presented	  difficulties.	  	  Although	  the	  use	  of	  an	  immune	  compromised	  animal	  will	  have	  reduced	  the	  impact	  of	  immunological	  rejection	  of	  transplanted	  cells,	  successful	  integration	  between	  human	  and	  rodent	  cardiomyoctes	  is	  questionable.	  	  For	  example,	  the	  average	  rat	  heart	  rate	  lies	  between	  300	  and	  400	  beats	  per	  minute(Swoap,	  Overton	  et	  al.	  2004),	  compared	  with	  the	  much	  slower	  average	  human	  heart	  rate	  of	  50	  to	  100	  beats	  per	  minute.	  	  These	  clear	  differences	  in	  heart	  rate	  may	  well	  prevent	  host-­‐graft	  integration(Mummery,	  Davis	  et	  al.	  2010).	  	  Further	  difficulties	  of	  integrating	  graft	  cells	  with	  host	  myocardium	  have	  been	  demonstrated	  in	  previous	  rodent	  studies	  where	  graft	  cells	  were	  identified	  to	  have	  coupled	  together,	  but	  were	  mostly	  separated	  from	  host	  myocardium	  by	  layers	  of	  scarred	  and	  fibrous	  tissue	  (Laflamme,	  Chen	  et	  al.	  2007,	  van	  Laake,	  Passier	  et	  al.	  2007).	  	  This	  lack	  of	  coupling,	  combined	  with	  the	  intrinsic	  pacemaker	  potential	  of	  the	  graft	  cells	  raises	  the	  possibility	  of	  serious	  arrhythmias	  as	  a	  side	  effect	  of	  myocardial	  cell	  therapy.	  	  These	  reasons	  are	  
	   239	  
thought	  to	  be	  the	  cause	  of	  severe	  arrhythmia	  seen	  in	  a	  human	  trial	  of	  autologous	  skeletal	  myoblast	  injection	  following	  myocardial	  infarction	  (Menasche,	  Alfieri	  et	  al.	  2008).	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7.4.6	  Comparison	  of	  results	  to	  the	  literature	  
There	  have	  been	  few	  reports	  in	  the	  literature	  of	  a	  tissue	  engineering	  approach	  combining	  biomaterials,	  soluble	  factors	  and	  cell	  therapy	  for	  cardiac	  failure	  (Table	  7.2).	  	  Davis	  et	  al.	  utilized	  a	  self-­‐assembling	  peptide	  nano-­‐fibre	  system	  for	  delivery	  of	  insulin-­‐like	  growth	  factor	  1	  (IGF-­‐1)	  and	  neonatal	  cardiomyocytes(Davis,	  Hsieh	  et	  al.	  2006).	  	  In	  a	  rat	  model	  of	  MI,	  they	  only	  demonstrated	  a	  significant	  improvement	  in	  left	  ventricular	  ventricular	  shortening	  in	  the	  combined	  nano-­‐fibre,	  IGF-­‐1	  and	  cell	  therapy	  group,	  implying	  that	  the	  combination	  of	  all	  3	  therapies	  was	  required	  for	  significant	  benefit.	  	  Takehara	  et	  al.	  used	  a	  porcine	  model	  of	  MI	  to	  investigate	  the	  combination	  of	  a	  gelatin	  hydrogel,	  basic	  fibroblast	  growth	  factor	  (bFGF)	  and	  human	  cardiosphere-­‐derived	  cells	  (hCDCs)(Takehara,	  Tsutsumi	  et	  al.	  2008).	  	  After	  4	  weeks	  they	  demonstrated	  a	  synergistic	  effect	  of	  hCDCs	  and	  the	  bFGF-­‐loaded	  hydrogel	  upon	  EF	  and	  infarct	  volume.	  	  Most	  recently	  Kraehenbuehl	  et	  al.	  utilized	  a	  combination	  of	  a	  matrix-­‐metallo-­‐proteinase	  (MMP)	  sensitive	  PEG	  hydrogel,	  thymosin	  β4,	  	  and	  human	  embryonic	  stem	  cell	  (hESC)-­‐derived	  vascular	  cells	  in	  a	  rat	  model	  of	  MI(Kraehenbuehl,	  Ferreira	  et	  al.	  2010).	  	  Using	  cardiac	  MRI,	  they	  demonstrated	  significant	  effects	  upon	  myocardial	  infarct	  size,	  left	  ventricular	  EDV	  and	  EF,	  which	  was	  most	  pronounced	  in	  the	  combined	  hydrogel-­‐thymosin	  β4-­‐cell	  therapy	  group.	  
Although	  it	  is	  difficult	  to	  compare	  results	  across	  studies	  due	  to	  differences	  in	  methodologies	  and	  models,	  there	  is	  published	  evidence	  to	  support	  the	  complimentary	  use	  of	  biomaterials,	  cells	  and	  growth	  factors	  in	  cardiac	  tissue	  engineering.	  	  Our	  study	  supports	  this	  notion	  as	  well,	  with	  our	  tissue	  engineering	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Summary	  and	  Conclusions	  	  
	  
8.1	  Cardiac	  Failure	  Cardiac	  failure	  is	  an	  important	  global	  health	  problem,	  affecting	  millions	  of	  patients	  worldwide(Roger,	  Go	  et	  al.	  ,	  Levy,	  Kenchaiah	  et	  al.	  2002,	  Roger,	  Weston	  et	  al.	  2004,	  Allender,	  Peto	  et	  al.	  2008).	  	  The	  ageing	  population,	  along	  with	  the	  obesity	  pandemic,	  and	  the	  rapid	  westernization	  of	  the	  developing	  world	  are	  all	  factors	  that	  will	  continue	  to	  keep	  cardiac	  failure	  as	  a	  leading	  cause	  of	  morbidity	  and	  mortality	  worldwide.	  	  	  	  
Despite	  our	  best	  efforts,	  and	  advances	  in	  medical	  and	  interventional	  therapies,	  the	  underlying	  pathology	  –	  myocardial	  damage	  or	  death	  –	  remains	  irreversible.	  	  Patients	  who	  survive	  myocardial	  infarction	  are	  likely	  to	  be	  consigned	  to	  a	  lifetime	  of	  medication	  and	  inevitable	  progression	  of	  cardiac	  failure.	  	  New	  treatments	  to	  repair	  or	  regenerate	  injured	  myocardium	  would	  have	  the	  potential	  of	  transforming	  healthcare	  globally.	  	  	  
Significant	  discoveries	  in	  the	  field	  of	  stem	  cell	  technology	  may	  have	  the	  most	  potential	  to	  provide	  an	  answer	  to	  this	  clinical	  problem.	  	  The	  abilities	  of	  stem	  cells	  to	  indefinitely	  self-­‐renew,	  and	  differentiate	  into	  a	  range	  of	  cell	  types	  should	  make	  them	  the	  ideal	  source	  for	  the	  repair	  of	  damaged	  cardiac	  tissue.	  	  Work	  in	  this	  field	  has	  captured	  the	  imaginations	  of	  clinicians	  and	  the	  public.	  	  For	  example,	  early	  pre-­‐clinical	  work	  has	  demonstrated	  the	  formation	  of	  human	  myocardium	  within	  infarcted	  rat	  hearts	  using	  embryonic	  stem	  cell-­‐derived	  cardiomyocytes	  (ESC-­‐CM)	  (Laflamme,	  Gold	  et	  al.	  2005,	  Laflamme,	  Chen	  et	  al.	  2007),	  and	  studies	  have	  also	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demonstrated	  improvements	  in	  cardiac	  function	  following	  the	  use	  of	  these	  cells	  (Caspi,	  Huber	  et	  al.	  2007,	  Laflamme,	  Chen	  et	  al.	  2007).	  	  	  
Ethical	  concerns	  surrounding	  the	  use	  of	  embryonic	  tissue,	  as	  well	  as	  immunological	  issues	  and	  safety	  concerns	  regarding	  teratoma	  formation	  have	  been	  addressed	  by	  the	  use	  of	  adult	  stem	  cell	  populations.	  	  These	  have	  also	  been	  demonstrated	  to	  produce	  significant	  improvements	  in	  cardiac	  function	  in	  animal	  models	  from	  a	  range	  of	  different	  cells	  including	  skeletal	  myoblasts	  (Menasche	  2008),	  cardiac	  progenitor	  cells	  (CPCs)(Oh,	  Bradfute	  et	  al.	  2003,	  Wang,	  Hu	  et	  al.	  2006),	  cardiospheres(Carr,	  Stuckey	  et	  al.	  ,	  Lee,	  White	  et	  al.	  ,	  Smith,	  Barile	  et	  al.	  2007),	  mesenchymal	  stem	  cells	  (MSCs)(Dai,	  Hale	  et	  al.	  2005,	  Silva,	  Litovsky	  et	  al.	  2005,	  Rose,	  Jiang	  et	  al.	  2008),	  and	  adipose-­‐derived	  stem	  cells	  (ADSCs)(Cai,	  Johnstone	  et	  al.	  2009,	  Schenke-­‐Layland,	  Strem	  et	  al.	  2009).	  
As	  the	  excitement	  in	  this	  field	  captured	  the	  imaginations	  of	  clinicians	  and	  the	  public	  alike,	  several	  human	  trials	  have	  been	  completed	  investigating	  the	  potential	  role	  of	  cell	  therapy	  for	  cardiac	  failure	  post	  myocardial	  infarction.	  	  	  
The	  majority	  of	  randomized	  controlled	  trials	  have	  used	  autologous	  stem	  cells	  from	  bone	  marrow	  origin	  (BMCs),	  with	  small	  sample	  sizes.	  	  A	  recent	  meta-­‐analysis	  (Jiang,	  He	  et	  al.)	  included	  18	  studies	  in	  their	  analysis	  of	  randomized	  controlled	  trials	  involving	  autologous	  stem	  cell	  treatments	  for	  left	  ventricular	  failure	  following	  MI.	  	  They	  found	  that	  at	  3	  months,	  BMC	  therapy	  was	  associated	  with	  a	  significant	  increase	  in	  LVEF	  of	  2.95%	  compared	  with	  standard	  medical	  therapy.	  	  This	  beneficial	  effect	  was	  maintained	  at	  6	  months	  with	  LVEF	  improved	  by	  4.18%,	  and	  at	  12	  months	  with	  LVEF	  improved	  by	  3.48%.	  	  Overall,	  the	  LVEF	  increased	  by	  2.93%.	  	  LVEDV	  was	  also	  improved	  in	  the	  BMC	  treated	  group	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compared	  with	  standard	  medical	  therapy	  at	  3	  months	  (-­‐15.5ml),	  6	  months	  	  	  	  	  	  	  	  	  	  	  (-­‐7.25ml)	  and	  12	  months	  (-­‐11.85ml).	  	  These	  changes	  were	  reflected	  again	  in	  improvements	  in	  MI	  area	  of	  4.08%,	  3.81%	  and	  3.51%	  at	  3,	  6	  and	  12	  months	  of	  follow	  up	  respectively.	  	  However,	  important	  clinical	  endpoints	  including	  repeat	  MI,	  exacerbation	  of	  heart	  failure	  and	  death	  showed	  no	  improvements.	  	  Therefore,	  overall	  the	  results	  from	  human	  trials	  have	  been	  modest,	  although	  importantly	  these	  studies	  did	  demonstrate	  safety	  with	  no	  increased	  risk	  of	  events	  including	  arrhythmia,	  restenosis/thrombosis,	  worsening	  heart	  failure,	  recurrent	  MI,	  death,	  and	  re-­‐hospitalisation.	  	  Further	  work	  in	  this	  area	  is	  clearly	  required	  to	  optimize	  cell	  therapy	  strategies.	  	  	  	  	  
The	  field	  of	  biomaterials	  has	  also	  made	  huge	  advances	  in	  the	  past	  decade,	  with	  the	  focus	  now	  extending	  beyond	  bulk	  mechanical	  properties,	  and	  allowing	  design	  on	  the	  cellular,	  molecular	  and	  chemical	  level	  –	  to	  radically	  improve	  the	  interaction	  and	  integration	  between	  synthetic	  and	  biological	  systems(Place,	  Evans	  et	  al.	  2009).	  	  With	  this	  has	  emerged	  the	  field	  of	  tissue	  engineering,	  with	  the	  aims	  of	  developing	  biological	  substitutes	  that	  can	  restore,	  maintain	  or	  improve	  tissue	  and	  organ	  function.	  	  Cardiac	  failure	  seems	  to	  be	  an	  ideal	  clinical	  candidate	  for	  these	  strategies.	  	  	  	  	  	  
The	  aims	  of	  this	  thesis	  were	  to	  create	  a	  tissue	  engineering	  strategy	  for	  the	  treatment	  of	  cardiac	  failure	  following	  myocardial	  infarction.	  	  To	  achieve	  this	  aim,	  all	  three	  ‘pillars’	  of	  tissue	  engineering	  were	  included	  –	  biomaterials,	  cells	  and	  soluble	  factors.	  	  A	  combination	  of	  these	  strategies	  was	  then	  applied	  to	  a	  rat	  model	  of	  myocardial	  infarction.	  
	  
	   250	  
8.2	  	  Biomaterial	  design	  and	  characterization	  
Chapter	  3	  outlines	  the	  design,	  development	  and	  basic	  characterization	  of	  our	  biomaterial.	  	  An	  injectable	  hydrogel	  system	  was	  decided	  upon	  due	  to	  its	  potential	  future	  application	  in	  minimally	  invasive	  catheter	  based	  cardiac	  interventions.	  	  Polyethylene	  Glycol	  (PEG)	  was	  chosen	  to	  be	  the	  backbone	  of	  the	  hydrogel	  as	  it	  is	  well	  understood,	  easily	  modifiable,	  and	  already	  present	  in	  a	  large	  number	  of	  human	  applications	  (Van	  Tomme,	  Storm	  et	  al.	  2008,	  Lin	  and	  Anseth	  2009)	  .	  	  	  	  	  
The	  hydrogel	  was	  created	  using	  previously	  developed	  methods	  using	  the	  Michael	  addition	  reaction	  between	  acrylate	  and	  thiol	  side	  groups	  (Elbert,	  Pratt	  et	  al.	  2001).	  	  Four-­‐armed	  PEG	  acryate	  monomers	  were	  crosslinked	  with	  PEG	  dithiol	  molecules.	  	  The	  Michael	  addition	  reaction	  was	  shown	  to	  occur	  quickly	  within	  minutes,	  at	  near	  physiological	  pH.	  	  Using	  the	  Michael	  addition	  reaction	  also	  allowed	  facile	  incorporation	  of	  short	  peptide	  sequences	  within	  the	  hydrogel	  backbone.	  	  Rheological	  analysis	  demonstrated	  that	  hydrogel	  elasticity	  could	  be	  easily	  modified	  by	  adjusting	  PEG	  concentration,	  with	  a	  10%	  gel	  approximating	  that	  of	  healthy	  myocardium,	  and	  a	  20%	  hydrogel	  approximating	  the	  elasticity	  of	  infarcted	  myocardium.	  	  When	  left	  in	  PBS,	  the	  hydrogels	  degraded	  spontaneously	  within	  2-­‐3	  weeks.	  	  Furthermore,	  using	  rat	  bone	  marrow	  derived	  mesenchymal	  stem	  cells	  (RBMSCs)	  we	  were	  able	  to	  demonstrate	  that	  the	  PEG	  hydrogel	  was	  capable	  of	  maintaining	  living	  encapsulated	  cells.	  	  	  	  The	  properties	  demonstrated	  in	  our	  experiments	  (gelation	  time,	  elasticity,	  degradation,	  cell	  viability,	  potential	  for	  peptide	  modification)	  are	  similar	  to	  previously	  published	  reports	  (Kraehenbuehl,	  Ferreira	  et	  al.	  ,	  Rane,	  Chuang	  et	  al.	  ,	  Dobner,	  Bezuidenhout	  et	  al.	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2009,	  Kadner,	  Dobner	  et	  al.	  2012)and	  support	  the	  use	  of	  a	  PEG	  hydrogel	  as	  being	  a	  suitable	  candidate	  for	  cardiac	  tissue	  engineering.	  	  	  
	  
8.3	  Hydrogel	  injections	  
Chapter	  4	  describes	  our	  initial	  experiments	  with	  hydrogel	  injections	  into	  the	  non-­‐infarcted	  myocardium.	  	  The	  aims	  of	  these	  experiments	  were	  to	  establish	  a	  safety	  profile	  for	  hydrogel	  injections.	  
In	  the	  first	  series	  of	  experiments	  a	  Langendorff	  model	  was	  used	  with	  20%	  PEG	  hydrogel	  injections.	  	  This	  model	  demonstrated	  no	  immediate	  adverse	  effects	  of	  injection	  in	  terms	  of	  arrythmia,	  heart	  rate,	  or	  left	  ventricular	  pressure	  following	  injection.	  	  Mixing	  of	  the	  hydrogel	  with	  evans	  blue	  dye	  also	  demonstrated	  a	  greater	  retention	  of	  the	  dye	  in	  hydrogel	  groups	  compared	  with	  dye	  injection	  alone.	  	  	  	  	  
The	  second	  experiment	  involved	  injecting	  the	  20%	  hydrogel	  into	  an	  in	  vivo	  rat	  heart,	  with	  pressure-­‐volume	  loop	  analysis	  after	  injection.	  	  This	  demonstrated	  a	  significant	  increase	  in	  end	  diastolic	  volume	  (EDV)	  and	  end	  systolic	  volume	  (ESV),	  and	  a	  fall	  (not	  statistically	  significant)	  in	  end	  systolic	  pressure	  (ESP),	  and	  end	  diastolic	  pressure	  (EDP).	  	  There	  was	  also	  a	  drop	  in	  ejection	  fraction	  (EF)	  following	  injection	  (p=0.054),	  although	  stroke	  volume	  (SV)	  appeared	  to	  be	  maintained.	  	  The	  end	  diastolic	  pressure	  volume	  relationship	  (ESPVR)	  was	  also	  increased	  following	  hydrogel	  injection	  (p=0.06).	  	  These	  results	  follow	  a	  trend	  that	  is	  often	  seen	  in	  cardiac	  failure	  patients,	  and	  were	  interpreted	  potentially	  as	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resulting	  from	  injection	  of	  a	  stiff	  PEG	  hydrogel,	  with	  an	  elastic	  modulus	  similar	  to	  infarcted	  myocardium.	  	  	  
The	  third	  experiment	  therefore	  involved	  injection	  of	  a	  10%	  PEG	  hydrogel	  (with	  elastic	  modulus	  similar	  to	  healthy	  myocardium)	  into	  the	  in	  vivo	  heart	  with	  cardiac	  MRI	  follow	  up.	  	  Injection	  of	  the	  softer	  hydrogel	  showed	  no	  significant	  effects	  on	  ventricular	  geometry	  (EDV,	  ESV),	  or	  ventricular	  function	  (EF,	  SV).	  
From	  these	  experiments	  it	  was	  concluded	  therefore	  that	  an	  intramyocardial	  injections	  of	  a	  hydrogel	  mimicking	  the	  mechanical	  properties	  of	  healthy	  myocardium	  did	  not	  have	  severe	  adverse	  effects	  to	  prevent	  its	  use	  in	  a	  cardiac	  tissue	  regeneration	  strategy.	  	  	  
	  
8.4	  	  Cells	  and	  soluble	  factors	  
Following	  development,	  characterization	  and	  demonstration	  of	  safety	  of	  our	  biomaterial,	  the	  next	  step	  in	  our	  investigation	  was	  to	  determine	  the	  ideal	  cell	  type	  and	  soluble	  factor	  for	  a	  cardiac	  tissue	  regeneration	  strategy.	  
Induced	  pluripotent	  stem	  cell-­‐derived	  cardiomyocytes	  (iPS-­‐CM)	  are	  an	  exciting	  potential	  source	  of	  cells	  for	  cardiac	  regeneration,	  as	  they	  are	  potentially	  expandable	  in	  culture,	  and	  can	  avoid	  many	  of	  the	  immunological	  and	  ethical	  issues	  associated	  with	  other	  pluripotent	  stem	  cell	  sources(Yoshida	  and	  Yamanaka	  ,	  Yamanaka	  2009).	  	  One	  previous	  study	  had	  shown	  the	  beneficial	  effects	  of	  injecting	  iPS	  cells	  (without	  differentiation	  into	  cardiomyocytes)	  into	  myocardial	  infarcts	  with	  improvements	  in	  EF	  and	  ventricular	  remodelling(Nelson,	  Martinez-­‐Fernandez	  et	  al.	  2009).	  	  A	  more	  recent	  study	  used	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iPS-­‐CM	  in	  a	  mouse	  model	  of	  MI	  and	  also	  demonstrated	  improvements	  in	  EF	  and	  ventricular	  geometry(Singla,	  Long	  et	  al.).	  	  Similar	  positive	  results	  have	  been	  gained	  by	  the	  use	  of	  human	  embryonic	  stem	  cell	  derived	  cardiomyocytes	  (hESC-­‐CM)(Caspi,	  Huber	  et	  al.	  2007,	  Laflamme,	  Chen	  et	  al.	  2007,	  van	  Laake,	  Passier	  et	  al.	  2007,	  Shiba,	  Fernandes	  et	  al.	  2012).	  	  Therefore	  iPS-­‐CM	  would	  appear	  to	  be	  an	  excellent	  choice	  for	  our	  cardiac	  tissue	  engineering	  strategy.	  	  	  
Chapter	  5	  describes	  the	  use	  of	  erythropoietin	  (Epo)	  as	  a	  protective	  agent	  firstly	  on	  RBMCs	  and	  then	  on	  induced	  pluripotent	  stem	  cell-­‐derived	  cardiomyocytes	  (iPS-­‐CM).	  	  	  	  Epo	  was	  chosen	  due	  to	  its	  previously	  demonstrated	  tissue	  protective	  effects	  on	  myocardium(Calvillo,	  Latini	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2003,	  Moon,	  Krawczyk	  et	  al.	  2006),	  and	  established	  clinical	  use	  in	  the	  treatment	  of	  anaemia(Cheetham,	  Smith	  et	  al.	  1998).	  
Our	  first	  experiment	  used	  a	  hydrogen	  peroxide	  injury	  model	  on	  RBMC	  cultures.	  	  1u/ml	  Epo	  was	  shown	  to	  have	  a	  protective	  effect	  in	  this	  model	  as	  evidenced	  by	  the	  preservation	  of	  healthy	  cell	  morphology	  on	  cell	  staining.	  	  Higher	  doses	  (10u/ml)	  of	  Epo	  however	  was	  shown	  to	  cause	  cellular	  injury.	  	  	  
The	  second	  experiment	  used	  a	  doxorubicin	  injury	  model	  on	  iPS-­‐CM	  cultures.	  	  Again,	  1u/ml	  Epo	  was	  demonstrated	  to	  have	  a	  protective	  effect	  in	  this	  model	  using	  a	  luminescent	  cell	  viability	  assay.	  	  Higher	  doses	  (10u/ml)	  were	  again	  shown	  to	  have	  a	  detrimental	  effect	  upon	  cell	  viability.	  	  	  	  	  	  
The	  results	  of	  these	  experiments	  therefore	  supported	  the	  use	  of	  moderate	  doses	  of	  Epo	  with	  iPS-­‐CM	  in	  our	  tissue	  engineering	  strategy.	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8.5	  	  The	  Myocardial	  Infarction	  model	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8.6	  	  	  Tissue	  engineering	  for	  cardiac	  failure	  
Chapter	  7	  describes	  our	  final	  experiment,	  where	  our	  tissue	  engineering	  strategy	  was	  applied	  to	  a	  rat	  model	  of	  MI.	  	  All	  3	  ‘pillars’	  of	  tissue	  engineering	  were	  represented.	  	  The	  biomaterial	  arm	  was	  represented	  by	  the	  injectable	  PEG-­‐based	  hydrogel,	  the	  cellular	  arm	  by	  iPS-­‐CM,	  and	  the	  soluble	  factor	  arm	  by	  Epo.	  	  Outcomes	  were	  measured	  using	  cardiac	  MRI	  to	  assess	  function,	  as	  well	  as	  histological	  analysis.	  	  As	  expected,	  MI	  caused	  significant	  ventricular	  dilatation	  and	  a	  fall	  in	  EF.	  	  Ventricular	  dilatation	  was	  attenuated	  at	  an	  early	  stage	  by	  injections	  of	  PEG	  hydrogel	  combined	  with	  Epo,	  iPS-­‐CM	  injections	  and	  a	  combination	  of	  PEG	  hydrogel,	  Epo	  and	  iPS-­‐CM,	  all	  of	  which	  reduced	  EDV	  measurements.	  	  Ejection	  fraction	  was	  demonstrated	  to	  be	  significantly	  improved	  over	  the	  course	  of	  the	  experiment	  following	  injection	  of	  a	  PEG	  hydrogel	  and	  Epo	  combination,	  iPS-­‐CM,	  and	  a	  PEG	  hydrogel,	  iPS-­‐CM	  with	  Epo	  combination.	  	  	  
These	  encouraging	  effects	  on	  cardiac	  geometry	  and	  function	  were	  also	  supported	  by	  the	  histological	  data	  that	  demonstrated	  significantly	  greater	  infarct	  thickness	  following	  injection	  in	  all	  our	  experimental	  groups,	  as	  well	  as	  significantly	  greater	  scar	  muscle	  content	  in	  groups	  receiving	  injections	  of	  PEG	  hydrogel,	  iPS-­‐CM,	  or	  a	  combination	  of	  PEG	  hydrogel,	  iPS-­‐CM	  and	  Epo.	  	  	  
Immunohistochemistry	  and	  quantitative	  polymerase	  chain	  reaction	  (qPCR)	  analysis	  did	  not	  demonstrate	  the	  presence	  of	  intramyocardial	  human	  cells	  within	  the	  rat	  myocardium,	  lending	  credence	  to	  the	  hypothesis	  that	  improvement	  of	  cardiac	  function	  is	  due	  to	  paracrine	  effects	  rather	  than	  the	  direct	  contractile	  effects	  of	  transplanted	  cells.	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These	  results	  provide	  further	  support	  for	  combined	  tissue	  engineering	  strategies,	  and	  correlate	  well	  with	  the	  results	  of	  other	  studies	  that	  have	  also	  attempted	  a	  similar	  approach	  (Kraehenbuehl,	  Ferreira	  et	  al.	  ,	  Davis,	  Hsieh	  et	  al.	  2006,	  Takehara,	  Tsutsumi	  et	  al.	  2008).	  	  	  
	  
8.7	  Future	  Work	  and	  Conclusions	  
Currently	  further	  work	  is	  being	  undertaken	  within	  our	  lab	  to	  refine	  aspects	  of	  our	  strategy.	  	  Introduction	  of	  extracellular	  matrix	  proteins,	  and	  growth	  factors	  incorporated	  into	  the	  hydrogel	  aim	  to	  modify	  the	  interactions	  between	  cells	  and	  the	  hydrogel	  to	  improve	  transplanted	  cell	  attachment	  and	  survival.	  	  It	  is	  hypothesized	  that	  these	  measures	  may	  lead	  to	  further	  improvements	  in	  cardiac	  	  function	  following	  MI.	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